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Introduction: Tuberculosis (TB) is a global health problem, causing morbidity, mortality and 
devastating social and economic impacts. Pediatric TB is particularly challenging due to difficulties 
in diagnosis. Children are particularly susceptible to respiratory infections and this may be influenced 
by the microbial colonization of the respiratory tract, which may play a role in the clinical presentation 
and pathogenesis of TB. The nasopharyngeal microbiome is critical for respiratory health and may 
impact on the development, presentation and diagnosis of TB disease. Antibiotics contribute to 
microbial dysbiosis which may lead to the development, progression or exacerbation of other 
diseases. However, there is limited data describing the nasopharyngeal microbiota of children with 
and without TB, or the effect of TB treatment on the nasopharyngeal microbiome. 
Methods: Respiratory samples were obtained from pediatric patients with suspected pulmonary TB 
(PTB) at baseline and follow up visits (2 and 6 months). Participants were classified as having 
bacteriologically confirmed PTB, clinically diagnosed PTB or unlikely PTB (well-defined ill controls).  
Respiratory pathogens were detected in all baseline respiratory samples using the Seegene 
Allplex™ Respiratory Panel 4 and a Pneumocystis jirovecii real-time PCR assay.  
The nasopharyngeal microbiome of 26 participants was characterized and the effect of TB treatment 
determined by 16S rRNA sequencing, using the Illumina Miseq platform. 
Results: Seventy children were included; 27.1% were categorized with bacteriologically confirmed 
PTB, 32.9% with clinically diagnosed PTB and 40% with unlikely PTB.  The most frequently detected 
bacterial pathogens were Haemophilus influenzae (52/70, 74.2%) and Streptococcus pneumoniae 
(42/70, 60%). There was no association between the presence of bacterial pathobionts/pathogens 
and TB disease. 
Due to poor sequence quality resulting from load shedding during sequencing, the reverse reads 
were excluded from microbiome analysis. The most commonly detected phyla in all samples were 
Proteobacteria, Fusobacteria, Firmicutes and Bacteroidetes. Common familia included 
Streptococcaceae, Pasteurellaceae, Moraxellaceae, Prevotellaceae, Veillonellaceae and 
Neisseriaceae. There were no significant differences in the microbiome profile or alpha and beta 
diversity between TB cases and controls at baseline. However, differential abundance testing 
showed 4-5 fold differences in abundance of Pasteurellaceae and Prevotellaceae between the TB 
cases and ill controls. There was also no significant difference in microbiota profile or alpha diversity 
at 2 or 6 months in TB cases, who received TB treatment.  However, differential abundance testing 
identified a reduction in the abundance of Veillonellaceae, Staphylococcaceae, Prevotellaceae, 
Neisseriaceae, Enterobacteriaceae and Aerococcaceae in TB cases after treatment.  
Conclusion: This study observed no significant differences between the respiratory pathogens in 
children with and without PTB. Similarly, no differences in alpha or beta diversity were observed 
between the respiratory microbiota of TB cases and controls, or after TB treatment. 
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However, differences in abundance of some families, between TB cases and controls at baseline, 
and before and after TB treatment, suggest that further research on this topic is warranted, 
considering the numerous limitations which may have impacted the findings of this study. This study 
contributed to the data available regarding respiratory microbiota in children with suspected PTB in 





Inleiding: Tuberkulose (TB) is ‘n wêreldwye gesondheidsprobleem wat morbiditeit en mortaliteit 
veroorsaak en verrykende sosiale en ekonomiese impakte het. Pediatriese TB is veral uitdagend 
weens diagnose moeilikhede. Kinders is veral vatbaar vir respiratoriese infeksies en dit kan 
beïnvloed word deur die mikrobiese kolonisasie van die respiratoriese kanaal wat ‘n rol kan speel in 
die kliniese aanbieding en patogenese van TB. Die nasofaringeale mikrobioom is krities vir 
respiratoriese gesondheid en kan die ontwikkeling, aanbieding en diagnose van TB beïnvloed. 
Antibiotika kan bydra tot disbiose van die nasofaringeale mikrobiota wat kan lei tot die ontwikkeling, 
bevordering of verergering van ander siektes. Alhoewel, daar is beperkte data wat die nasofaringeale 
mikrobiota van kinders met en sonder TB, of die effek van TB behandeling op die nasofaringeale 
mikrobioom beskryf. 
Metodes: Respiratoriese monsters is geneem vanaf pediatriese pasiënte met moontlike pulmonêre 
TB by basislyn- en opvolgbesoeke (2 en 6 maande). Deelnemers is geklassifiseer as volg: met 
bakteriologies-bevestigde PTB, klinies gediagnoseerde PTB of onwaarskynlike PTB (goed 
beskryfde siek kontrole).  
Respiratoriese patogene is in alle basislyn respiratoriese monsters opgespoor, deur die gebruik van 
Seegene Allplex™ Respiratory Panel 4 en ‘n Pneumocystis jirovecii PKR toets.  
Die nasofaringeale mikrobioom van 26 deelneemers was karakteriseer en die effek van TB 
behandeling bepaal, deur 16S rRNA volgordebepaling, geteiken met Illumina Miseq tegnologie. 
Resultate: Sewentig kinders is ingesluit; 27.1% met bakteriologies-bevestigde PTB geklassifiseer 
is, 32.9% met klinies gediagnoseerde PTB en 40% met onwaarskynlike PTB.  Die mees algemeen 
opgespoorde bakteriële patogene was Haemophilus influenzae (52/70, 74.2%) en Streptococcus 
pneumoniae (42/70, 60%). Daar was geen verwantskap tussen die teenwoordigheid van sekere 
bakteriële “pathobionts”/patogene en TB siekte nie. 
As gevolg van die slegte kwaliteit van die volgordes as gevolg van beurtkrag, was die “reverse reads” 
nie ingesluit in die mikrobioom analise nie. Proteobacteria, Fusobacteria, Firmicutes en 
Bacteroidetes was die mees algemeen opgespoorde filums. Algemene gesinne het onder andere 
Streptococcaceae, Pasteurellaceae, Moraxellaceae, Prevotellaceae, Veillonellaceae en 
Neisseriaceae ingesluit. Daar was geen merkwaardige verskille in die mikrobiota profiele of alfa en 
beta diversiteit tussen TB gevalle en kontrole by basislyn nie. Alhoewel, differensiaal oorvloed toetse 
wys dat daar 4-5 vou verskillende in die oorvloed van Pasteurellaceae en Prevotellaceae tussen die 
TB gevalle en kontrole groep. Daar was boonop geen merkwaardige verskille in die mikrobiota 
profiele of alfa diversiteite in TB gevalle wat TB behandeling ontvang het by 2 of 6 maande nie. 
Alhoewel, differensiaal oorvloed toetse het ŉ vermindering in die oorvloed van Veillonellaceae, 
Staphylococcaceae, Prevotellaceae, Neisseriaceae, Enterobacteriaceae and Aerococcaceae 





Hierdie ondersoek het geen merkwaardige verskille tussen die respiratoriese patogene in kinders 
met en sonder PTB waargeneem nie. Ingelyks, geen verskille in alfa en beta diversiteit tussen die 
respiratoriese mikrobiota van TB gevalle en kontrole, of na TB behandeling was waargeneem nie. 
Alhoewel verskille in die oorvloed van sommige gesinne, tussen TB gevalle en kontrolle by basislyn, 
en voor en na TB behandeling voorstel dat verder navorsing gedoen moet word op hierdie onderwerp 
aagesien dat daar baie beperkings was wat die bevinding kon beïnvloed. Hierdie studie het bygedra 
tot die tekort aan beskikbare data met betrekking tot die respiratoriese mikrobiota in kinders met 
moontlike PTB in ‘n TB endemiese omgewing en het die uitdagings van die uitvoer van mikrobioom 
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CHAPTER 1:  
Literature Review 
Tuberculosis (TB) is a renowned disease that contributes significantly to morbidity and mortality 
worldwide (Lewinsohn, Gennaro and Scholvinck, 2004), and was one of the first infectious 
diseases declared a global health emergency by the World Health Organization (WHO). TB is 
recognized as the leading cause of death from a single infectious agent, ranked above HIV/AIDS 
for the last 5 years (World Health Organization, 2019). Each year approximately 10 million people 
become ill and according to the WHO, approximately 1.2 million TB deaths were estimated among 
HIV negative people and an additional 251 000 deaths among HIV positive people in 2018 (World 
Health Organization, 2019). In children (< 15 years of age), 1.1 million incident cases are reported 
globally, indicating that approximately 11% of TB occurs in children (World Health Organization, 
2019). In 2018, the global estimates for TB mortality in HIV negative and positive children (<15 
years) in Africa were 60000 and 30000, respectively (World Health Organization, 2019). Although 
a relative small proportion of TB cases are reported in children, they represent ongoing 
transmission of TB from adults to children in communities (Tsai et al., 2013). South Africa is 
classified as a high burden TB country, with one of the world’s worst TB epidemics driven by HIV 
(Churchyard et al., 2014). 
1.1 Etiology of Tuberculosis 
Robert Koch identified the etiological agent responsible for TB, the “tubercle bacillus”, in 1882 
(Gradmann, 2006); it later became known as Mycobacterium tuberculosis (M.tb). Mycobacteria 
are classified within the Mycobacteriaceae family and can be described as aerobic, non-motile, 
acid-fast bacilli (AFB) that are either straight or slightly curved (0.2-0.6 mm wide and 1-10 mm 
long). They can be classified according to the measurement of growth (slow or rapid growing) and 
the ability to produce pigment (photochromogens, scotochromogens and non-chromogens) 
(Saleem and Azher, 2013). For instance, M.tb can be described as an obligate aerobic, large non-
motile, acid-fast bacillus, non-spore forming, catalase positive and oxidase negative bacterium 
and classified as a non-chromogenic (non-pigmented) slow growing bacterium with a generation 
time of 15-20 hours (Lawn and Zumla, 2011; Saleem and Azher, 2013; Dunn, Starke and Revell, 




1.2 Clinical presentation 
TB can manifest in many ways depending on the immune system of an individual. In some 
instances, an individual may become infected with TB without becoming diseased; that is often 
referred to as latent TB (Piccini et al., 2014). During latent TB an infected individual does not 
present with symptoms of TB disease. In this case the immune system controls further spread by 
enclosing bacteria within a calcified shell, known as a granuloma. These granulomas protect the 
lungs from further damage and if these bacteria are contained, an individual will not present with 
symptoms or be contagious and therefore cannot spread the disease (Kim et al., 2010). When an 
individual’s immune system is compromised, latent TB may progress to active TB. 
Although the granulomas contain the bacteria and act as a host defense mechanism, these 
granulomas provide an environment for the persistence of M.tb (Shaler et al., 2013). The 
progression to active disease occurs when these granulomas rupture and M.tb is no longer 
contained, resulting in M.tb inhabiting the lungs, damaging surrounding tissue (Kim et al., 2010) 
and reaching the part of the lungs that connects to the airway where bacilli can be expectorated 
(Ehlers and Schaible, 2012). 
Without treatment, 5-10% of infected individuals will develop TB disease in their lifetime; 
approximately half of those who develop active TB will do so within 2 years of being infected 
(CDC, 2011). However, the risk of developing TB is greater in the presence of predisposing 
factors, especially HIV, which increases the risk 16-27 times (‘WHO | Tuberculosis and HIV’, 
2019). Others at increased risk of progression to active TB disease are those affected by other 
conditions affecting the immune system like malnutrition, diabetes mellitus, smoking, sepsis, renal 
failure, chemotherapy, organ transplantation, chronic alcohol consumption and long term use of 
corticosteroids (Knechel, 2009; World Health Organization, 2018). 
The clinical manifestation of TB is dependent on where in the body M.tb proliferates. Pulmonary 
TB (PTB) occurs in about 85% of TB patients and is therefore the most prominent form of TB 
disease (Fogel, 2015). The usual clinical signs and symptoms associated with PTB include 
chronic cough, night sweats, blood tinged sputum, weight loss, shortness of breath, fever chest 
pain and pleurisy (inflammation of the pleura membrane surrounding the lungs) (Fogel, 2015). 
However, these signs and symptoms are not always evident in all PTB cases and may vary 
between age groups. TB can also occur outside of the lungs (extrapulmonary TB); in the spine, 





1.3 Pediatric TB 
Pediatric TB has not always been a priority of global TB control as much of the focus has been 
on the identification and effective management of the most infectious cases of TB to reduce the 
transmission of infection with M.tb. This group is usually represented by adults or adolescents 
with sputum smear positive PTB. Furthermore, the true burden of TB disease in children is 
obscured due to diagnostic difficulties involving both atypical clinical presentation and low 
confirmation rates due to paucibacillary disease.  
Generally, children infected with TB have a higher risk of progressing towards disease within the 
first year after exposure or infection (Marais and Schaaf, 2010). Additionally, children are at a 
higher risk of developing more severe, disseminated forms of TB disease such as TB meningitis 
and miliary TB (Donald, Marais and Barry, 2010). Progression from infection to disease is 
determined by factors such as age at the time of exposure, nutritional and immune status, genetic 
factors, virulence of the organism and the magnitude of the initial infection. Children can develop 
TB within two to 12 months after initial TB infection (Cruz and Starke, 2007). The greatest risk of 
disease progression after infection is seen in young children <5 years of age (especially in those 
<2 years), where children between 5 and 10 years’ experience a lower risk of disease progression, 
followed by an increase in risk in the adolescent group (>10 years) (Seddon et al., 2018). It is 
recognized that TB primarily affects the lungs and it has previously been reported that pulmonary 
TB accounts for 60-80% of cases in children (Cruz and Starke, 2007). 
Children with PTB present with symptoms such as a chronic, unremitting cough that does not 
improve and is present for more than two weeks, a fever of more than 38°C for at least two weeks 
with other common causes having been excluded, and weight loss or failure to thrive (Adams and 
Starke, 2019). These symptoms are however nonspecific, especially in the youngest children, 
and are similar to those of common childhood diseases, including pneumonia, generalized 
bacterial and viral infections, malnutrition and HIV infection (Tsai et al., 2013). Schaaf et al (1995) 
found no differences with respect to weight loss, chronic cough and duration of symptoms 
between children with culture confirmed TB and other lung diseases. The only differences 
between the two groups were history of contact with an infectious TB case and a positive 
tuberculin skin test (TST) as a marker of TB infection.  
The evidence of lung disease is not always clear, especially in children between the age of 5-10 
years where they present with radiographically apparent clinically silent disease (Table 1.1). 




disease (Cruz and Starke, 2007). HIV infected individuals can also present with nonspecific signs 
and symptoms, with clinical and radiographic features which overlap with other lung diseases, 
such as pneumonias or chronic lung diseases (Swaminathan, 2004). The nonspecific and 
overlapping respiratory features observed in pediatric TB contribute to the difficulty in diagnosing 
TB in children. 
Table 1.1: The frequency of symptoms and signs of PTB according to age. (Cruz and Starke, 
2007) 
Clinical feature Infants (<2 years) Children (5-10 years) Adolescents (>10 years) 
Symptom 
Fever common uncommon common 
Night sweats rare rare uncommon 
Cough common common common 
Productive cough rare rare common 
Haemoptysis never rare rare 
Dyspnoea common rare rare 
Sign 
Rales common uncommon rare 
Wheezing common uncommon uncommon 
Fremitus rare rare uncommon 
Dullness to percussion rare rare uncommon 






1.4 TB Diagnosis  
Most TB deaths can be averted with early diagnosis and appropriate treatment. An estimated 58 
million people/individuals were successfully treated for TB between 2000 and 2018, but there is 
still a gap between the number of people being notified and treated for TB and people becoming 
ill from TB (World Health Organization, 2019). The rapid diagnosis of PTB is difficult and the early 
detection of PTB continues to be challenging for clinicians, especially in young children (Ryu, 
2015), since there is not a high quality diagnostic test available for paucibacillary disease.  
Diagnosis of TB in children is based on bacterial confirmation or clinical presentation alone. M.tb 
detection is required for bacteriological confirmation of TB; this includes sputum smear 
microscopy, culture-based techniques and rapid molecular tests, like GeneXpert MTB/RIF (Ultra). 
Pediatric TB is typically paucibacillary; as fewer organisms are involved in the disease process. 
As a result only an estimated 40% of children with TB are bacteriologically confirmed (±10% 
smear positive) and the other 60% of cases are diagnosed based on a combination of clinical 
signs and symptoms, radiography, epidemiology and tests of infection (Chiang, Swanson and 
Starke, 2015; Dunn, Starke and Revell, 2016). 
1.4.1 Bacteriological diagnosis 
Sputum smear microscopy involves the examination of bacteria under a microscope after Ziehl-
Neelsen (Figure 1.1) or Auramine O staining; which exploits the acid-fast nature of the 
mycobacterial cell envelope. Smear microscopy is a simple, yet rapid and inexpensive test for the 
diagnosis of pulmonary TB that offers good specificity, but has low sensitivity when it comes to 
detecting M.tb in patients with non-cavitary pulmonary disease or low bacillary load in sputum; 
this is particularly evident in children and HIV positive patients (Ryu, 2015; World Health 






Figure 1.1: The diagnosis of TB based on the detection of M. tuberculosis. (A) Sputum smear microscopy 
using Ziehl-Neelsen staining; mycobacterial cells are visualized as pink rods, as indicated by the arrow. (B) 
Culture-based detection; colonies can be observed on Lowenstein Jensen medium. 
http://textbookofbacteriology.net/tuberculosis.html 
M.tb culture is the gold standard for the diagnosis of M.tb, and allows for accurate speciation and 
phenotypic drug-susceptibility testing to be performed (Dunn, Starke and Revell, 2016). M.tb 
culture can be done on either solid (Lowenstein Jensen and Middlebrook 7H11) or liquid medium 
(Middlebrook 7H9) or on automated liquid culture systems such as the Bactec MGIT (BD) or 
BacT/Alert systems (Dunn, Starke and Revell, 2016). The automated system assists in reducing 
the detection time in comparison to solid medium culture which has a slow turnaround time of 
4-6 weeks for culture positivity (Balajee and Dhana Rajan, 2011;World Health Organization, 
2017). 
Technological advancements have allowed the introduction of the GeneXpert MTB/Rif, a rapid 
molecular test that has become an important diagnostic measure for the detection of M.tb and 
drug resistance. This automated diagnostic technique detects M.tb DNA directly from sputum 
samples and is able to detect mutations associated with resistance to rifampicin (RIF) using 
nucleic acid PCR amplification. In 2010, the WHO endorsed the use of the GeneXpert MTB/Rif in 
TB endemic areas such as South Africa. In 2017, the GeneXpert MTB/Rif Ultra was launched and 
was found to be significantly more sensitive compared to the Xpert MTB/Rif for the detection of 
low bacillary loads. This technique is particularly useful in the case of smear negative TB patients, 
culture positive specimens, extrapulmonary specimens (CSF) and specimens obtained from 
children.  
Drug susceptibility testing is important for accurate treatment. In addition to the GeneXpert, rapid 
drug susceptibility testing can be done using line probe assays (LPA) and sequencing 





to fluoroquinolones and injectable anti TB drugs (second-line LPAs). However, culture-based 
methods currently remain the reference standard for drug susceptibility testing (World Health 
Organization, 2017). 
1.4.2 Diagnosis of pediatric TB 
Accurate diagnosis and confirmation of pediatric TB is particularly challenging and is exacerbated 
by two biological factors, namely the inability to expectorate sputum and the paucibacillary nature 
of childhood TB (Chiang, Swanson and Starke, 2015). To circumvent challenges in obtaining 
sputum from children, alternative specimen collection methods can be used, such as gastric 
aspiration, induced sputum, string test, nasopharyngeal aspiration, bronchoalveolar lavage, stool 
or urine (Marais and Schaaf, 2010). However, each method is not without benefit or limitation 
(Marais and Schaaf, 2010). Due to the paucibacillary nature of the disease test sensitivities are 
reduced, especially in acid fast smear microscopy and mycobacterial culture tests (Chiang, 
Swanson and Starke, 2015). Even with meticulous specimen collection, only 10-15% of sputum 
samples reveal acid fast bacilli (AFB) and approximately 30-40% of sputum cultures remain 
negative in probable pediatric TB cases (Marais et al., 2006). As a result, bacteriological 
confirmation is achievable in less than 50% of children and 75% of infants (Adams and Starke, 
2019).  
In cases where bacteriological confirmation is not possible, PTB is diagnosed using clinical criteria 
such as signs and symptoms, tests for TB infection (tuberculin skin test; TST or interferon gamma 
release assay; IGRA), exposure history and radiographic findings. However, the TST and IGRA 
tests only determine infection status without information about recent or old infection. A positive 
test of infection in high burden countries and nonspecific clinical and radiographic findings can 
contribute to uncertainty in clinical diagnosis (Chiang, Swanson and Starke, 2015). Nevertheless, 
the diagnosis of TB in children is largely based on, (1) well defined symptoms (Marais et al., 
2004), 2) recent close contact with an infectious TB case, (3) a positive TST or IGRA result, and 




1.5 TB Treatment  
In 1940, it was discovered that streptomycin killed M.tb, however the success was short lived as 
it was realized that M.tb had the propensity to acquire/develop antibiotic resistance. This led to 
the establishment of the initial combined treatment therapy with the following antibiotics; 
streptomycin, para-aminosalicylic acid (PAS) and INH (Sotgiu et al., 2015).  
The principle of combined treatment therapy is still in practice, aiming to eliminate the actively 
replicating and dormant/near dormant mycobacteria by using a combination of drugs with varying 
actions, while attempting to prevent the emergence of drug resistant organisms; and all being 
achieved with a minimum risk of toxicity (Graham, 2011). 
Current treatment regimens involve a cocktail of drugs that is taken in two phases, an initial 
intensive phase and continuation phase. The cocktail of drugs is taken intensively for 2 months 
(intensive phase) to kill rapidly growing bacilli (bactericidal drugs) aiming to reduce the microbial 
load. This reduces the inflammation process, symptoms and clinical signs (clinical recovery) and 
terminates disease transmission (Sotgiu et al., 2015). This is followed by a 4 month continuation 
phase to eradicate slower growing more persistent bacilli and those in acidic environments, to 
prevent relapse (sterilizing drugs) (Graham, 2011; Tsai et al., 2013; Sotgiu et al., 2015). In cases 
of drug susceptible TB, the two drugs INH and RIF are usually sufficient during the continuous 
phase, whereas in the initial phase pyrazinamide (PZA) with or without ethambutol (EMB) is 
added.  
Generally, TB treatment drugs are divided into first line drugs (FLDs) and second line drugs 
(SLDs). FLDs include INH, RIF, PZA and EMB and are used in combination in cases of drug 
susceptible TB. SLDs are used for the treatment of multidrug resistant TB (MDR-TB), which is 
resistance to two of the most effective FLDs, RIF and INH (World Health Organization, 2013). 
SLDs include 6 classes of drugs, namely aminoglycosides, polypeptides, fluoroquinolones, 
thioamides, cycloserine and para-aminosalicylic acid (Saleem and Azher, 2013); of which 
fluoroquinolones and aminoglycosides (second line injectable agents, amikacin (AMK), 
capreomycin (CAP) or kanamycin (KAN)) are the main drugs used (Jnawali and Ryoo, 2013). 
New drug regimens including delamanid and bedaquiline have been introduced and bedaquiline 
has been approved for use in adolescents and adults in South Africa.  
In more recent years extensively drug resistant TB (XDR-TB) has been reported; defined as 
resistance to RIF and INH with the additional resistance to at least one drug in each of the two 




injectable agents (CDC, 2013). Drug resistance contributes to the persistence of TB which 
threatens global TB care and prevention as the remaining treatment options are limited, less 
effective, have more side effects and are expensive, especially in low income countries (Sotgiu 
et al., 2015). 
The principles of TB treatment are the same for adults and children (Tsai et al., 2013), consisting 
of the intensive and continuation phases to rapidly kill and eradicate slower persistent bacilli, 
respectively. Due to the fact that laboratory confirmation is uncommon and often delayed in 
children, treatment is often guided by the culture and drug susceptibility results of the index case. 
According to the South African guidelines for the management of TB in children, during 
uncomplicated TB disease (e.g. low bacillary load such as PTB with minimal lung parenchyma 
involvement) the TB treatment regimen is comprised of 3 or 4 drugs (RIF, INH, PZA without or 
with EMB) for the first two months (intensive phase), followed by 2 drugs (RIF and INH) during 
the continuation phase lasting for 4 months (Table 1.2). The continuation phase could be 
extended to 7 months during complicated TB (e.g. high bacillary load PTB- smear positive, 
parenchymal involvement and cavities on chest X ray). On the other hand, the length of treatment 
for drug resistant TB will be 12 months or more depending on the extent of the disease. Also, an 
extended treatment regimen of 9 months may be considered for HIV infected and HIV uninfected 
children as a result of a slower treatment response rate. The duration of treatment and dosing of 
drugs are all based on adult data as pediatric data is lacking. Studies are underway to investigate 
treatment shorting in children with TB. Drug dosages used during treatment depends on the 
weight of the child and is adjusted accordingly throughout the course of treatment (South African 




Table 1.2: First line and second line anti-TB drugs recommended for children (South African National Department of Health, 2013); mechanisms of 
action, spectrum of activity and activity against other Gram positive and Gram-negative bacteria (Naidoo et al., 2019). 
 
Antibiotic name Antibiotic action Mechanism of action Spectrum of activity Activity against 
G+ G- 
Drug susceptible TB: First line drugs (FLDs) 
Isoniazid 
Bactericidal/static 
Inhibits mycolic acid and acyl carrier 
protein reductase 
Narrow (M.tb, M. kansasii,  
M. xenopi)  
N N 
Rifampicin Bactericidal Targets DNA dependent RNA polymerase broad Y Y  
Pyrazinamide Bactericidal Targets membrane energy metabolism Narrow (M.tb) N N 
Ethambutol Bacteriostatic Targets arabinosyl transferase Narrow (M.tb, M. avium) N N 
Drug resistant TB: Second Line drugs (SLDs) 
Ethionamide/ Prothionamide weakly Bactericidal Targets peptide synthesis Narrow Y Y 
Fluoroquinolones 
Bactericidal Inhibits DNA replication Broad Y Y Levofloxacin 
Moxifloxacin 
Aminoglycosides 






Bacteriostatic Inhibition of cell wall synthesis Broad Y Y 
Para-aminosalicylic 
Bacteriostatic 
Inhibition of folic acid synthesis and cell 
wall synthesis 
Narrow N N 
New drugs 
Bedaquiline Bactericidal Targets ATP synthesis Narrow N N 
Delamanid Bactericidal Targets mycolic acid synthesis Narrow N N 





1.6 TB and the Microbiome 
Respiratory health has been linked to the microbial colonization of both the upper and lower 
respiratory tract. Biesbroek et al (2014) provided insight into microbial succession in the 
respiratory tract in infancy and linked early life profiles to microbiota stability and respiratory health 
characteristics. Understanding this is important, as children are prone to the development of 
respiratory infections due to an immature immune system.  
The susceptibility to respiratory infections may be linked to the origin of respiratory infections, 
namely the nasopharynx (van den Bergh et al., 2012). The rich microbial carriage in the 
nasopharynx is seen as a reservoir for both commensals and potential or invasive pathogens 
(García-Rodríguez and Fresnadillo Martínez, 2002), which plays an important role in microbial 
spread as well as disease development. A multitude of microorganisms inhabit this site including 
viruses and fungi, however it is particularly hospitable to bacterial species (Mizgerd, 2014); all of 
which form part of the microbiome, a term that was initially used to “signify the ecological 
community of commensal, symbiotic and pathogenic microorganisms that share our body 
space”(The NIH HMP Working Group, 2009). The microbiome has been described to aid in 
maintaining normal host physiology, developing and educating the immune system, metabolizing 
complex substrates and providing crucial protection against opportunistic pathogens (Shukla et 
al., 2017). Studies have shown that our microbiomes change us, by promoting health through 
their beneficial actions or by increasing susceptibility to disease through a phenomenon called 
dysbiosis (Gerber, 2014).  
1.6.1 Nasopharyngeal microbiome 
The organisms found in in the respiratory tract form part of the respiratory microbiome. The 
respiratory tract is a composite system that is anatomically divided into the upper and lower 
respiratory tract. Its surface is completely inhabited by niche specific bacterial communities (as 
well as viruses and fungi) of which the upper respiratory tract has the highest bacterial densities 
(Man, de Steenhuijsen Piters and Bogaert, 2017).  
The first description of the nasopharyngeal “microbiome” in children was executed by Bogaert et 
al (2011), where 5 prominent phyla were identified, namely Proteobacteria, Firmicutes, 
Bacteroidetes, Actinobacteria and Fusobacteria with Moraxella, Haemophilus, Streptococcus, 
Flavobacteria, Dolosigranulum, Corynebacterium and Neisseria being the most predominant 
genera. This study also showed that the microbiota in the nasopharynx is highly diverse and that 




Man et al (2017) reviewed numerous studies and found that a wide variety of microorganisms can 
be detected in the upper respiratory tract during the first hours of life of healthy term neonates. 
Furthermore, within the first week of life, niche differentiation in the upper respiratory tract leads 
to the accumulation of bacterial such as Staphylococcal, Corynebacterium, Dolosigranulum and 
Moraxella spp; of which microbiota profiles characterized by Corynebacterium and 
Dolosigranulum early in life and Moraxella spp at 4-6 months of age correspond with a stable 
bacterial composition and respiratory health. However, early life microbiota are highly dynamic 
and can be attributed to both host and environmental factors (Figure 1.2) such as mode of 
delivery, feeding type, siblings, season and antibiotic exposure (Bogaert et al., 2011; Man, de 
Steenhuijsen Piters and Bogaert, 2017; Esposito and Principi, 2018) with environmental factors 
having the largest described influence.  
 
Figure 1.2: Host and environmental factors contributing to changes in the respiratory microbiome 





1.6.2 The respiratory microbiota and clinical presentation of PTB 
Pediatric TB does not present as obviously as TB in adults, and the challenge is that PTB presents 
similarly to other lower respiratory tract infections. Studies have shown that lower respiratory 
infections are often polymicrobial (Dube et al., 2016; Zar et al., 2016), and that other respiratory 
microorganisms (or pathogens) may be the cause of the initial clinical suspicion of TB or contribute 
to the severity of PTB. Dube et al (2016) described the prevalence of respiratory pathogens in 
children hospitalized with suspected PTB in Cape Town, South Africa. They found that in 97% of 
all children with suspected PTB, another respiratory pathogen, including bacteria and viruses, 
could be detected. The children with PTB had a microbial profile which consisted of C. 
pneumoniae, hMPV, coronavirus 043, influenza C virus, rhinovirus and cytomegalovirus and 
those without TB had a microbial profile which consisted of P. jirovecii, H. influenzae spp, RSV, 
M. pneumoniae, influenzae B virus and enteroviruses. However, their results of differences in 
microbial profile between children with and without PTB failed to reach statistical significance and 
warranted further investigation (Dube et al., 2016). Schaaf et al (1995) found that 42% of the 
children with initial suspicion were found not to have TB and were diagnosed with bacterial or viral 
pneumonia, bronchopneumonia or asthma, which implies that the presentation of these diseases 
are similar and symptoms can overlap (Schaaf et al., 1995). However, limited data is available 
with regard to other respiratory pathogens and their role in pediatric PTB. Therefore, investigating 
the prevalence of respiratory co-infections in children with TB may provide insight into their role 
in the clinical presentation and the pathogenesis of PTB.  
1.6.3 The microbiome and diagnosis of PTB 
The diagnosis of pediatric TB is challenging, as previously discussed. Microbiome research has 
shown that during certain diseases specific microbial profiles can be identified. The composition 
of microbial communities in the nasopharynx seems to differ between different disease states with 
certain phyla and genera associated with different diseases. Infants with cystic fibrosis have been 
shown to have nasopharyngeal microbial profiles with Staphylococcus aureus, Streptococcus 
mitis, Corynebacterium accolens and bacilli as the most abundant organisms, while in healthy 
controls, Corynebacterium spp and Haemophilus influenzae were more abundant (Prevaes et al., 
2016). Microbial profiles were also found to differ between children with pneumonia and healthy 
children. Children with pneumonia were found to have less diverse microbial communities in 
comparison to healthy participants (Sakwinska et al., 2014). The decrease in richness and 
diversity of the microbiota was shown to be associated with disease and is a common theme in 




To our knowledge there is no data available on the respiratory microbiome of children with PTB; 
before the start of TB treatment, during and after treatment. A better understanding of the 
respiratory microbiome of children with and without PTB could contribute to the understanding of 
the role that the microbiome plays in TB pathogenesis. 
1.6.4 TB treatment and the microbiome 
The main objective of combined TB treatment regimens is to eliminate M.tb while preventing 
resistance with minimum risk of toxicity. However, drug resistance and drug toxicity may not be 
the only issues to consider. Most of the antibiotics used in the TB treatment regimen, especially 
the second line drugs, have broad-spectrum activity (Table 1.2). As such, other organisms 
besides M.tb may become unintentional targets during the process of eradicating M.tb. Recent 
microbiome research has shown that although antibiotics are necessary to combat disease or 
infection, they present an external interference that contributes to microbial imbalances on or 
inside the body as a consequence of dysbiosis. This is a well described phenomenon that has 
been described in gut microbiome research, but has since been suggested to occur on any 
exposed surface or mucus membrane such as the vagina, skin or the respiratory system (Martín 
et al., 2014). Like the gut microbiome, the respiratory microbiota is established at birth with 
subsequent changes continuing for several months, and it has been suggested that early 
respiratory microbiota composition determines respiratory health in children (Man, de 
Steenhuijsen Piters and Bogaert, 2017; Esposito and Principi, 2018). However, the microbial 
communities that inhabit different niches in our bodies change throughout our lives and these 
changes are attributed to many factors; progression during childhood, altered diets, travel, illness 
and treatment regimens. The risk of treatment regimens such as TB treatment regimens causing 
dysbiosis is concerning in children since their microbiomes are still being established. Especially 
since dysbiosis causes the disruption of either the composition or overall numbers of “normal 
microbiota” which can result in the outgrowth of dominant, usually pathogenic bacterial genera 
over the diverse microbial community, which may lead to the development, progression or 
exacerbation of disease (Shukla et al., 2017). This is especially important for TB treatment as 
treatment is taken for an extended period (for a minimum of six months) compared to other 




The effects of first line TB treatment have previously been described to cause intestinal 
microbiome dysbiosis in humans and mice. Wipperman et al (2017) found that TB treatment did 
not affect the overall diversity of the intestinal microbiome in humans but that it reduced multiple 
immunologically relevant commensal bacteria. Also, that treatment can have long lasting effects 
on the microbiome since dysbiosis was seen to persist after treatment (Wipperman et al., 2017). 
In the mouse model study, they found that TB treatment had a temporary effect on intestinal 
microbial diversity and that the altered microbial structure as a result of therapy persisted up to 3 
months after therapy ended. The study also compared monotherapy and combination therapy of 
the first line TB drugs and found that rifampin (RIF) was a major contributor to the altered microbial 
structure (Namasivayam et al., 2017). These studies show that although FLDs (INH, PZA EMB 
and RIF) primarily target M.tb they can cause dysbiosis which persists after treatment. 
Determining the effect of FLDs on the nasopharyngeal microbiome is important since RIF belongs 
to the rifamycin family, which is said to have broad spectrum of activity on Gram positive bacteria 
of the skin and respiratory microbial communities (Hong et al., 2016). This is important as during 
suspicion of TB children may be placed on TB treatment without bacteriological confirmation of 
disease and monitored for improvement (South African National Department of Health, 2013), 
which could potentially have adverse effects on the nasopharyngeal microbiome. Recognizing TB 
treatment as a potential cause of antibiotic induced dysbiosis may potentially allow for 






1.7 Problem statement 
TB is a worldwide problem that results in morbidity and mortality and has a devastating social and 
economic impact. Pediatric TB is particularly challenging due to difficulties in diagnosis as a result 
of non-specific signs and symptoms, the paucibacillary nature of the disease and the overlap with 
other common childhood illnesses in these age groups. The nasopharyngeal microbiome 
(microbiota) is critical for respiratory health and impacts on the development, presentation and 
diagnosis of TB disease. In addition, TB treatment may result in dysbiosis of the nasopharyngeal 
microbiome which may lead to the development, progression or exacerbation of other diseases. 
There is limited data describing the nasopharyngeal profiles of children with and without TB, and 
the effect of TB treatment on the nasopharyngeal microbiota/microbiome. 
1.8 Aims and objectives 
This is a pilot study which aims to  
(1) Compare the respiratory microbiota of children with bacteriologically confirmed, clinically 
diagnosed and unlikely PTB  
(2) Describe the effect of TB treatment on the respiratory microbiota in children with PTB. 
The aims will be achieved by completing the following objectives: 
1. Determine the presence of various bacterial pathogens and the fungal pathogen 
Pneumocystis jirovecii in respiratory samples collected from children with bacteriologically 
confirmed, clinically diagnosed and unlikely PTB.  
2. Describe the respiratory microbiota in children with PTB (bacteriologically 
confirmed/clinically diagnosed) and in those without PTB (well defined ill controls) at 
baseline. 
3. Describe the effect of TB treatment on the respiratory microbiota in children with PTB 
(bacteriologically confirmed/clinically diagnosed) after 2 and 6 months in comparison to 





1.9 Study Population 
This substudy forms part of a larger ongoing prospective cohort study conducted by the Desmond 
Tutu TB Centre, which aims to improve the diagnosis of pulmonary tuberculosis (PTB) in children 
with suspected PTB. Children with suspected PTB are enrolled from the Tygerberg and Karl 
Bremer (respectively, tertiary and secondary level) provincial hospitals in Cape Town and are 
routinely followed up for six months.  
Ethical approval for this study was obtained from the Health Research Ethics Committee of 
Stellenbosch University (parent study N11/09/282- PI Dr E Walters and substudy N15/04/034). 
Inclusion Criteria: 
1. Children aged 0-13 years 
2. A child with more than one of the following (Graham et al., 2012): 
i. Persistent unremitting cough (or cough significantly worse than usual in child with 
chronic lung disease, including HIV-related) of >2 weeks duration, unresponsive 
to a course of appropriate antibiotics. 
ii. Poor growth documented over the preceding 3 months [clear deviation from a 
previous growth trajectory and/or documented crossing of centile lines in the 
preceding 3 months; and/or weight-for-age Z score of ≤2 in the absence of 
information on previous/recent growth trajectory AND not responding to nutritional 
rehabilitation (or to antiretroviral therapy if HIV infected). 
iii. Persistent unexplained lethargy or reduced playfulness/activity reported by the 
caregiver. 
iv. Any duration of cough with at least one of the following: 
i. Documented exposure to a known TB source case (regardless of smear 
status) OR 
ii. Reactive Mantoux skin test OR 
iii. Chest radiograph suggestive of TB (Marais et al., 2004). 






1. Presence of only extra-thoracic TB without signs of PTB. 
2. Receipt of TB treatment for >2 days in the previous two weeks. 
3. Severe illness resulting in unstable clinical condition.  
4. Any condition which would constitute an absolute contra-indication to any of the sampling 
procedures required by the study e.g. acute severe asthma, pertussis-syndrome or raised 
intracranial pressure as contra-indications for sputum induction. 
5. Residence in remote areas with no ready access to transport for follow-up visits. 
Following enrolment, participants with suspected PTB based on the eligibility criteria were 
classified as having “bacteriologically confirmed PTB” (TB confirmed by liquid mycobacterial 
culture and/or GeneXpert MTB/RIF), “clinically diagnosed PTB” (without bacteriological 
confirmation but with clinical and radiological evidence of PTB disease), or “unlikely PTB” (TB 
excluded after intensive investigation based on alternative diagnosis and/or clinical improvement 
without TB treatment) (Figure 1.3). Diagnostic categories were only assigned once all diagnostic 
test results were obtained (after a maximum of 8 weeks after enrolment) and after careful follow 
up. Treatment as per standard care was determined by a hospital clinician after baseline sampling 
at the entry to the study. Participants who started TB treatment were defined as TB cases and 
included participants that were assigned to either clinically diagnosed or bacteriologically 
confirmed PTB categories. Those not on TB treatment were defined as well-defined ill controls 
(unlikely PTB group), which included participants that were determined not to have PTB and were 
therefore not on TB treatment (but may be on other antibiotics) (Figure 1.3). Clinical assessment 






Figure 1.3: Overview of diagnostic categories assigned to participants and the characterization of those 
participants as either TB cases or well-defined ill controls.  
1.10 Sample collection 
Gastric aspirates (GA) and induced sputa (IS) were collected from all of the enrolled children to 
detect Mycobacterium tuberculosis (M.tb) using routine diagnostic procedures. In addition, a 
nasopharyngeal aspirate (NPA) was collected from a subgroup of children for viral, bacterial and 
microbiome analysis; and used in this sub study. NPAs were obtained from study participants at 
the following time points: baseline (entry into study) and follow-up at 1, 2 and 6 months after 
enrolment or start of TB treatment. In some cases, IS samples were collected instead of NPAs. 
The samples were collected between December 2015 and January 2017. 
NPAs were collected by the study team after a minimum of 2 hours nil per os (NPO) (fasting). The 
collection of the NPA samples was done according to the standard operating procedure (SOP 
PC012- Nasopharyngeal aspiration) by well-trained study nurses. At least 1 ml of specimen was 
collected and stored out of direct sunlight, at 4-8°C, until it was transported to the laboratory. 
Commercial viral transport medium (Davies Diagnostics, Grenada Spain) was added to the 
samples at the Division of Medical Virology, Stellenbosch University/National Health Laboratory 
Service. 
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CHAPTER 2:  
Detection of “other” respiratory pathogens in children suspected of 
pulmonary tuberculosis 
2.1 Introduction 
TB is of concern globally; however South Africa has been recognized as one of the high TB burden 
countries (World Health Organization, 2018). Davies and colleagues (2005) suggested that two 
aspects likely contribute to the risk of TB development: (1) the risk of an individual being infected 
is contingent on the incidence of TB in the community (i.e. work and living) and (2) the risk of 
infection leading to disease is contingent on several factors that impinge on an individual (i.e. age, 
maturity of the immune system, genetics and environmental factors). Respiratory co-infection may 
play an important role in the risk of progression towards TB disease by influencing the immune 
response of the host. However, limited data is available with regard to the involvement of other 
respiratory pathogens in PTB, particularly in children (Dube et al., 2016). 
Microbial colonization of both the upper and the lower respiratory tract plays a major role in 
respiratory health. The significance of the upper respiratory airway is that it serves as an entry 
point for microbes into the body and a connective channel between the outside world and the 
lower respiratory tract. The nasopharynx forms part of the upper respiratory tract and is 
particularly hospitable to bacteria (Mizgerd, 2014). It is densely colonized by a wide range of 
microorganisms including commensal bacteria and pathobionts (potential pathogens) such as 
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (García-
Rodríguez and Fresnadillo Martínez, 2002). It is likely that most individuals are colonized with 
these pathogens at least once early in life and as many as 54% and 33% of children are colonized 
with S. pneumoniae and H. influenzae respectively by the age of one (Faden et al., 1997). These 
bacteria can be carried without causing clinical symptoms, however when conditions in the host 
are altered, invasion of adjacent sites and/or the bloodstream can lead to disease (García-
Rodríguez and Fresnadillo Martínez, 2002).  
Community acquired pneumonia (CAP) is an important cause of morbidity and mortality 
worldwide. Both S. pneumoniae and H. influenzae have been reported as etiological agents of 
CAP, with S. pneumoniae as the most common cause (Ruiz et al., 1999; Cillóniz et al., 2011). 
The Pneumonia Etiology Research for Child Health (PERCH) study group found that in children, 




major cause of pneumonia, except in severe pneumonia cases where bacteria were more 
common (O’Brien et al., 2019). Other bacterial agents involved in CAP are atypical pathogens 
Mycoplasma pneumoniae, Chlamydophila pneumoniae, Coxiella burnetti and Legionella 
pneumophila which have been described in up to 35% of CAP episodes (Cillóniz et al., 2011). 
Other organisms that are less likely to cause pneumonia but have been reported are Bordetella 
pertussis and Bordetella parapertussis (Elahi et al., 2008). These are closely related Gram-
negative bacterial species that typically cause whooping cough. 
The fungal pathogen Pneumocystis jirovecii is also a cause of pneumonia in 
immunocompromised hosts, such as  cancer patients undergoing chemotherapy, individuals 
taking immunosuppressants and most commonly, HIV-infected people (Truong and Ashurst, 
2019). Immunocompetent infants infected with P. jirovecii can be asymptomatic carriers or have 
mild respiratory disease (Morris et al., 2008). 
These pathobionts and pathogens are clinically significant causes of respiratory diseases to which 
children are particularly susceptible, however the relationship between these organisms and TB 
disease in children has yet to be explored. Co-infection or colonization with other respiratory 
pathogens may influence susceptibility and possibly the severity of respiratory diseases such as 
TB. Various studies have shown the involvement, interaction and implication of respiratory 
pathogens in respiratory diseases such as pneumonia, asthma and otitis media, and even in 
suspected TB in adults (Bosch et al., 2013, 2016; Brealey et al., 2015; Mhimbira et al., 2018). 
However, less focus has been placed on the identification of respiratory pathogens in children 
with suspected PTB (Dube et al., 2016). Dube et al (2016) found that in children under the age of 
15 years (median age 36 months) presenting with PTB in South Africa, the most common bacteria 
identified were M. catarrhalis, S. pneumoniae, H. influenzae spp and Staphylococcus aureus, with 
less common bacteria identified as M. pneumoniae, B. pertussis and C. pneumoniae. The study 
also included viruses and found the most common to be metapneumovirus, rhinovirus, influenza 
virus C, adenovirus, cytomegalovirus and coronavirus O43. Both viruses and bacteria were 
identified. This study showed that multiple potential pathogens are present in the nasopharynx of 
children presenting with TB. The identification of these organisms may contribute to our 
understanding of the clinical presentation in children during suspicion of TB disease and to our 
understanding of the pathogenesis of tuberculosis disease in children. 
The aim of this chapter was to describe the presence of respiratory pathogens in respiratory 
samples from children with suspected PTB, classified as bacteriologically confirmed, clinically 




real-time Polymerase Chain reaction (PCR) assays; the Seegene Allplex™ Respiratory Panel 4 
and an “in-house” real-time PCR assay for the detection of multiple respiratory pathogens that 
are of clinical significance. In addition, we studied the associations between various risk factors 
and the carriage of respiratory pathogens.  
2.2  Materials and Methods 
2.2.1  Sample collection 
Baseline respiratory samples were obtained from children with suspected TB recruited for the 
study. The baseline samples included nasopharyngeal aspirates (NPA) and induced sputum (IS) 
samples, as outlined in Section 1.10 (Chapter 1). Samples were stored at -20°C prior to DNA 
extraction, as it was the temperature at which the samples were stored prior to receipt for our 
study. Although not ideal, samples were kept at this temperature to ensure consistency, for the 
microbiome analysis (Chapters 3-4). 
2.2.2  DNA extraction 
DNA was isolated from the NPA and IS samples using the QIAamp DNA mini kit (Qiagen, 
Netherlands) as per adaptation of the Body Fluid Protocol in the Qiagen QIAamp DNA Mini and 
Blood Mini Handbook (Addendum 1). The basic workflow of the DNA extraction procedure is 
described in Figure 2.1. Two hundred microliters of each sample was added to 20 µl Proteinase 
K and lysed with 200 µl AL lysis buffer in a microcentrifuge tube. The contents were then 
transferred to a mini spin column, where the DNA was adsorbed onto the QIAamp silica 
membrane during a brief centrifugation step. The DNA bound to the QIAamp membrane was 
washed twice to remove residual contaminants. Purified DNA was eluted in 50 µl AE buffer and 





Figure 2.1: Basic workflow of DNA extraction using the Qiagen QIAamp DNA extraction Kit. (adapted from the 
Qiagen DNA mini and Blood mini Handbook) 
200µl 




The purity (A260/A280 and A260/A230 ratios) and DNA concentration (ng/µl) of the isolated DNA 
was measured using the BioDrop µLite (Biodrop, United Kingdom). Based on the DNA yield, 
samples with a DNA concentration >50 ng/µl were diluted to approximately 50 ng/µl to avoid 
possible PCR inhibition due to high starting template nucleic acid concentrations.  
2.2.3  Seegene Allplex Respiratory Panel 4 PCR 
The Seegene Allplex™ Respiratory Panel 4 (Seegene Allplex RP4) assay is a qualitative (in vitro) 
multiplex real-time PCR assay that allows for the simultaneous amplification and detection of 
single or multiple pathogens, namely, S. pneumoniae, L. pneumophila, H. influenzae,  
B. parapertussis, B. pertussis, M. pneumoniae, C. pneumoniae, with a limit of detection of 100 
copies. 
The Seegene Allplex Respiratory Panel assays use Seegene’s proprietary technologies: Multiple 
Detection Temperature (MuDT), Tagging Oligonucleotide Cleavage Extension (TOCE), Dual 
Priming Oligonucleotides (DPO), Real Amplicon Detection (ReAD) and Annealing Control Primer 
(ACP) to enable the detection of multiple targets in a single fluorescence channel without melting 
curve analysis (Lee et al., 2015). The Seegene Allplex RP4 primarily exhibits MuDT™ based on 
multi-Ct (threshold cycle) values in a single fluorescence channel without melt curve analysis for 
the detection of multiple targets, on real-time PCR instruments. This technology is advantageous 
because it overcomes the present technology barrier of “one channel, one Ct”. TOCE utilizes 
primer oligonucleotide (DPO) pairs, pitchers and catchers which are designed to detect a specific 
DNA target (Lee et al., 2015). The real-time PCR preparation was executed as described by the 
manufacturer. Two separate master mixes were prepared. The Respiratory Panel-Bacteria 
Internal Control (RP-B IC) was included in the master mix for the samples to detect PCR inhibition, 
but not for the controls as the IC is premixed in the positive control sample (RP4 PC) and is 
excluded from the negative control where no amplification is expected. All reagents were briefly 
vortexed and centrifuged before use.  
The PCR master mix was prepared as follows for the samples (per reaction): 5 µl 5X MuDt Oligo 
Mix (RP4 MOM, primer), 5 µl 5X Anyplex PCR master mix (with UDG, premix), 2 µl RP-B Internal 
Control and 5 µl RNase-free water. Following PCR master mix preparation, 8 µl of sample nucleic 
acid was added to each of the white eight-strip low- profile PCR tubes (Biorad Laboratories, USA) 
containing an aliquot of PCR master mix. The PCR master mix for the controls was prepared in 




Positive Control (positive control) or 8 µl of RNase free water (negative control). The eight strip 
PCR tubes were sealed with optical flat eight-cap strips, as fluorescence is detected from above. 
The Seegene Allplex Respiratory Panel assay was performed on the CFX-96™ Real Time PCR 
system (CFX, Bio-Rad, United States). The CFX setup prior to running the assay is divided into 
two main steps: Step A: protocol setup where the thermal profile was set (Table 2.1) and Step B: 
plate setup where the fluorophores were selected (FAM, HEX, Cal Red 610 and Quasar 670) 
(Table 2.2); followed by the selection of plate size (96 well) and plate type (BR White).  
Table 2.1: Thermal profile setup on CFX-96™ Real Time PCR machine. (Allplex Respiratory panel 4 
(Respiratory bacteria), Cat. No. RP9803Y) 
Step No. of cycles Temperature Duration 
1 
1 
50 °C 20 min 
2 95°C 15 min 
3 
45 
95°C 10 secs 
4* 60°C 1 min 
5* 72°C 10 secs 
6 Go to step 3, 44 more times 
* Fluorescence detection. 
Table 2.2: Fluorophores used for the detection of analytes. 
 Analyte 
Fluorophore  Graph 1 Graph 2 
FAM S. pneumoniae L. pneumophila 
HEX H. influenzae B. parapertussis 
Cal Red 610 M. pneumoniae B. pertussis 
Quasar 670 Internal Control (IC)* C. pneumoniae 
*Detection of Internal Control in the Quasar 670 channel is not required for a positive result for target pathogens as a 




The quantitation data obtained from the Seegene Allplex RP4 PCR run on the CFX was exported 
using the Seegene Export tool, where folders were automatically created (QuantStep4 and 
QuantStep5) to save the amplification curve data. The Seegene Viewer for Real Time PCR 
instruments (V2.0) was used to open the exported QuantStep4 data file, followed by the selection 
of test kit (Seegene Allplex Respiratory panel 4-8 strip) from the product menu, from which the 
results could be checked for each well that was selected. A Ct value of ≤45 indicates a positive 
result and a Ct value of >45 or N/A (not detected) is considered a negative result.  
2.2.4  Pneumocystis jirovecii real time-PCR 
A real-time PCR for the detection of P. jirovecii (PCP) has previously been developed (Huang et 
al., 1999) and optimized in the Division of Medical Microbiology at Stellenbosch University  
(D. Banda, MSc 2016). This assay detects the Major Surface Glycoprotein (MSG) gene of  
P. jirovecii using the intercalating fluorescent DNA dye, SYBR Green I, and melt-curve analysis. 
Due to the large copy number, >100 copies/genome, MSG is considered an appropriate target to 
establish a sensitive method for the detection of P. jirovecii in clinical specimens (Huang et al, 
1999). 
MSG Heminested primers (Table 2.3) were used to amplify a 249 bp fragment of a highly 
conserved region of the P. jirovecii (Pneumocystis carinii) MSG gene (Huang et al,1999). The 
PCR master mix preparation was done as previously described (D. Banda 2016); 12.5 µl of 2x 
Qiagen Rotor-Gene SYBR Green I master mix, 0.5 µl (50 µM) of each primer (1 µM final 
concentration) and 9.5 µl of RNase-free H2O per reaction. Two microliters of sample nucleic acid 
was added to each reaction. Each experimental run included the pCR2.1 plasmid containing 
HUMSG14 (GenBank accession nF AF033205) and a PCP positive clinical sample (determined 
by immunofluorescence as part of routine diagnostic procedures) as positive controls and a no 
template control. 
Table 2.3: MSG Heminested primer sequences and product sizes. (Huang et al., 1999) 
Primer name Sequence 5’-3’ Product size (bp) 
JKK14/15 (upstream)  GAATGCAAATCYTTACAGAGACAACAG 
249 






Real-time PCR amplification was carried out using the Rotor-Gene Q analyzer (Qiagen) that was 
manually set to the following cycling program; an initial enzyme activation of 95ºC for 5 minutes, 
followed by 40 cycles of denaturation for 5 seconds and annealing/extension/data acquisition at 
60°C for 10 seconds. The amplified products were analyzed using melt curve analysis software 
that is programmed on the Rotor-Gene software (version 2.02.4). The Rotor-Gene software 
calculated the derivative of intensity of fluorescence (acquired to Melt A on green) where the 
derivative peak (dF/dT) represented the melting temperature value (Tm) of the MSG gene 
fragment. For the melt curve analysis the following criteria was used; the melting temperature 
ramp was set from 70-90°C rising by 0.5°C each step. The Tm value of the PCP positive plasmid 
control (84.5°C) was used to define the derivative peak bin which was set to 4°C (2°C on either 
side of the Tm). All samples with peaks which conformed to the following defined thresholds were 
considered positive: (1) dF/dT threshold of >1 and (2) derivative peak within the defined derivative 
peak bin.  
2.2.5 Clinical data collection 
Case report forms (CRF) were completed for each participant enrolled in the study. The 
information collected included social demographics, presenting symptoms, history of TB, HIV and 
TB exposure, HIV status (HIV exposed uninfected, HIV infected, HIV unexposed), concurrent 
illnesses, current and recent antibiotic treatment, clinical examination and the TB result obtained 
after intensive investigation. In addition, information on well known risk factors for respiratory 
illnesses were included; age, gender, breastfeeding (including duration), prenatal or postnatal 
exposure to smoke, mode of delivery (caesarean section (CS) or natural vaginal delivery (NVD)), 
day care attendance, household size and whether the child had siblings or not.  
2.2.6  Statistical Analysis 
Statistical analysis was done using IBM SPSS Statistics 25 software. Chi square and Fischer 
exact tests (where applicable) were done to determine the statistical significance between the 
detection of respiratory pathogens in relation to the TB and unlikely TB groups and any other risk 
factors or two-way associations. Results were considered statistically significant if the p value was 
0.05 or less. The statistical analysis was done in consultation with a biostatistics consultant from 
the Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch 
University through support from the Faculty of Medicine and Health Science’s Dean’s fund in 






From the 75 participants enrolled in the parent study between December 2015 to January 2017 
(Chapter1, Section 1.10), 72 baseline respiratory samples were received for this sub-study, these 
included NPA (n= 68) and IS samples (n=4). Three participants refused sample collection or 
withdrew from the study. Of the 72 participants from whom samples were obtained, 42 were 
defined as TB cases (58.3%), based on either bacteriological confirmation (19/42, 45.2%) or 
clinical diagnosis (23/42, 54.8%). The remaining 30 (41.7%) participants were defined as well-
defined ill controls (unlikely TB). There were no statistically significant differences between the 
demographics of the different groups. The demographic details are described in Table 2.4. Of the 
participants, 18.6% (13/70) were HIV-infected of whom 15.3% (2/13) had bacteriologically 
confirmed PTB, 53.8% (7/13) were clinically diagnosed with PTB and 30.8% (4/13) did not have 
PTB. Two of the 72 baseline samples were excluded due to insufficient sample for DNA extraction. 
Both samples were from the unlikely TB control group.  
The median age of participants was 21.5 months (interquartile range (IQR), 9-45 months).  
Fifty-six percent (39/70) of the participants were under the age of two, 30% (21/70) were 2-5 years 
of age and 14% (10/70) were over the age of 5 years. 55.7% (39/70) of participants included in 
this study were male of which 53.8% (21/39) were cases (Table 2.4). Table 2.4 describes 




















70 (100) 19 (27.1) 23 (32.9) 28 (40.0) 
Age in months1 
(median, IQR)  
21.5 (36) 21.5 (39) 24 (38.5) 21.5(39)  
Sex2         
Male 39 (55.7) 9 (47.4) 12 (52.2) 18 (64.3) 
Female 31 (44.3) 10 (52.6) 11 (47.8) 10 (35.7) 
TB treatment2     
Yes   42 (60) 19 (100) 23 (100) N/A 
Multi Drug Resistant 4 (9.5) 3 (15.8) 1 (4.3) N/A 
HIV status2           
Yes 13 (18.6) 2 (10.5) 7 (30.4) 4 (14.3) 
No 54 (77.1) 15(78.9) 16 (69.6) 23 (82.1) 
Unknown 3 (4.3) 2 (10.5) 0 (0) 1 (3.6) 
HIV Exposure2     
Yes 15 (21.4) 4 (21.1) 6 (26.1) 5 (17.9) 
No 53 (75.7) 15 (78.9) 15 (65.2) 23 (82.1) 
Unknown 2 (2.9) 0 (0) 2 (8.7) 0 (0) 
HIV Infected2     
Yes  13 (18.6) 2 (10.5) 7 (30.4) 4 (14.3) 
No 57 (81.4) 17 (89.5) 16 (69.6) 24 (85.7) 
Smoking exposure 
(prenatal)2 
        
Yes 26 (37.1) 7 (36.8) 10 (43.5) 9 (32.1) 
No 26 (37.1) 6 (31.6) 10 (43.5) 10 (35.7) 
Unknown 18 (25.7) 6 (31.6) 3 (13) 9 (32.1) 
Mode of Delivery2     
Normal Vaginal Delivery 54 (77.1) 15 (78.9) 17 (73.9) 22 (78.6) 
Caesarean Section 14 (20) 4 (21.1) 4 (17.4) 6 (21.4) 
Unknown 2 (2.9) 0 (0) 2 (8.7) 0 (0) 
Breast fed2         
Yes 58 (82.9) 16 (84.2) 21 (91.3) 21 (75) 
No 11 (15.7) 3 (15.8) 2 (8.7) 6 (21.4) 
Unknown 1 (1.4) 0 (0) 0 (0) 1 (3.6) 
Length of 
breastfeeding2 
        
0-4 months 28 (40) 8 (42.1) 10 (43.5) 10 (35.7) 
5-10 months 18 (25.7) 5 (26.3) 4 (17.4) 9 (32.2) 
>10 months 8 (11.4) 2 (10.5) 3 (13) 3 (10.7) 
Unknown 16 (22.9) 4 (21.1) 6 (26.1) 6 (21.4) 
Day Care Attendance2         
Yes 25 (35.7) 4 (21.1) 10 (43.5) 11 (39.3) 
Siblings2         
Yes 55 (78.6) 14 (73.7) 17 (73.9) 24 (85.7) 
1 Continuous data is expressed as a median with interquartile range (IQR) in between brackets. 2 Proportions are expressed 





2.3.1  Pathogen detection  
The Seegene Allplex RP4 kit was used to detect the presence of seven clinically significant 
bacterial pathogens in the 70 respiratory samples. Valid results were obtained for all of the 
samples based on the detection of the RP-B internal control with or without detection of other 
bacterial pathogens. The in-house real-time PCR targeting the Major Surface Glycoprotein (MSG) 
gene was used to detect P. jirovecii in the 70 respiratory samples. Based on the thresholds 
defined in section 2.2.4, the MSG gene was only detected in the positive control samples (Figure 
2.2).  
 
Figure 2.1: Representative P. jirovecii melt curve. The yellow and brown melt peaks represent the PCP 
plasmid positive control and PCP positive control sample respectively, while no peaks were obtained for 
any of the respiratory samples obtained from the participants in this study. 
The most frequently detected pathogens were H. influenzae and S. pneumoniae which were 
detected in 74.2% (52/70) and 60% (42/70) of the samples, respectively. The bacterial pathogens, 
C. pneumoniae (8/70; 11.4%), M. pneumoniae (4/70; 5.7%) and B. parapertussis (1/70; 1.4%) 
were less common, while L. pneumophila, B. pertussis and P. jirovecii (fungal pathogen) were not 






Figure 2.2: The percentage of samples (n=70) in which pathogens were detected 
Similar trends in the frequencies of the various pathogens were seen in the TB cases 
(bacteriologically confirmed and clinically diagnosed) and the unlikely PTB group (Figure 2.4). 
There was no significant difference between the presence of S. pneumoniae or H. influenza in 
the TB cases and unlikely TB groups (p=0.921 and 0.655 respectively). H. influenzae was 
detected 74.3% (52/70) of samples; 76.2% (32/42) in the TB group and 71.4% (20/ 28) in the 
unlikely TB group (p=0.655). S. pneumoniae was detected in 60% (42/70) of samples; 59.5% 
(25/42) in the TB group and 60.7% (17/28) in the unlikely TB control group (p=0.921).  
C. pneumoniae was most frequently detected in the unlikely TB group, while M. pneumonia was 
more common amongst the TB cases, however the low numbers of positive samples precluded 
statistical analysis. B. parapertussis was detected in a single sample from a bacteriologically 






















Figure 2.3: Pathogens detected in defined participant categories 
In 88.6% (62/70) of samples at least one respiratory pathogen was detected, with two or three 
bacterial pathogens detected in the majority of samples (57.1%, n=40/70) (Table 2.5). There was 
no significant difference between the number of pathogens detected in the TB and unlikely TB 





























































Table 2.5: The number of bacteria detected in the TB and unlikely TB groups. 
H. influenzae was detected alone in 15/70 samples (21.4%), while S. pneumoniae (6/70, 8.6%) 
and C. pneumoniae (1/70, 1.4%) were less commonly detected alone. H. influenzae and  
S. pneumoniae was the most frequently detected bacterial pathogen pair, present in 29/70 
(41.4%) samples, while H. influenzae and C. pneumoniae (2/70, 2.9%), S. pneumoniae and  
C. pneumoniae (2/70, 2.9%) and H. influenzae and M. pneumoniae (1/70, 1.4%) were less 
commonly detected. In samples where three bacteria were detected, both H. influenzae and  
S. pneumoniae were identified with either C. pneumoniae (2/70, 2.9%), M. pneumoniae (2/70, 
2.9%) or B. parapertussis (1/ 70, 1.4%). There were no differences between confirmed and 
clinically diagnosed cases.  
2.3.2 Evaluation of risk factors for the presence of respiratory pathogens 
The presence of bacterial pathogens in relation to multiple risk factors was evaluated using 
univariable analysis. Due to the small sample size, no multivariable analysis was performed. 
Normal vaginal delivery (NVD) was associated increased risk for the presence of bacterial 
pathogens, in comparison to caesarean section delivery (p=0.006), while any breastfeeding was 
associated with a reduced risk for the presence of bacterial pathogens (p=0.01). However, no 
statistically significant association was observed between length of breastfeeding and the 
presence of bacterial pathogens (p=0.29).  
A trend toward significance was observed for both smoking exposure and day care attendance 
as risk factors for the presence of bacterial pathogens (p=0.17 and 0.145, respectively) (Table 
2.6). Gender, age, having siblings and HIV infection were not associated with the presence of 
bacterial pathogens (Table 2.6). 
























None 4 (9.5) 4 (14.3) 8 
0.553 
One 15 (35.7) 7 (25) 22 
Two 19 (45.2) 16 (57.1) 35 
Three 4 (9.5) 1 (3.6) 5 




Table 2.6: Risk factors for the presence of bacterial pathogens. 
Risk factor  Total population 
 (n = 70) 
No bacterial 
pathogen detected  
One or more bacterial pathogen 
detected  
p-value 
Mode of delivery1    
0.006* 
C/S 14 5 (35.7) 9 (64.3) 
NVD 54 3 (5.6) 51 (94.4) 
Unknown 2 0 (0) 2 (100) 
Breastfeeding  
(any length of time)1 
   
0.01* No  11 0 (0) 11 (100) 
Yes 58 7 (12.1) 51 (87.9) 
unknown 1 1 (100) 0 (0) 
Length of 
breastfeeding1 
   
0.29 
0-4 months  28 4 (14.3) 24 (85.7) 
5-10 months 18 2 (11.1) 16 (88.9) 
>10 months 8 2 (25) 6 (75) 
Unknown  16 0 (0) 16 (100) 
Prenatal smoke 
exposure1  
   
0.17 No 26 3 (11.5) 23 (88.5) 
Yes  26 1 (3.8) 25 (96.2) 
Unknown  18 4 (22.2) 14 (77.8) 
Attended day care1    
0.145 
Yes  25 1 (4) 24 (96.0) 
Siblings1    
0.239 




Table 2.6: Continued: Risk factors for the presence of bacterial pathogens 
Risk factor percentages calculated as row percentages in brackets. * Statistically significant result (Chi-square).
Age1    
0.65 <2 years  39 4 (10.3) 35 (89.7) 
2-5 years  21 2 (9.5) 19 (90.5) 
> 5 years 10 2 (20) 8 (80)  
Gender (male)1    
0.681 Male  39 5 (12.8) 34 (87.2) 
Female  31 3 (9.7) 28 (90.3) 
HIV infected1    
0.461 Yes  13 2 (15.3) 11 (84.6) 




2.4  Discussion 
Detection of pathobionts and pathogens  
Of the seven bacterial species that can be detected using the Seegene assay only  
H. influenzae, S. pneumoniae, M. pneumoniae, C. pneumoniae and B. parapertussis were 
detected, and the fungal pathogen P. jirovecii was not detected in any of the respiratory samples. 
There was a high burden of respiratory pathogens in children suspected of PTB, of which  
H. influenzae (74.4%) and S. pneumoniae (60%) were the most commonly detected. The 
presence of H. influenzae and S. pneumoniae is not surprising as they are among the frequent 
colonizers of the nasopharynx and are often identified in respiratory samples. Moreover, studies 
have found that acquisition and colonization by H. influenzae and S. pneumoniae (among others) 
can occur as early as a few days to a few months after birth (García-Rodríguez and Fresnadillo 
Martínez, 2002). Another study conducted in Cape Town also found that S. pneumoniae and  
H. influenzae were commonly detected in children with suspected PTB (Dube et al., 2016), 
however H. influenzae was more frequently detected in our study (74.4% vs 29% in their study), 
and S. pneumoniae was more frequently detected in their study (42%). This may be a result of 
the age group (±36 months versus ± 22 months in our study), the type of DNA extraction that was 
conducted, the type of kit used for the detection of nucleic acid targets (FTD resp33 Kit, Fast-
track Diagnostics, Luxembourg vs Seegene Allplex Respiratory Panel 4 in our study) or the 
specific sample type that was used (NP swabs versus NPAs in our study).  
The other respiratory pathogens, M. pneumoniae, C. pneumoniae and B. parapertussis, were less 
frequently detected in the respiratory samples. Generally, the detection of these pathogens in 
respiratory samples is associated with cases of infection and disease, rather than colonization. 
Both M. pneumoniae and C. pneumoniae are atypical pathogens that can cause disease ranging 
from mild to severe acute respiratory infections. They are also pathogens that are more frequently 
seen in older children (Principi et al., 2001). The clinical manifestation of disease ranges from 
tracheolobronchitis to atypical pneumonia followed by extrapulmonary complication and from 
pharyngitis, bronchitis and sinusitis to community acquired pneumonia (CAP), respectively (Del 
Valle-Mendoza et al., 2017). Both M. pneumoniae and C. pneumoniae are important causes of 
atypical CAP, but C. pneumoniae has been identified as a more frequent cause, that is often 




B. parapertussis was only detected in 1 sample. It’s involvement in respiratory disease has been 
linked to the less severe form of whooping cough. The incidence of infections caused by  
B. parapertussis is not well known. Liko et al (2017) established that this is due to laboratories 
not distinguishing between Bordetella species and B. parapertussis either not being reported or 
being misreported as B. pertussis, while another study suggested that it is neglected because of 
its lower incidence and milder symptoms and its similarities with B. pertussis (Elahi et al., 2008). 
One study suggested that it may even be as common as B. pertussis, especially in children who 
have yet to attend school (He, 1998). Despite this, studies have reported that this pathogen can 
cause up to 20-30% of cases of whooping cough (Elahi et al., 2008) which indicates that it might 
become a serious health problem. 
B. pertussis and L. pneumophila were not detected in any of the samples. Numerous studies have 
successully used nasopharyngeal samples for the detection of B. pertussis by PCR. Protection 
against B. pertussis infection is possible through vaccination which may explain why the 
participants in this study were negative. Although the samples used in this study were negative 
for B. pertussis, this pathogen is still not under control in any country and represents the most 
prevalent vaccine-preventable childhood disease (Locht, 2016). This was evident in the study 
conducted by Dube et al (2016) where B. pertussis was found to be fairly common (12/214, 6%) 
in children, which could imply that the detection of this pathogen in our study could also be limited 
by the small sample size (sample size of 70 vs 214). The type of clinical specimen also influences 
the detection of a particular pathogen. A study that investigated the diagnosis and incidence of 
pertussis in children found that induced sputum samples had a higher sensitivity for the diagnosis 
of Bordetella spp, where they identified more confirmed cases on IS samples than on NP 
specimens (Rudzani Muloiwa; Felix S. Dube; Mark P. Nicol; Heather J. Zar; Gregory D. Hussey, 
2016). 
L. pneumophila causes CAP but is one of the less frequently involved pathogens and contributes 
to approximately 8% of CAP in South Africa. Individuals in this study may be negative because 
those at higher risk of infection are persons over the age of 50. Additionally, unlike the other 
respiratory pathogens in this study, human to human transmission of  
L. pneumophila has not been reported and one usually becomes infected as a result of exposure 
to contaminated water droplets (NICD, 2016). The presence or absence of this bacterium in 
respiratory samples would therefore provide insight into the efficacy of water management 
systems that are currently in place in certain communities. Perhaps in other regions where water 




P. jirovecii was included in this study as it is a clinically significant pathogen. Pneumocystis 
pneumonia is mostly identified in HIV infected individuals, and HIV is a major driver of TB in South 
Africa, thus the reason for the inclusion. Additionally, it has been reported that HIV uninfected 
infants with underlying predisposing factors such as HIV exposure and malnutrition are also 
susceptible to pneumocystis pneumonia (McNally et al., 2007; Morrow et al., 2010). Lower 
respiratory tract samples such as bronchoalveolar lavage or induced sputum are predominantly 
used for the detection of P. jirovecii during standard laboratory diagnosis (Samuel et al., 2011). 
However, in children, obtaining these specimens can be challenging as invasive collection is not 
well tolerated. Therefore, upper respiratory tract specimens (nasopharygeal aspirates) which are 
easier to obtain have been used in combination with PCR for the detection of P. jirovecci in 
children. PCR has been shown to be more senstive than the standard diagnostic measures in 
both upper and lower respiratory samples (Samuel et al., 2011). This allows more desirable 
clinical specimen in children and improves on the overall turnaround time for diagnosis . 
Of the participants in this study, 18.6% were HIV-infected, however none of the participants in 
this study were positive for this fungal pathogen. Studies have found that PCR sensitivity is 
dependent on the type and nature of the specimen, the degree of immunosuppresion in infected 
individuals and the gene targets used (mtLSU rRNA, ITS locus, MSG) (Olsson et al., 1993; Gupta 
et al., 2009). However, the use of the MSG gene has previously been shown to be useful for the 
detection of P. jirovecii in upper respiratory tract samples (NPA) from children <14 years, in Cape 
Town (Samuel et al., 2011). The main differences between their study and our study is the use of 
a different DNA extraction kit (Nuclisense Easy Mag) and the use of fluoresence resonance 
energy transfer probes in a qualitative touchdown PCR. In agreement with the present study, 
Gupta et al (2009) detected no P. jirovecii in NPA samples when using MSG, mtLSU or ITS as 
gene targets. Although different factors can contribute to the detection of P. jirovecii in samples, 
the use of antimicrobial agents such as co-trimoxazole could also be a factor to consider. This 
antimicrobial agent has contributed to the decline of Pneumocystis pneumonia since its use as a 
prophylaxis against Pneumocystis pneumonia in HIV exposed infants (Zar, 2010). However, the 
use of co-trimoxazole in this study population was not determined and therefore the statement 
may or may not be a valid reason for the decline in the detection of P. jirovecii in the participants, 




The detection of no pathogens in a few of the samples (n=8,11.4 %), may be that the samples 
did not have the specific pathogens present or that these samples contained other respiratory 
pathogens, including viruses and other fungi which are not detected by the tests used in this 
study. Microorganisms within a specific niche such as the nasopharynx can include numerous 
other commensals or pathobionts (potential pathogens) that all interact with one another.  
Bosch et al (2013) suggested that microbes have developed various interaction tools that lead to 
positive and negative interactions, where positive associations generate favorable conditions for 
microorganisms via mutualism, commensalism, symbiosis or the assistance with immune 
evasion. On the other hand, negative associations may be a result of interspecies interactions, 
where there is direct competition between organisms for a specific niche, or when the hosts 
immune response disproportionally affects a competing organism. In this study negative 
associations between microorganisms could have resulted in the loss of certain organisms in the 
participants (Bosch et al., 2013). Additionally, Rodriguez et al (2002) reported that viridans 
streptococci can antagonize colonization by other streptococci, such as α-haemolytic 
streptococci, which can inhibit the growth of S. pneumoniae, H. influenzae and M. catarrhalis. Of 
those samples that were negative for all pathogens, one was an ill-control, which could imply that 
other respiratory organisms may have influenced the clinical presentation and brought about the 
suspicion of disease. More so, antibiotics majorly influence the presence of commensals and 
pathogens. Participants in this group were on antibiotics which may have contributed to the loss 
of these pathogens, although the use of antibiotics was not taken into consideration when the 
analysis was done. 
The detection of pathogens in relation to TB  
No associations could be made between the absence or presence of one or more respiratory 
pathogens and TB disease. This may be due to the fact that all participants in this study were ill 
and may have been exposed to antibiotic treatment, or that a healthy control group was not 
included.  
Similar trends in the detection of various pathogens were seen in TB cases (bacteriologically 
confirmed and clinically diagnosed) and unlikely TB groups with no significant difference between 
the most prevalent organisms (S. pneumoniae and H. influenzae) and the defined categories. The 
detection of C. pneumoniae was equally distributed in both categories (unlikely-TB control group 
and TB cases), while M. pneumoniae appeared to be more common among the TB cases. 
However, the small sample size precluded statistical analysis and therefore warrants the need for 




population and more robust statistical analysis. The information obtained from a larger study 
would be more informative as it would provide a more accurate representation of the community 
and the defined categories.  
The detected pathogens such as C. pneumoniae and M. pneumoniae in the unlikely TB group 
may have contributed to respiratory disease in these children. However, whether these pathogens 
caused disease in these patients should be further evaluated as the detection of pathogens does 
not necessarily imply infection and could represent asymptomatic colonization. A method that 
could assist in differentiating between infection vs asymptomatic colonization is quantitative PCR 
as it can be used simultaneously to detect and quantify the pathogen and pathogen load, 
respectively. Studies have shown that quantitative PCR can assist in diagnosis and determining 
disease severity during viral or bacterial respiratory infections from nasopharyngeal or sputum 
samples (Borg et al., 2003; Gadsby et al., 2015). A challenge with this may be determining 
appropriate cutoff values to differentiate between infection vs asymptomatic colonization. 
Furthermore, it should be recognized that the nasopharynx is a complex niche that is constantly 
exposed to different pathogens, including viruses which are common pathogens in respiratory 
diseases in children and are therefore vital to explore. Bosch et al (2013) reviewed numerous 
studies and summarized how the presence of viruses can influence bacterial colonization, (1) 
through predisposing bacterial adherence as a result of an altered mucosal surface, (2) disrupting 
the first line of defense of the respiratory tract; the epithelium barrier, (3) the upregulation of 
adhesion proteins which alters the hosts defense mechanism, (4) the production of viral factors 
such as neuraminidase which allows bacteria to enter host cells and (5) impairing the hosts 
immune system components (Bosch et al., 2013). It would be interesting to determine whether 
viruses or viral-bacterial co-infections contributed to the clinical suspicion of respiratory disease 
and what type of viral-bacterial interactions exist (if any) in these children.  
The number of bacteria detected in the TB and ill control group were found to not be statistically 
different. The detection of most of the atypical pathogens (C. pneumoniae, M. pneumoniae B. 
parapertussis) in the TB group could suggest that the atypical pathogens identified may have 
contributed to the clinical presentation or symptoms and possibly allowed for the early detection 
of TB. However, the association between the presence of atypical pathogens and the clinical 
presentation and/ or symptoms was not determined because only a few positive samples were 
identified and would not be sufficient for analysis.  
Not many atypical pathogens were identified in the ill control group which may indicate that the 




such as viruses. Considering other respiratory pathogens may be more informative in determining 
if respiratory pathogens influenced the suspicion of TB in the ill control group, especially since 
lower respiratory tract infections in children are believed to be polymicrobial in nature. At this point 
investigation of the relationship between bacterial pathogens and clinical presentation or 
suspicion of TB was limited by sample size, the lack of healthy controls and the limited bacterial 
pathogens that could be detected with the Seegene Allplex RP4 assay. The detection of viruses 
in these samples is currently being conducted and has yet to be compiled with the bacteriological 
findings in this study, which may provide insight into the interactions between the bacteria and 
viruses in the TB case group in addition to providing insight into what contributed to the initial 
suspicion of PTB in the control group. 
Mhimbira et al (2018) conducted a study that investigated the clinical signficance of bacteria and 
viruses in adult TB participants and household contacts, and found that TB patients had a lower 
prevalence of bacterial pathogens than the controls. Our findings were contradictory in that the 
TB group had more bacteria present than the ill control group (although not significant).This may 
be because our study focused on children, and respiratory pathogens in the nasopharynx differ 
between adults and children as it is in a constant state of flux as bacteria are acquired and 
eliminated or reacquired throughout life. Additionally, Mhimbira et al (2018) found that TB patients 
were more likely to have severe TB when they were co-infected with both viruses and bacteria, 
which raises the importance of including viruses in this study and also the signifcance of 
polymicrobial disease. 
There are limited studies which have investigated the role of respiratory pathogens in children 
with PTB. The study from Dube and colleagues found no clear association between TB 
categorisation and the detection of specific pathogens but did see a dominant microbial profile in 
children with PTB that consisted of C. pneumoniae, hMPV, coronavirus O43, influenza C virus, 
rhinovirus and cytomegalovirus, which failed to reach statistical significance. Whereas in those 
without TB, P. jirovecii, H. influenzae spp, RSV, M. pneumoniae, influenza B virus and 
enteroviruses were more consistently detected (Dube et al., 2016). 
Evaluation of risk factors 
Various risk factors for the presence of bacterial pathogens were investigated. The presence of 
bacterial pathogens was negatively associated with being breastfed, although length of 
breastfeeding did not affect this correlation. Normal vaginal birth was associated with increased 
risk for the presence of bacterial pathogens. However, it should be mentioned that these findings 




less than 5 and therefore these results should be interpreted with caution, and may be attributed 
to the small sample size. 
Studies have hypothesized that breastfeeding offers a protective effect for respiratory tract 
infections. Biesbroek et al (2014) was one of the first to describe a correlation between infant 
feeding and microbial composition of the upper respiratory tract, where it was suggested that 
lactic acid bacteria may contribute to the protective effect of breastfeeding against respiratory 
infections. However, other studies have found that breastfeeding doesn’t substantially influence 
nasopharyngeal colonization with respiratory pathogens (Kaleida et al., 1991; Bakhshaee et al., 
2015). The duration of breastfeeding has been shown to reduce the risk of respiratory tract 
infections when breastfed for 6 months and longer (Tromp et al., 2017; Wang et al., 2017), 
however this was not observed in our study, possibly due to the small sample size. 
Mode of delivery can influence nasopharyngeal microorganisms by favouring the development of 
potentially protective or negative microorganisms (Esposito and Principi, 2018). This is important 
as early microbial composition has been shown to influence respiratory health in children 
(Biesbroek, Tsivtsivadze, Elisabeth A M Sanders, et al., 2014). Microbiome studies found that 
children delivered by natural vaginal birth acquire microorganisms resembling their mothers 
vaginal microbiota, where those born via C-section harbor bacterial communities similar to those 
found on the skin surface (Dominguez-Bello et al., 2010).  
Numerous factors can influence nasopharyngeal carriage rates in children, ranging from age to 
sleeping position (García-Rodríguez and Fresnadillo Martínez, 2002). In this study no significant 
associations were detected for the remaining risk factors, although associations between prenatal 
smoke exposure and day care, and presence of bacterial pathogens showed a trend towards 
significance. A study conducted in Russian children found that both prenatal smoke exposure and 
postnatal environmental smoke exposure have adverse effects on respiratory health which 
increases the risk of respiratory illnesses such as asthma, bronchiolitis and respiratory infections 
(Jaakkola et al., 2006). The increased risk for respiratory illness may be due to an increase in 
susceptibility to viral and bacterial colonization as a result of damaged and inflamed 
nasopharyngeal mucosa (García-Rodríguez and Fresnadillo Martínez, 2002). Day care centers 
provide the perfect environment for pathogen exposure and transmission due to the frequent 
close person to person contact. This is similar in children with siblings who are also more likely to 
be any bacteria positive in comparison to those who did not have siblings (García-Rodríguez and 
Fresnadillo Martínez, 2002). HIV infection did not seem to influence the presence of pathogens 





Pulmonary TB is a well-studied disease; however, little is known about respiratory co-infections 
and their role in TB disease. Due to the fact that respiratory pathogens play a huge role in overall 
respiratory health, only a few studies have looked at respiratory pathogens in relation to TB 
disease in adults (Lockman et al., 2003; Mhimbira et al., 2018), but less so in children  
(Dube et al., 2016). This chapter investigated associations between the presence of respiratory 
pathogens (and pathobionts) in children with suspected PTB, by detecting a variety of respiratory 
pathogens in children categorized as TB cases and children with unlikely TB.  
This pilot study found no association between the presence of respiratory pathogens (and 
pathobionts) in the nasopharynx and the defined TB categories (bacteriologically confirmed PTB, 
clinically diagnosed PTB and unlikely PTB cases). This may be due to the limited sample size, 
the limited respiratory pathogens that could be detected with the techniques used, and the fact 
that children with other respiratory illnesses were used as control group or the involvement of 
other respiratory pathogens such as viruses. Further studies describing the nasopharyngeal 
microbiota in the same population are described in Chapter 4 to determine whether microbial 






The description of the respiratory microbiome using 16S rRNA gene 
sequencing  
3.1 Introduction 
In 2007, the Human Microbiome Project (HMP) initiated multiple projects that aimed to fulfill 
various goals, namely (1) to use improved sequencing technology to characterize the microbiome 
of multiple body sites (the gastrointestinal tract, vagina, mouth, skin and nasal cavity), (2) to 
determine whether associations exist between the microbiome and health or disease in different 
medical conditions, and (3) to provide both a standardized data resource and new technological 
approaches to allow microbiome studies to be broadly undertaken in the scientific community 
(The NIH HMP Working Group, 2009). Since then, numerous microbiome studies have been done 
on multiple body sites describing marked differences between the microbiome in healthy and 
diseased states, using different technological approaches. More so, the microbiome has since 
been dubbed the human health biomarker as it aids in maintaining normal host physiology, 
developing and educating the immune system, metabolizing complex substrates and providing 
crucial protection against opportunistic pathogens (Shukla et al., 2017). 
Traditionally, microscopy and culture-based techniques were used to study and differentiate 
microorganisms, but it was soon realized that these techniques provided a limited scope of the 
vast microbial world. The introduction of molecular approaches in diagnostic laboratories 
improved on the turnaround time, specificity and sensitivity for the identification and 
characterization of medically relevant microorganisms that were usually not identifiable with 
traditional culture techniques (i.e. phenotypic identification). This included fastidious, non-viable, 
slow growing and non-cultivable organisms (Shilts et al., 2016). Conventional molecular 
techniques such as denaturing gradient gel electrophoresis, terminal restriction fragment length 
polymorphism and fluorescent in situ hybridization are nucleic acid based techniques which were 
commonly used to study bacterial communities and diversity before the introduction of high 
throughput sequencing technologies (Case et al., 2007). High throughput sequencing such as 
next-generation sequencing (NGS) has revolutionized the study of microbial communities as a 
result of its ability to generate a comprehensive catalogue of microbial sequences present in 
different ecological niches within a large host organism such as humans (Martín et al., 2014). 
With the advent of and improvement in sequencing technologies, characterizing microbial 




Illumina sequencing technologies, which with its reduced costs, comparatively high sequencing 
depth (Klindworth et al., 2013) and increase in sequencing length, has become the most widely 
used sequencing platform (Ravi, Walton and Khosroheidari, 2018).  
The 16S ribosomal ribonucleic acid (rRNA) gene has become the most commonly used genetic 
marker to study bacterial phylogeny and taxonomy. This may be attributed to its presence in all 
bacteria, the fact that 16S rRNA functionality has not changed over the years suggesting that 
random sequence changes are a more accurate measure of time, and its size: the 16S rRNA 
gene is large enough (1500 bp) for informatics purposes (Janda and Abbott, 2007). The full-length 
16S rRNA gene can be used for accurate taxonomic identification; however, due to cost 
constraints and limitations of NGS technology, one or a few of the 9 hypervariable regions are 
usually targeted. Amplicon based studies depend on the annealing of amplification primers to 
conserved regions that flank the variable regions (V1-V9) of the 16S rRNA gene (Myer et al., 
2016). Once the 16S rRNA gene or variable region is amplified the amplicon sequences are 
assessed qualitatively and highly similar sequences are clustered into operational taxonomic units 
(OTUs), which are then aligned against standard reference database, such as Greengenes 
(McDonald et al., 2012), SILVA (Yilmaz et al., 2014) or Ribosomal Database Project (RDP) (Cole 
et al., 2014). This is attained through various bioinformatic pipelines for example, mothur (Schloss 
et al., 2009), QIIME (Caporaso et al., 2010) or UCHIME (Edgar et al., 2011). Potentially, OTUs 
may be classified to the species level, where others may only be classified up to genus or family 
level, due to the “varying resolution in sequencing reads of specific regions of the 16S rRNA gene 
used for distinguishing different types of bacteria” (Shukla et al., 2017). The OTUs can then be 
analyzed in terms of presence or absence, (relative) abundance or phylogenetic diversity 
(Morgan, Segata and Huttenhower, 2013).  
The purpose of this chapter is to describe and assess the technical approach used to analyze the 
respiratory microbiome in children with and without PTB, as well as to describe the challenges of 
microbiome sequencing in resource limited settings. These results were used to achieve the aims 





3.2 Materials and Methods:  
16S rRNA gene sequencing was performed on the baseline and two- and six-month follow-up 
respiratory samples from children with drug susceptible TB and well-defined ill controls to describe 
the respiratory microbiomes in these population groups. The wet and dry laboratory workflow 
utilised for the 16S rRNA microbiome sequencing and analysis is outlined in Figure 3.1. 
 
Figure 3:1: Wet and dry laboratory workflow for 16S library preparation, sequencing and analysis (Adapted 

















PCR Clean-Up (2) 
(section 3.2.3.2)



















3.2.1 Sample selection 
For the microbiome pilot study, nasopharyngeal aspirate (NPA) and induced sputum (IS) samples 
were obtained from study participants at baseline and follow-up visits at months two and six after 
enrolment or start of TB treatment, as described in Chapter 1, section 1.10. Twenty-six 
participants were selected for the microbiome analysis based on the availability of baseline, month 
two and month six follow up samples. NIH 2015 case definitions were used retrospectively to 
classify children in the diagnostic categories; confirmed TB cases, unconfirmed TB cases and 
unlikely TB cases. The confirmed TB cases were bacteriologically confirmed by culture or 
GeneXpert MTB/ Rif on one or more respiratory samples. The unconfirmed TB cases were not 
bacteriological confirmed and had to have at least 2 of the following: 1) Well defined symptoms 
and signs suggestive of TB); 2) Chest radiograph consistent with tuberculosis (dual read by 
experts); 3) Close tuberculosis exposure or immunologic evidence of M. tuberculosis infection; 4) 
Positive response to tuberculosis treatment (requires documented positive clinical response on 
tuberculosis treatment). In the unlikely TB cases (well-defined ill controls), TB was ruled out after 
intensive TB investigation and careful clinical follow-up (Graham et al, 2015). To be consistent 
with the terminology used in this study, the term clinically diagnosed was used for the unconfirmed 
TB cases. All but one had all three NPAs available (Figure 3.2).  
 
Figure 3.2: The breakdown of preselected samples for the microbiome analysis. TB cases; NIH 2015 



















3.2.2 DNA Extraction  
DNA was extracted from the respiratory samples using the QIAamp DNA mini kit (Qiagen, 
Netherlands) and the purity and DNA yield was measured using the BioDrop µLite (BioDrop, 
United Kingdom) as described in Chapter 2, section 2.2.2.  
The extracted DNA was diluted to 20 ng/µl in 10 mM Tris pH 8.5 (Inqaba Biotechnical Industries 
(pty) Ldt.) and 2 µl of each diluted DNA sample was sent for Qubit analysis at the Central 
Analytical Facility, Stellenbosch University. The concentration was determined using the Qubit™ 
1X dsDNA HS (high sensitivity) Assay Kit (Thermo Fischer Scientific) on the Qubit™ 4 
Fluorometer. Qubit analysis is a fluorometric quantification method that uses double stranded 
DNA (dsDNA) binding dyes to select for dsDNA (over RNA) and accurately quantifies DNA in the 
range of 10 pg/µl to 100 ng/µl. Based on the Qubit results the DNA samples were further diluted 
with 10 mM Tris pH 8.5 to 10 ng/µl to ensure that all DNA samples were of similar concentration 
and to minimise possible PCR inhibitors. The diluted DNA was stored in low DNA binding 0.2 ml 
PCR tubes at -20°C.  
The purity and DNA yield were measured using the BioDrop µLite after diluting the DNA to  
10 ng/µl. The DNA purity was assessed according to standard DNA purity absorbance ratios at 
A260/A230 (DNA=2.0-2.2) and A260/A280 (DNA=~1.8-2.0).  
Sequencing controls 
Several controls were included to assess for contamination that could have been introduced 
during the sample preparation (example: viral transport medium) or during DNA extraction 
(example: elution buffer) for each of the kits that was used (Table 3.1). The storage medium and 
negative controls were spiked with DNA from a known bacterium (Serratia spp.) at a concentration 
representative of the biological samples (10 ng/µl). This was done so that possible contaminants 
present in the controls would not be overamplified during PCR i.e. spiking the controls allows the 
“competing DNA” from a known bacterium to reduce the over amplification of contaminants. 
Serratia spp. was chosen as it was not expected to be a contaminant in the no-template controls 
and unlikely to be observed in the samples. Four separate QIAamp DNA mini kits were used for 
DNA extraction and therefore a sample storage control (Elution Buffer) and a negative extraction 
control (NEC) were included for each DNA extraction kit. In addition, an internal sequencing 
control (PhiX) was included (and is further described in section 3.2.4.8). All mock control, negative 
control and clinical samples were prepared in the student research laboratory and the non-
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The bacterial strains used for the preparation of the mock and spiked controls were obtained from 
the National Health Laboratory Service diagnostic laboratory at Tygerberg Hospital. DNA from a 
Serratia spp clinical isolate was used for the spiked controls and Staphylococcus aureus (ATCC 
BA 1026), Klebsiella pneumoniae (ATCC BAA 1706), Escherichia coli (ATCC 25922), 
Enterococcus faecalis (ATCC 51299) and Pseudomonas aeruginosa (ATCC 27953) were used 
for the mock controls (Table 3.1). DNA was extracted from individual pure cultures using the 
Qiagen QIAamp DNA mini kit using the protocols for Gram-negative and Gram-positive bacterial 
plate cultures as per the manufacturer’s instructions. The purified DNA was eluted in 50µl AE 
buffer and stored at -20°C until further use. 
3.2.3  16S rRNA library preparation 
The library preparation was performed as described in the Illumina 16S Metagenomic Sequencing 
Library preparation protocol (Addendum 2) with only minor modifications, as described in the 
following sections. The basic 16S Library preparation workflow is included in Figure 3.1. The 16S 
rRNA gene amplification and sequencing was done using the next generation sequencing Illumina 
Miseq™ (California, USA) platform at the Institute for Microbial Biotechnology and Metagenomics, 
Department of Biotechnology, University of the Western Cape.  
3.2.3.1 16S rRNA Amplicon Polymerase Chain Reaction (PCR) 
The 16S rRNA amplicon PCR was performed using modified primers, 515F_short and 
805R_short (Claassen-Weitz et al., 2018) (Table 3.2), targeting the V4 hypervariable region of 
the 16S rRNA gene. These primers were modified from primers 515F and 806R (Caporaso et al., 
2011) by incorporating ambiguous bases, to allow for more diversity to be detected. Overhang 
adapter sequences were appended on the 5’ end of the primers for compatibility with the Illumina 




Table 3.2: 16S rRNA V4 PCR primers. 
Primer Name Primer Sequence 5'-3' 
515F forward overhang 




805R Reverse overhang 




The locus specific sequences are indicated in blue and the 5’ overhang adapters in black. Ambiguous bases are H= 
A/C/T, Y = C/T, N = A/T/C/G 
Each PCR reaction consisted of 12.5 µl of Phusion Hot start 2X mastermix (New England Biolabs, 
USA), 5 µl of the diluted sample DNA (10 ng/µl in 10 mM TRIS), 1.25 µl each of amplicon PCR 
515 Forward and 805 Reverse primers (10 µM) and 5 µl of PCR grade H2O, to a final volume of 
25 µl per sample. The Kapa HiFi Hot start Ready mix (Kapa Biosystems, South Africa) 
recommended in the protocol was substituted with Phusion Hot start 2X mastermix as it offered 
more robust high-fidelity performance. The procedure was conducted in low DNA binding 0.2 ml 
PCR tubes using the Applied Biosystems Proflex PCR system (Life Technologies, United States) 
that was manually set to the touchdown PCR cycling conditions described in Table 3.3. All 
baseline and follow up samples from a participant were included in a single PCR batch to avoid 
PCR bias between samples obtained from the same participant. 
Table 3.3: 16S rRNA V4 touchdown Amplicon PCR cycling conditions. 
 Temperature (°C) Time Number of cycles 
Enzyme activation 98 30 sec X1 
Initial denaturation 98 5 sec 
X10 Annealing 65 30 sec 
Extension 72 30 sec 
Initial denaturation 98 5 sec 
X20 Annealing 55 30 sec 
Extension 72 30 sec 
Final Extension 72 5 min 
X1 





3.2.3.2 PCR clean-Ups (1 and 2) 
PCR clean up steps were incorporated after each PCR (Amplicon PCR and Index PCR), to purify 
the amplicon, remove free primers and primer dimers, and to prepare the final library before 
quantification. This was achieved using the Agencourt AMPure XP PCR purification system, 
where double (and single stranded) DNA fragments are bound to paramagnetic AMPure XP 
beads (Beckman Coulter Genomics) in an optimized buffer, freeing the samples from excess 
primers, nucleotides, salts and enzymes after washing with 80% ethanol. The ratio (v/v) of 
AMPure XP beads to PCR product used for the Amplicon PCR was 1.8X in 19 µl of PCR product, 
while a ratio of 1.2X in 45 µl PCR product was used for the Index PCR. The basic constituents 
and steps followed for the PCR cleanup are described in Figure 3.3.; the full procedure is 
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Figure 3.3: Basic workflow for PCR Clean-up using the Agencourt AMPure XP PCR purification system. 




3.2.3.3 Nextera XT Index PCR 
The Index PCR was done to attach dual indices and Illumina sequencing adapters at either end 
of the amplified sequences (Figure 3.4) using the Nextera Index Kit (Illumina Inc, USA) to create 
a library. Each sample was labelled with one of each of the 12 unique Index 1 (i7) and eight index 
2 (i5) indices, to enable the identification of 96 distinct sample libraries. Each sample and control 
was assigned an index pair, based on the 96 well plate design (Addendum 3 and 4, respectively).  
 
Figure 3.4: Index 1 and 2 appended to either end of amplified 16S rRNA V4 sequence. P5 and P7 
represent the regions that bind to the oligos on the flow cell. (Adapted from protocol 16S Metagenomic 
Sequencing Library preparation protocol) 
 
Each Index PCR reaction consisted of 25 µl of 2x KAPA HiFi Hot start Ready mix, 5 µl Amplicon 
DNA, and 5 µl each of Nextera XT Index primer 1 (N7xx) (orange caps, yellow solution) and 
Nextera XT Index primer 2 (S5xx) (White caps, clear solution) and 10 µl PCR grade water 
(Qiagen, Germany), to amount to a final volume of 50 µl per sample. The procedure was 
conducted in low DNA binding 0.2 ml PCR tubes and carried out using the Applied Biosystems 
Proflex PCR system. The PCR cycling conditions were manually set to the following cycling 
conditions; a denaturation step at 95°C for 3 minutes, an amplification step at 95°C, 55°C and 
72°C for 30 seconds each for 8 cycles, followed by a final extension step at 72°C for 5 minutes. 
The final library was purified using 56 µl of AMPure beads, as previously described in Section 
3.2.4.1.  
All PCR products were visualized on a 2% agarose gel using the UVitec Cambridge Alliance 2 
gel documentation system after each PCR amplification and clean up step. 
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3.2.3.4 Library Validation 
To validate the library construction, 11 samples were selected for Agilent 2100 Bioanalyzer 
(model G2939B) analysis at the Central Analytical Facility (CAF), Stellenbosch University. The 
Agilent 2100 Bioanalyzer is a commercially available chip-based nucleic acid analysis system. 
The microchip consists of micro-channels that are filled with a sieving polymer and an intercalating 
fluorescent dye. This microfluidic technology allows DNA to be separated according to mass and 
DNA concentration to be determined, when an electrical charge is applied. Four microliters of 
purified Indexed PCR product for each sample was submitted and amplicon size and 
concentration were determined using the Agilent High Sensitivity DNA Kit (Agilent Technologies, 
Germany). Data were recorded using the 2100 Expert software B02.08.s1648 (SR3).  
3.2.3.5 Library Quantification and normalization 
The final libraries were quantified using the Qubit dsDNA High Sensitivity (HS) Assay kit on a 
Qubit Fluorometer, at the Institute for Microbial Biotechnology and Metagenomics, University of 
Western Cape. This was done to determine the concentrations of the sample libraries before 
normalization and pooling. 
The DNA concentration of each sample was converted to nM using the average library size 
determined by the Agilent 2100 Bioanalyzer. The uniquely indexed final sample libraries were 
diluted to 4 nM with 10 mM Tris pH 8.5 in a final volume of 50 µl before pooling. 
3.2.3.6 Sample library pooling 
Pooling was done essentially as described in the 16S Metagenomic Sequencing Library 
preparation protocol (Addendum 5). Eight separate pools (A-H) were prepared containing 10 µl 
of each of 12 sample libraries, at a concentration of 4 nM each. The final pooling step involved 
aliquoting 20 µl from each pooled library group (A-H) into a single micro-centrifuge tube.  
3.2.3.7 Library denaturing and Miseq loading 
The v3 reagent kit (Illumina, USA) was used for sequencing; it consisted of the reagent cartridge, 
Hybridization buffer (HT1), Incorporation buffer (PR2 bottle) and the Miseq flow cell. Five 
microliters of freshly prepared 0.2 N NaOH was combined with the 4 nM pooled library  
(5 µl) in a microcentrifuge tube and vortexed briefly before incubation at room temperature for 5 
minutes. Nine hundred and ninety microliters of pre-chilled Hybridization Buffer (HT1) was added 




denatured DNA was placed on ice until final dilution to 8 pM (240 µl of denatured library was 
added to 360µl of pre-chilled HT1).  
3.2.3.8 Denaturation and Dilution of the PhiX control 
Ten nanomolar PhiX library (Control Kit v3; FC-110-3001) was diluted to 4 nM by combining 3 µl 
of 10 mM Tris pH 8.5 with 2 µl of PhiX library and then denatured using 5 µl of 0.2 N NaOH. The 
solution was quickly vortexed and incubated at room temperature for 5 minutes. To result in a  
20 pM PhiX library, 10 µl denatured PhiX library was added to 990 µl of pre-chilled HT1. The 
denatured 20 pM PhiX library was then diluted to the same concentration as the Amplicon library, 
by adding 240 µl of the 20 pM denatured library to 360 µl of pre-chilled HT1.  
Five hundred and seventy microliters of the pooled amplicon library and 30 µl of diluted PhiX 
control (both 8 pM) were combined and heat denatured at 96°C for 2 minutes. The final library 
mixture contained 5% PhiX which served as an internal control for the low diversity library. After 
incubation the tube was inverted and placed in an ice-water bath for 2 minutes before immediately 
loading the library into the Miseq reagent cartridge. This was done to ensure efficient template 
loading on the Miseq flow cell. 
3.2.3.9 Preparing for sequencing on the Miseq machine 
Prior to sequencing, the Miseq machine was set up according to the Miseq system guide and the 
final components required for sequencing were loaded into the machine. 300 bp paired end 
sequencing was performed for a total of 602 cycles (2x301 cycles; an extra cycle was added for 
phasing and prephasing calculations). Ideally, the ends of each read could be overlapped to 
generate high quality, full length reads of the V4 region in an ~ 65 hour run. The protocol assumed 
that for 96 indexed samples >100 000 reads could be generated per sample. According to 
Illumina, at 2 X 300bp paired end sequencing >70% of bases will have a quality score higher than 
30 (Q30) (https://emea.illumina.com/systems/sequencing-platforms/miseq/specifications.html). 






Figure 3.5: Miseq Workflow. (Illumina Miseq System Guide- # 1000000061014 v00) 
: 
Miseq denatured library 
loading
Preparation for cluster 
generation and sequencing
Miseq v3 cartridge thawed 
in a room temperature water 
bath (~60-90 minutes)
Denatured diluted library 
combined with the PhiX 
control
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reagent cartridge in the 
designated reservoir 
On the software interface, 
Sequence is selected to 
start the run setup steps
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the flow cell. Load the Flow 
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emptied waste bottle. Load 
the reagent cartridge
Review run parameters and 
pre-run check results. Start 
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Run can be monitored from 
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3.2.4  Generation of fastq files 
Sequence information (sequence ID, sequence read, blank and quality score) was stored in the 
form of a basic file type (text file); fastq file. Paired-end data had two files (forward and reverse 
sequence) that should have the same number of lines and sequence order. Fastq files were 
generated by calculating the amount of successfully completed and extracted cycles and 
requeuing analysis as explained in Addendum 6.  
3.2.5  FAST Quality Control (QC) 
FastQC was performed on the raw sequencing reads to determine the quality of the sequencing 
reads and to identify any issues or biases in the data which could affect the downstream analyses. 
FASTQ files (containing both the biological sequences and quality control information) obtained 
for each sample were inputted into an open source web-based platform, Galaxy, that used the 
FastQC package tool version 0.11.7 (Babraham Institute informatics) to determine the sequencing 
quality. FastQC provides a quality control report which identifies issues which originate either in 
the sequencer or in the starting library material. The Phred score was used to describe the quality 
of the output and was presented as an integer value i.e. Q=10, Q=20, Q=30. These values 





) and therefore the larger the 
integer value the greater the confidence in the output. The quality control checks the per base 
sequence quality which shows an overview of the range of quality values across the bases 
(warning sign indicates that 25% of data is less than 10 or has a median less than 25, failed sign 
indicates that 25% for any base is less than 5 or if the median for any base is less than 20), per 
sequence quality informs about sequences with universally low quality values (good sign indicates 
that the mean Q >27, warning sign indicates that the mean Q<27 (equates to 0.2% error rate) and 
failed sign indicates that the mean Q<20 (equates to a 1% error rate)), per base GC, per sequence 
GC and per base N content (N is substituted where the sequencer is unable to confidently make 
a base call) (warning sign indicates any position shows an N content of >5%, failed sign indicates 
any position with an N content of >20%) as well as identifying duplicate and overrepresented 
sequences of a certain length (Kmers) (https://www.bioinformatics.babraham.ac.uk). MultiQC 
(version 1.7) was used to aggregate FastQC output quality indicators from the entire dataset, 




The MultiQC reports were used to summarize the number of samples that had forward and 
reverse reads that met the quality control criteria for per base quality, per sequence quality, the 
per base N content (conventional bases substituted with N) and to determine the average 
sequence length of the forward and reverse reads. 
3.2.6  Data analysis Pipeline 
Quantitative insight into microbial ecology (QIIME) is an opensource bioinformatics pipeline that 
was used to pre-process the raw DNA sequencing data (Caporaso et al., 2010). This section 
briefly describes the bioinformatic analysis pipeline used to analyze single reads using QIIME 
(version 1.9.1). 
Single (forward) read analysis was done essentially as described by (Dumbrell, Ferguson and 
Clark, 2016) and subsequent steps were followed according to an established bioinformatics 
pipeline used at the Division of Molecular Biology and Human Genetics, Stellenbosch University. 
The samples were demultiplexed immediately after the sequencing run at the University of the 
Western Cape, therefore the file names were used to identify which sequences belonged to which 
sample. A quality filtering step was implemented using Phred scores of Q>=20 in QIIME before 
assigning OTUs. OTUs were assigned using an open reference picking approach, where the 
sequences were clustered at 97% similarity using UCLUST (version 1.2.22) and aligned against 
the Greengenes reference database (gg_13_8, modified 15 August 2013). Sequences that did 
not match the reference sequence collection were subsequently clustered de novo. Open 
reference picking in QIIME included taxonomy assignment, sequence alignment and tree-building 
steps. The commands used for generating the outputs can be found in Addendum 7. 
Files obtained from QIIME were imported into R studio (version 1.2.5001) to graphically represent 
and interpret the sequencing data. The packages used in R studio included Phyloseq (version 
1.28.0) and the Microbiome R package (Leo Lahti et al (Bioconductor, 2017-2019)). The minimum 
and maximum number of reads for the 95 samples included in the sequencing run was determined 
using these packages. OTU counts for the samples and controls were transformed to the relative 
abundance which included a filter (Abundance > 0.02) that filtered out low abundance taxa. 
Datafiles were subset for the samples and controls and aggregated at the different taxonomic 
ranks (phylum, class, order, family and genus). Alpha diversity (e.g. Simpson and Shannon), beta 
diversity (e.g. Bray-Curtis) and other statistical analysis were also conducted in R and further 





This nasopharyngeal microbiome pilot study included seventy-seven respiratory samples (one 
participant had no month 2 follow up sample) obtained from 26 participants, and eighteen control 
samples.  
3.3.1  DNA quality assessment of samples 
The median DNA concentration of the samples based on Qubit analysis was 54.3 ng/µl 
(Interquartile range (IQR) 27.6 ng/µl-153.9 ng/µl) and the average A260/A230 and A260/A280 
DNA purity ratios were 2.0 (Standard deviation (SD) = 0.9) and 1.9 (SD= 0.5), respectively. 
Approximately 17% (n=13/77) and 78% (n=60/77) of the samples were not in the desired ranges 
for the A260/A230 and A260/A280 respectively. Despite the poor quality of some of the samples, 
all were subjected to PCR because of the limited samples available. 
3.3.2  16S rRNA library preparation  
The V4 region of the 16S rRNA gene was successfully amplified in all clinical samples and spiked 
negative controls; no products were observed for the negative template controls. A substantial 
loss of PCR product was seen after the clean-up steps for each PCR (amplicon and index) for 
some samples; however, all cleaned amplicon PCR products for samples and controls were used 
for the index PCR. Two samples failed to produce visible bands after the Index PCR. All amplicon 
PCR products were between 300-400 bp and the indexed PCR products were between 400-500 
bp, as expected. An example of PCR products from the mock control is given in Figure 3.6, 
indicating an 80-100bp increase in size between the amplicon and index products, resulting from 



















A subset of cleaned V4 amplicon and Index PCR products were subjected to Bioanalyzer analysis 
to confirm the product sizes and to ensure that indexing was successful. The cleaned amplicon 
PCR product size was determined to be approximately 375 bp and the indexed PCR product size 
was approximately 460 bp, consistent with the anticipated increase of 83 bp, based on the size 
of the index and adaptors.  






Figure 3.6: Representative gel of amplified amplicon and indexed PCR products from a mock control 
sample: Lane 1: amplified Amplicon PCR product, Lane 2: cleaned amplicon PCR product, Lane 3: 





3.3.3  Illumina Miseq sequencing 
Sequencing of the pooled 16S rRNA libraries was performed on the Illumina Miseq at UWC. The 
sequencing run was expected to take approximately 65 hours, producing read lengths of 2 x 
301bp, and an output of >20 million reads; with the assumption of >100 000 reads per sample for 
96 indexed samples. However, due to load-shedding and failure of the back-up generator during 
the sequencing run; the run was prematurely aborted resulting in incomplete sequencing of the 
reverse reads. Five hundred and ninety cycles completed successfully, and the length of the 
reverse reads was determined to be ~272bp in comparison to the expected fully sequenced read 
length of 301bp. In addition, the secondary analysis was not performed on the Miseq reporter, 
therefore no information was obtained from the sequencing run with regard to cluster graphs, 
sample table summaries and the cluster pie chart representing the classification breakdown for 
the samples. As a result of the incomplete sequencing run, fastq files were manually generated 
as described in section 3.2.4.  
3.3.4  Sequencing quality: FASTQ quality control (QC) assessment  
The average length of the forward read across samples and controls was 296bp whereas the 
average length of the reverse read was 271bp based on the MultiQC reports. The per sequence 
quality scores showed that 95% of the forward reads had a mean Q >27 in comparison to the 
reverse reads where none passed QC; 72.6% (n=69/95) failed and 27.3% had warning signs. 
Based on the per base N content 97.9% of the forward reads passed QC, however all of the 
reverse reads had warning signs indicating that some positions in the read had an “N” content of 
more than 5%. None of the forward or reverse reads for the samples and controls met the per 
base sequence content quality criteria indicating that the lower quantile for any base was less 
than 5 or the median of any base had a Q <20. 
Based on the individual FASTQ quality assessment, quality scores for the forward reads averaged 
Q= >30 up to position 175bp on the read length, while the average quality score for the reverse 
reads was Q= >20 up to position 100bp, after which the quality score decreased further. The 
length of the forward read ranged from 35-301bp while the length of the reverse read ranged from 
35-272bp for the samples and controls. Figure 3.7 is a graphical representation of the quality 
scores across the bases for the forward and reverse read from the mock control. Due to the poor 
quality and length of the reverse reads, subsequent analysis was based on the analysis of only 





Figure 3.7: A graphical representation of the Fast Quality Control (QC) report for the forward (A) and reverse 






3.3.5  Taxonomic classification 
The median number of forward reads for the samples was 34 942 (IQR= 25 569). The median 
number of forward reads for un-spiked controls (H20, MCKEC, MCKEV, NTC1-3, PCR, WRR) 
was 37 106 (IQR= 43 972) where the median number of reads for the spiked controls (EB1-4, 
NEC1-4, TRIS and VTM) was 59 203 (IQR= 32 649). 
OTUs were clustered at 97% similarity and aligned against the Greengenes database. The 
taxonomic ranks investigated were phylum, class, order, family and genus; the main focus being 
on the phylum, family and genus ranks. At the phylum level the most abundant phyla observed 
across samples and sequencing controls belonged to Proteobacteria, Firmicutes, Fusobacteria, 
Bacteroidetes and Actinobacteria (Figure 3.8). The data was sub-set into samples and 
sequencing controls and analyzed separately. This chapter focuses on the classification of OTUs 
from the controls to inform the analysis of the samples in Chapter 4. 
The sequencing controls included two mock controls, a within run repeat, elution buffer, viral 
transport media, H2O, negative extraction control, non-template control and a positive PCR 
control. The two mock controls were composed of DNA from 5 known bacteria namely S. aureus, 
K. pneumoniae, E. coli, E. faecalis and P. aeruginosa and were included as sequencing controls 
(Table 3.1). Mock control 1 had equal volumes of DNA from each organism regardless of the 
concentration and Mock 2 had equal concentrations of DNA from each organism. The PCR 






Figure 3.8: The relative abundance of phyla observed across samples and sequencing controls. WRR- Within run repeat, VTM- Viral transport media, TRIS- Tris 
buffer, PC- Positive control, NTC- Negative template control, NEC- Negative extraction control, MCKEV- Mock control (equal volume), MCKEC- Mock control 





Proteobacteria and Firmicutes were the dominant phyla identified in the mock controls, while only 
Proteobacteria was identified in the positive control (Figure 3.9). At the genus level, 
Staphylococcus sp, Pseudomonas sp and Klebsiella sp were successfully identified in both mock 
controls (Figure 3.10). However, Escherichia sp and Enterococcus sp were not identified and may 
be included in the large portion of unclassified genera. Similarly, E. coli could not be classified in 
the positive control and a large portion of unclassified genera was observed. Serratia sp was also 
identified in both the mock and positive controls, which was not expected, but it was present at a 
lower relative abundance in comparison to the other genera detected. The number of reads 
associated with the genus Serratia sp in the mock controls (number of reads: 914 (MCKEC) and 
1264 (MCKEV)) and positive control (number of reads: 2884) were less than the spiked controls 
which had a median read count of 54887 (IQR 4543-71773) associated with the genus Serratia 
sp. 
Due to the large proportion of unclassified genera in the mock and PCR positive controls, 
classification to a higher taxonomic rank (family) was considered to provide a more accurate 
description of taxa. However, the expected proportions of each family (Enterobacteriaceae: 
Enterococcaceae: Staphylococcaceae: Pseudomonadaceae: 2:1:1:1) were not observed in the 
mock controls (Figure 3.11). In addition, Planococcaceae were detected at the family level, which 






Figure 3.9: The relative abundance of phyla observed in (A) Mock control 1-equal volume, (B) Mock control 2- equal concentrations and (C) the 
PCR positive control (E. coli). 
 





Figure 3.10: The relative abundance of genera observed in (A) Mock control 1 - equal volume, (B) Mock control 2- equal concentrations and (C) 
Positive control (E. coli). 
 
  





Figure 3.11: The relative abundance of family observed in (A) Mock control 1-equal volume, (B) Mock control 2- equal concentrations and (C) 
Positive control (E. coli). 
 
 




The other controls included were used to identify possible contaminants introduced during DNA 
extraction (NEC), PCR amplification (H20 and Non-template control (NTC) and storage (EB, TRIS 
and VTM). All of the spiked controls (EB, NEC, VTM) except TRIS produced similar results (Figure 
3.12), with Serratia as the predominant genus; consistent with the spiked DNA. Only 63 reads 
were obtained for the TRIS control, which may have contributed to the difference in profile. NTC 
2 also resembled the spiked controls although it was not spiked. This may have been a result of 
human error: the controls may have been indexed incorrectly during the indexing PCR. While H20, 
NTC1 and NTC3 had the most artefacts or genera detected, they were also the controls with the 
smallest number of reads present (number of reads 66 (H20), 335 (NTC1) and 255 (NTC3) which 
may indicate that contamination is low. Analysis to the family level did not provide any additional 
information regarding the OTUs detected (Addendum 9), especially for the large proportion of 
unclassified genera observed in NTC 1. 
 
Figure 3.12: The relative abundance of genera observed in other sequencing controls. Elution buffer (EB), 





3.4 Discussion  
Chapter 3 focused on describing the technical aspects involved in conducting the microbiome 
pilot study; the DNA quality, sequencing quality based on the assessment of the sequencing 
controls and the challenges faced in low -resource settings.  
DNA quality 
Most of the DNA isolated from the respiratory specimens did not meet the desired DNA purity 
requirements. This may be due to the low bacterial burden in some of the respiratory specimens 
(low biomass samples) included and the fact that low DNA concentrations can influence DNA 
quality scores (Lucena-Aguilar et al., 2016), in addition to the duration and condition of storage 
which may have compromised the DNA in the samples. Also, a column-based kit was used which 
may have contributed to the poorer quality; this type of kit usually produces poorer quality DNA; 
however, they are generally accepted to be the best for these sample types. Although the DNA 
purity was suboptimal, all except 2 samples were PCR amplifiable. Sample 65 was one of the 
samples with the poorest purity measures (A260/A280 and A260/A230) where sample 76 had 
somewhat acceptable purity readings but may not have amplified due to the presence of PCR 
inhibitors.  
16S rRNA amplification 
In our study the V4 region of the 16S rRNA gene was amplified. The change in the target region 
from the standard V3 – V4 Illumina protocol implemented at UWC was based on the fact that with 
a shorter target region, a full overlap of the target region could be achieved with the Illumina paired 
end sequencing and possibly reduce sequencing error (Schirmer et al., 2015). The V4 region is 
also one of the sub regions that best represents the full length of the 16S rRNA gene (Yang, Wang 
and Qian, 2016). The starting DNA concentration for the Amplicon PCR was increased from 
5ng/µl to 10ng/µl to increase the PCR yield. This was done to reduce the impact of the substantial 
loss of PCR product that occurred during the clean-up steps. The reason for the loss of PCR 
product could not be determined, but may include the extended period of time (i.e. 3-4 weeks) 
over which the clean-ups were conducted, or the AMPure beads being over dry (drying beads for 
longer than 5 minutes after ethanol wash step) as suggested by Quail et al (2009), as the protocol 
followed in our study included drying the beads for 10 minutes.  
It should be mentioned that the PCR (Amplicon and Index) steps were conducted in our setting 
(Medical Microbiology research laboratory, Stellenbosch University) and then the amplified PCR 




subsequent library preparation steps. Under ideal circumstances these steps would be conducted 
in a single facility with designated laboratory stations for each step in the protocol; however, this 
was not possible due to limited resources and time-constraints regarding equipment availability. 
Illumina Miseq sequencing 
The sequencing run was expected to run for 602 cycles (additional cycles added for phasing/ pre-
phasing calculations), however, due to well documented problems with electricity generation and 
infrastructure in South Africa, our sequencing run was aborted at around 590 cycles as a result 
of load shedding and failure of the back-up generator. As a result, no information was received 
with regard to the sequencing run based on the Miseq software outputs. Furthermore, the 
interrupted sequencing run may have impacted the length of the reverse read but it did not 
necessarily contribute to the poor sequence quality of the reverse read or the average quality of 
the forward read.  
It is likely that the sequencing quality of the forward and reverse reads was a result of the poor 
starting DNA quality, but it may also be due to other factors. A useful source of information 
regarding sequencing quality may have been explained in the Miseq sequencing run report as it 
would have provided useful insight into the overall sequencing quality (the sequencing run 
information was not provided by the facility). This would have provided information on the cluster 
density which is a critical metric for measuring sequencing performance, as it impacts data quality 
and yield from a run (influences run quality, reads passing filter, Q30 scores and total data output) 
(Illumina, 2019). Fadrosh et al (2014) reported that although Illumina is useful for the 
characterization of microbial communities using 16S rRNA amplicon sequencing, it does not 
perform well on low sequence diversity samples (or in samples dominated by only a few bacteria); 
the overall quality was reported to be significantly lower in comparison to a more diverse or 
random library. This is a result of issues inherent to the technology, during cluster identification 
and phasing/pre-phasing rate determination, where a balanced base composition through the 
initial 12 to 18 cycles of the run is required to generate high quality data (Fadrosh et al, 2014). A 
PhiX control was proposed to modulate the overall sample base composition in low diversity 
samples to facilitate a successful sequencing run (Fadrosh et al, 2014). In our pilot study a 5% 
PhiX control was included to provide a balanced fluorescent signal at each cycle to improve the 
quality of the sequencing run. Since the overall sequencing quality was not optimal it may indicate 
that the PhiX control added was insufficient for this dataset. This should be investigated further 
as a spike-in of up to 50% can be included for low diversity samples (Fadrosh et al, 2014) 




Analyzer or Hiseq). Furthermore, Fadrosh et al (2014), proposed incorporating a heterogeneity 
spacer to primers that contains your target region, index and linker sequence and is optimized for 
the Illumina sequencing platform, to address the low sequence diversity issue, as it offers a more 
balanced composition throughout the sequencing run. This method was however optimized for 
the V3-V4 region and may have to be optimized when using paired end sequencing for other 
target regions. It is known that sequencing quality falters towards the end of the read and that the 
reverse read quality is lower than the forward read due to the depletion of reagents with increased 
cycles. However, the exceptionally poor quality of the reverse read in this study was not expected. 
Personal communication with our collaborator at the University of the Western Cape informed 
that a similar issue was encountered specifically when using the v3 reagent kit, in comparison to 
when using the v2 kit which sequences shorter reads (2x250bp). 
The length of the reverse read was determined to be ~272 bp at ~ 590 cycles. Considering that 
the number of cycles is equivalent to the length of the read, the reverse is shorter than it should 
have been at 590 cycles by ~17 bp; in addition to the fact that sequencing was aborted before the 
remaining cycles could be repeated. The shorter read length may be due to phasing occurring 
during the sequencing run. Phasing causes sequencing of some molecules to lag behind due to 
problems with enzyme kinetics such as the 3’ terminator or the fluorophore not being removed. 
With increased sequencing cycles the number of affected sequences increases, therefore limiting 
the overall length of the read (Schirmer et al., 2015). Some clusters in the forward read could also 
have encountered this phenomenon since the average read length was 296 bp, although it did 
not vary from the fully sequenced read length by as many base pairs. Considering the aborted 
sequencing run and the poor sequencing quality, most service laboratories may have re-
sequenced the library, however this was not feasible for this study as there was insufficient DNA, 
time and resources available to do so. 
Data analysis 
Paired end sequencing could be viewed as a potential error correcting measure when forward 
and reverse reads are overlapped to form a consensus sequence that is less erroneous (Schirmer 
et al., 2015). Therefore, with the 2x 300 bp paired end sequencing of the V4 region (291 bp 
Amplicon product size) a full overlap of the region could have been expected and thus provided 
sufficient confidence in the consensus sequence that could be generated after aligning the 
forward and reverse reads. However, since the reverse reads were of suboptimal quality, a 
consensus sequence was not generated and therefore subsequent analysis was based on the 




default quality filtering steps were implemented. This was done to improve the sequencing quality 
of the reads without losing too many sequences because of stringent quality control measures. 
Additionally, since the output of reads was low, including more filtering steps could result in more 
data loss. This process is somewhat subjective as it becomes a tradeoff between quality cutoffs 
and having sufficient data to work with. The absence of more stringent quality control steps may 
have contributed to the inability to classify all taxa at the genus level (discussed further below) 
and may have contributed to bias in downstream analyses as a result of potentially incorrectly 
called nucleotides not being removed. In future studies, sequencing errors caused by Illumina 
sequencing could be reduced by trimming sequences based on the quality/ or length of the reads 
(FASTQ/A trimmer from the FASTX toolkit was used in this study to trim sequences to a specific 
length i.e. all sequences >301 bp), overlapping reads using either PANDAseq, which has been 
shown to be effective in removing errors but reduces the number of aligned sequences, or PEAR 
which retains the number of aligned sequences but reduces errors to a lesser extent, and lastly 
using an error correction program such as BayesHammer (Schirmer et al., 2015). 
Contamination 
Respiratory samples are considered to be low microbial biomass samples, which are prone to 
reagent and laboratory contamination, which means that microbial reads that are detected could 
potentially be from environmental sources. Therefore, in this pilot study several sequencing 
controls were included to assess possible contamination as well as the quality of sequencing, 
based on mock controls. Negative controls (NEC, VTM, TRIS and EB) included in our study were 
spiked at the same volume and concentration as our samples, so that the level of contamination 
in the negative controls would be representative of the study samples. All the spiked negatives 
had a high relative abundance of the spiked bacteria (Serratia) present with a smaller proportion 
which could consist of some contaminating DNA sequences. As the relative abundance threshold 
excluded all sequences with less than 2% abundance, contaminating sequences that were less 
abundant would have been excluded and are therefore not likely to negatively influence the 
sample data. Although all surfaces were decontaminated and all materials used were subjected 
to sterilization by UV light, possible contaminants were detected in the non-spiked controls (H2O, 
NTC 1 and 3) which were also the controls with the least reads present (in addition to TRIS). 
Some of the contaminants such as Methylobacterium, Acinetobacter, Corynebacterium and 
Streptococcus have previously been reported in literature (Salter et al., 2014). The other 
contaminants (Staphylococcus, Serratia, Prevotella, Paenibacillus, Neisseria, Moraxella, 




research subjects, investigators, laboratory surfaces, air or even have been present in laboratory 
reagents (Davis et al., 2018). Additionally, other reasons for the presence of unexpected OTU’s 
may be a result of spillover and/or microdroplet sprays that occurred during library preparation 
and index hopping that occurred during sequencing (DNA indices switched from one sample to 
another resulting in the misassignment of indices to samples/controls). Hornung et al (2019) 
reviewed numerous studies to show the issues and standards of controls included into 
microbiome research. For negative controls it was advised to focus on the number of reads; a 
negative control could be considered clean if it has fewer reads and therefore major contamination 
could be excluded. In our study the non-spiked controls had fewer reads that the samples, which 
suggests that contamination was not a major problem in this study. The outcome of negative 
controls should strongly be considered in low microbial biomass samples because low level of 
contamination can impact the results. Simply removing OTUs from negatives has been suggested 
but is only applicable if one is certain that these OTUs are actually contaminants and not truly 
present in the samples (Hornung, Zwittink and Kuijper, 2019). In this study common respiratory 
pathobionts (Staphylococcus, Neisseria, Moraxella, Streptococcus and Haemophilus) were 
identified in some of the negative controls and therefore simply removing OTUs would not be 
applicable. 
The mock controls and PCR positive controls were used as PCR and sequencing controls. These 
controls were included to evaluate the sequencing run. Based on the mock and positive controls 
some genera (Escherichia and Enterococcus) could not be classified. This may have been a 
consequence of the poor sequence quality or the fact that the sequencing read was not specific 
enough to distinguish the taxa at the genus level. It could imply that the sequencing quality was 
not sufficient for some organisms. However, the family level could be used to improve the 
interpretation, especially for the unclassified genera. The importance of including controls in 
microbiome research has become evident in recent years, and although there is no standard 
method for processing controls, it is highly recommended that they be included in microbiome 
studies (Hornung, Zwittink and Kuijper, 2019). Although some of the control taxa weren’t 
classified, they were not expected in the high abundance in the study samples. Therefore, based 
on the analysis discussed in this chapter, OTU classification to the phylum and family levels was 





As previously described, the DNA extraction quality in this pilot study was not optimal and may 
have influenced the sequencing quality. No sequencing run reports were obtained from the 
sequencing facility; this may have provided more insight into the overall sequencing quality. No 
samples were excluded because of the limited number of samples available for the study, as well 
as insufficient sample quantities for the re-extraction of DNA; this also restricted the possibility of 
resequencing the libraries. Nasopharyngeal samples are low biomass samples, which may have 
impacted on the poor DNA quality. Samples were stored at suboptimal temperatures (-20 °C). It 
is imperative to ensure that in future studies, samples are stored at optimal condtions ( -80 °C) 
and that DNA quality is of acceptable purity and yield, as both of these factors contribute to the 
robustness and reproducibility of sequencing results. Another limitation of this study is that even 
though paired end sequencing was done, only the forward read was used for generating OTUs; 
because of this the sequencing reads may not have been sufficient quality to obtain reproducible 
sequencing data.  
Microbiome research has shown that consistency is key for ensuring robust and reproducible 
results. Due to the fact that the study was conducted in a resource limited setting, certain 
challenges were faced including conducting the library preparation across two laboratories, 
transporting samples between the laboratories and load shedding. This could contribute to 
contamination as one does not have complete control of the working environment, and sample 
deterioration could occur as a result of fluctuating temperatures during transportation. 
Additionally, as a consequence of load shedding the sequencing run was interrupted and this 




3.5 Conclusion  
Next generation sequencing is fast evolving and is being implemented in research facilities for 
microbiome research. Microbiome research is a complex research field that requires numerous 
methodological approaches to be carefully considered to obtain adequate results, from sample 
collection to sequencing analysis. However, there is no consistency as various methodological 
approaches can be used. Furthermore much of what is known about microbiome research over 
the past 10 years has been pioneered by gastrointestinal microbiome studies, which accounts for 
about 40% of microbiome research (NIH Human Microbiome Portfolio, 2019). This implies that 
other microbiome niches such as the respiratory microbiome, which was previously thought to be 
a sterile site (Gallacher and Kotecha, 2016), are still being established and appropriate and 
adequate methodological approaches remain to be determined. It is therefore necessary to check 
the validity and the effects of certain methodological processes to ensure rigorous scientific 
research for the particular microbiome niche being investigated, especially for low biomass niches 
such as the respiratory tract.  
To improve on these challenges, particularly for respiratory microbiome research, samples should 
be collected and stored at a consistent temperature, DNA extraction techniques should be 
evaluated to determine which method provides the highest yield and purity for low biomass 
samples, and the library preparation optimized depending on the sequencing technology and 
where the samples will be sequenced. Lastly, the data analysis pipeline should include quality 
control steps that would allow for cleaner sequencing data without losing too much sequencing 
information.  
In this study it was observed that the overall DNA quality and sequencing quality was suboptimal 
and may have impacted the sequencing results and hence the generation of OTUs. This chapter 
highlighted the limitations to conducting microbiome research in resource limited settings. Due to 
the inconsistency of classification at genus level during optimization it was decided to perform 
further taxonomic classification on the sample set at higher taxonomic levels such as phylum and 
family level; and these analyses will be applied to address the aims of Chapter 4: (1) to compare 
the baseline respiratory microbiota of children with bacteriologically confirmed, clinically 
diagnosed and unlikely PTB and (2) to describe the effect of TB treatment on the respiratory 





CHAPTER 4:  
Tuberculosis and the Nasopharyngeal microbiome (microbiota) 
4.1 Introduction 
The respiratory tract plays a role in respiratory health, as described in Chapter 1. More specifically, 
the nasopharynx could be involved in susceptibility to respiratory infections and studies have 
found associations between respiratory microorganisms and respiratory tract infections, including 
pulmonary tuberculosis (PTB). However, the focus of previous research has been on the lung 
microbiome in adult tuberculosis (TB) patients and healthy controls. Research has shown that the 
microbial diversity differs between TB patients and controls (Cui et al., 2012; Botero et al., 2014), 
specifically that the relative proportion of respiratory microbiota at phylum and genus level can 
differ between TB case and control groups (Eshetie and Van Soolingen, 2019). Additionally, these 
studies highlight that Mycobacterium tuberculosis (M.tb) may not be the sole agent responsible in 
TB disease, but that interactions with other microbial pathogens and immunological factors also 
play a role (Eshetie and Van Soolingen, 2019).  
Although the lung is the major organ involved in PTB, disease development may occur prior to 
reaching this point. Some studies have found changes in the nasopharyngeal microbiome during 
respiratory diseases such as pneumonia and cystic fibrosis (Sakwinska et al., 2014; Prevaes et 
al., 2016). One study found unique bacterial colonization patterns associated with cystic fibrosis 
in infants prior to prophylaxis and antibiotic use (Prevaes et al., 2016) while a second study found 
that pneumonia etiologies could be associated with certain microbiota (Sakwinska et al., 2014). 
The nasopharyngeal microbiota has also been shown to determine the spread of infection to lower 
airways, the severity of accompanying inflammatory symptoms as well as the risk of future asthma 
development in infants (Teo, Mok, Pham, Kusel, Serralha, Troy, Barbara J. Holt, et al., 2015).  
When it comes to the nasopharyngeal microbiome and PTB, limited data is available. The first 
detailed study to describe respiratory “microbiota” in children with suspected TB in a TB endemic 
setting was conducted in Cape Town, South Africa (Dube et al., 2016). However, this study based 
the description of respiratory pathogens present in nasopharyngeal swab samples detected using 
a multiplex real time PCR based method, which does not allow characterization of the full range 
and complex network of microorganisms (especially bacteria) present in the nasopharynx, which 
is possible when using high throughput sequencing. Furthermore, the effect of TB treatment on 




This is important since antibiotics are known to induce dysbiosis which could contribute to future 
disease as a result of an unstable microbiome or loss of diversity; and studies have shown that 
TB treatment has the potential to cause dysbiosis (Namasivayam et al., 2017; Wipperman et al., 
2017). 
Chapter 4 aims to compare the respiratory microbiota of children with PTB, bacteriologically and 
clinically diagnosed PTB, and unlikely PTB and to describe the effect of TB treatment on the 
respiratory microbiota in children with PTB. Microbiota is used to describe microbial communities 
(bacteria, archaea, protists, fungi and viruses) (Eshetie and Van Soolingen, 2019) but the focus 





4.2 Material and Methods 
The wet laboratory and dry laboratory processing for the characterization of the nasopharyngeal 
microbiota in children with suspected TB is fully described in Chapter 3, section 3.2. Figure 4.1 
serves as a brief analysis workflow summary for this chapter for determining alpha and beta 
diversity.  
 
Figure 4:1: Brief analysis workflow summary for alpha- and beta- diversity analyses 
Microbiome diversity can be described in terms of alpha and beta diversity, which describe the 
within and between sample diversities respectively (Wagner et al., 2018). Two factors contribute 
to microbiota diversity, namely richness and evenness, where richness is the number of different 
taxa observed without regard to their frequency and evenness refers to the equitability of the taxa 
frequencies in a community (Wagner et al., 2018).  
Alpha diversity was assessed using the most commonly used alpha diversity measures, the 
Shannon index and Simpson index (Wagner et al., 2018) (Table 4.1). The Shannon and Simpson 
indices both provide insight into the diversity within a sample, i.e. the community within a sample. 
With greater diversity a higher index estimate can be expected. The index values range from 1.5 






















Table 4.1: Alpha diversity measures, index range and calculation. 
Alpha diversity 
index 










Simpson Index Evenness is more 
heavily weighted 






Diversity can also be described across a collection of samples. Beta diversity describes the 
relationship between two components, namely the local component (alpha; diversity in a single 
sample) and the regional component (gamma; diversity of a collection of samples) (Wagner et al., 
2018). Simply, beta diversity is used to describe the degree to which samples differ from each 
other and provide information on the microbial ecology that may not be apparent when looking at 
the composition of individual samples (Goodrich et al., 2014).  
To assess the diversity of the community structure across the collection of samples, beta diversity 
was measured using quantitative measures based on sequence abundance; Bray-Curtis 
(dissimilarity matrix) and weighted UniFrac, based on the relative abundance of operational 
taxonomic units (OTUs) at the family level. Dissimilarity results range between 0 and 1; where 0 
means that the two site compositions are shared whereas a value of 1 indicates that 2 sites do 
not share the same composition. UniFrac is a distance metric that differs from Bray-Curtis in that 
it incorporates the relative relatedness of community members by including the phylogenetic 
distance between the observed microorganisms (Lozupone and Knight, 2005). Bray Curtis and 
UniFrac are visualized using Principal coordinate analysis (PCOA) plots and/ or heatmaps. 
DeSeq2 package (v. 1.28.1) is a quantitative method that was used to determine differentially 
abundant taxa in this study. The analysis was done as described using the DeSeq2 with phyloseq 
tutorial. DeSeq2 uses tests such as negative binomial generalized linear models; dispersion 
estimates and logarithmic fold changes that allow for differential expression (Love, Huber and 
Anders, 2014). Raw (non-normalized) count data was used to quantify and determine differentially 
abundant taxa (at the family level) between the TB cases and ill control group at baseline and pre 
𝑝𝑖= proportion of species 𝑖, 𝑠 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑐𝑖𝑒𝑠, ∑ 𝑝𝑖
𝑠
𝑖=1 = 1, 𝑙𝑛 = 𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑙𝑜𝑔𝑎𝑟𝑖𝑡ℎ𝑚,  





and post TB treatment in the TB cases. Baseline and Ill control groups were used as the reference 
level. 
Alpha and beta diversity analyses as well as other non-parametric statistical tests were conducted 
in R studio. The input files used for further analysis in R included the output files generated in 
QIIME, namely the biom file and tre file (phylogenetic tree file), and a mapping file that contained 
sample information. The R packages used included Phyloseq (v. 1.29.09) which is a tool used to 
import store, analyze and graphically display complex phylogenetic sequencing data that has 
been clustered into OTUs and Vegan (v.2.5-6) which was used for alpha and beta diversity 
analysis, ordination methods and tools for the analysis of dissimilarities. All diversity measures 
were based on the relative abundance of OTUs at the family level (Figure 4.2).  
A non-parametric multivariate analysis of variance test, measured using the Adonis test in R 
studio (Version 1.2.5001) (adonis function | R Documentation, Anderson, 2001), was used to 
determine the statistical significance of differences in beta-diversity.. 
  
















Seventy-seven respiratory samples (nasopharyngeal aspirates (NPA) and some induced sputum 
(IS)) obtained from 26 participants, at recruitment (baseline), 2 months and six months, were 
evaluated at the phylum and family level. The most abundant phyla observed across all samples 
regardless of timepoint were Proteobacteria, Firmicutes, Bacteroidetes and Fusobacteria, with a 
few samples having Tenericutes and Actinobacteria present (Chapter 3, Figure 3.8). Common 
familia across all samples included Streptococcaceae, Pasteurellaceae, Moraxellaceae, 
Prevotellaceae, Veillonellaceae and Neisseriaceae. 
4.3.1  The respiratory microbiota in TB cases and ill controls 
4.3.1.1 Taxonomic classification of TB case and ill control samples at baseline 
The baseline samples were categorized as bacteriologically confirmed and clinically diagnosed 
TB cases (unconfirmed TB) (as described in section 3.2.1) and unlikely TB cases (well-defined ill 
controls). All but one TB case sample (sample 82) and two ill control samples (samples 30 and 
39) were NPAs; the others were IS samples.  
No distinct microbial profiles were observed in the TB case or ill control groups (Figures 4.3 and 
4.4). Twenty familia were identified in the case group (Figure 4.3). The most common familia 
included Streptococcaceae (84.6%, n=11/13), Moraxellaceae (61.5%, n=8/13), Pasteurellaceae 
(61.5%, n=8/13), Veillonellaceae (53.8%, n=7/13), Prevotellaceae (46.1%, n=6/13) and 
Neisseriaceae (46,1%, n=6/13). Familia identified in fewer samples and at a lower abundance 
included Staphylococcaceae, Mycoplasmataceae, Fusobacteriaceae, Corynebacteriaceae, 
Enterobacteriaceae, Gemellaceae, Chlamydiaceae, Paraprevotellaceae, Leptotrichiaceae, 
Flavobacteriaceae, Enterobacteriaceae, Burkholderiaceae, Aerococcaceae and 
Mycobacteriaceae. Leptotrichiaceae was identified in the sputum sample (Sample 82). 
In the ill control group 19 familia were identified, most of which were seen in the TB case group 
(Figure 4.4), including Streptococcaceae (92.3%, n=12/13), Pasteurellaceae (77%, n=10/13), 
Moraxellaceae (77%, n=10/13), Prevotellaceae (69.2% n=9/13), Veillonellaceae (61.5%, n=8/13), 
Neisseriaceae (38.5%%, n=5/13). Fusobacteriaceae (38.5%, n=5/13) and Paraprevotellaceace 
(38.5%, n=5/13) were more common in the ill control group and Spirochaetaeae, Micrococcaceae, 
Lachnospiraceae and Bifidobacteriaceae were only detected amongst the control samples. Other 
less common and less abundant familia observed in the control group samples included 




Aeorcoccaceae, most of which were also detected in the TB case group. The two IS samples 
differed from the NPA samples by the presence of a single family, Leptotrichiaceae.  
Similarly, no distinct microbial profiles were identified between the two case categories 
(bacteriologically confirmed or clinically diagnosed TB) (Figure 4.3). Familia observed in the 
bacteriologically confirmed TB group which were not found in the clinically diagnosed TB group 
included Staphylococcaceae, Enterobacteriaceae, Mycoplasmataceae and Mycobacteriaceae. 
Mycobacteriaceae was only detected in a single sample in the bacteriologically confirmed 
category. In the clinically diagnosed TB group all the samples differed; two of the samples were 
dominated by Moraxellaceae and Streptococcaceae, while samples 76 and 82 were the most 
diverse. Other familia observed only in this category included Chlamydiaceae and 
Burkholderiaceae which were not found in the bacteriologically confirmed category. 
4.3.1.2 Alpha and beta diversity between TB case and ill control samples at baseline 
The alpha diversity appeared to be lower in the TB case group than in the ill control group at 
baseline (Figure 4.5), although this was not statistically significant for either the Shannon (p=0.24) 
or Simpson (p=0.31) indices. For both indices, the alpha diversity of the case group samples 






Figure 4:3: The relative abundance of familia observed in the TB case group, categorized into (A) Bacteriologically 
confirmed TB and (B) Clinically diagnosed TB at baseline. Only families with a minimum of 2 % relative abundance are 
represented. 
 
Figure 4:4: The relative abundance of familia observed in the unlikely TB control group (well-defined ill controls) at 
baseline. Only families with a minimum of 2 % relative abundance are represented. 
  






Figure 4:5: Alpha Diversity between the TB case and ill control groups at baseline using (A) Shannon’s Index and (B) 
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The beta diversity between TB cases and ill controls showed no distinct clustering based on the 
Bray Curtis heatmap (Figure 4.6) or Bray Curtis PCOA analyses (Adonis test, R2= 0.242) (Figure 
4.7), which suggests that there is a similar taxa composition in the groups. Similarly, no difference 
was seen between the bacteriologically confirmed and clinically diagnosed TB groups or ill 
controls at baseline (Adonis test, R= 0.802) (Figure 4.8). Weighted UniFrac measures showed no 
distinct clustering between the TB case (bacteriologically confirmed and clinically diagnosed) and 
ill control groups at baseline (Adonis test, R2=0.02 and Pr (>F)= 0.72) (Addendum 10). Based on 
differential abundance testing using DeSeq2, TB cases were compared to the ill control group. 
Based on this a 5- and 4-fold lower abundance of Pasteurallaceae and Prevotellaceae was 
observed in the TB cases compared to the ill controls at baseline (Figure 4.9). Suggesting that 
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Figure 4:6: Bray Curtis dissimilarity metric heatmap between the samples at the family level. BL is baseline samples, M2 is month 2 samples, M6 is month 6 






Figure 4:7: Principal coordinate analysis (Bray-Curtis) showing the difference between respiratory 
samples obtained from the TB case and ill-control groups at all time points. The PCOA plots were based 
on OTUs classified at the family level. 
 
Figure 4:8: Principal coordinate analysis (Bray-Curtis) showing the difference between respiratory samples 
obtained from the TB case (bacteriologically confirmed TB or clinically diagnosed) and ill-control groups at 















4.3.2 The respiratory microbiota during TB treatment  
Follow up samples were obtained at two time points, month 2 and month 6, to investigate the 
microbial profiles of participants during TB treatment. One participant (from the unconfirmed TB 
category) did not have a month 2 sample collected and another participant had a sample collected 
at month 1 (Sample 72) instead of month 2. Month 6 follow up samples were obtained from all 
participants. All but three month 2 samples (Sample 31, Sample 60 and Sample 83) and 2 month 
6 samples (Sample 41 and Sample 84) were NPA samples. IS Samples 83 and 84 were obtained 
from the same participant.  
4.3.2.1 Taxonomic classification of TB cases at month 2 and month 6 
No distinct microbial profiles were observed at month 2 or month 6 for the TB case group. Twenty-
three familia were identified in the TB case samples at month 2 (Figure 4.10). Similarly to the 
baseline TB case samples, the most common familia observed were Streptococcaceae (83.3%, 
n= 10/12), Veiollonellaceae (66.7%, n= 8/12), Fusobacteriaceae (58.3%, n= 7/12), Prevotellaceae 
(50%, n= 6/12), Pasteurellaceae (50%, n= 6/12) and Neisseriaceae (50%, n= 6/12). Less 
commonly observed familia included Paraprevotellaceae, Mycoplasmataceae, 
Campylobacteriaceae and Gemellaceae. In comparison to the baseline, there seemed to be a 
decrease in the presence of Moraxellaceae. The microbial profiles of Sample 46 and Sample 72 
were completely different to the other month 2 samples. Sample 72 mainly consisted of 
Carnobacteriaceae, Lachnospiraceae, Ruminococcaceae and Bacteroideraceae, which were not 
present in any other the other samples. This could be indicative of the variability of the 
nasopharyngeal microbiota at different time points since this sample was a month 1 sample. 
Sample 46 was completely dominated by Enterobacteriaceae, which was not expected since it is 
usually present in low abundance in nasopharyngeal samples (Allen et al., 2014; Chonmaitree et 
al., 2017). This sample had a similar microbial profile to the PCR positive control and was thought 
to have been mistakenly spiked with the DNA from the PCR positive control. However, the 
possibility of it being the positive control was ruled out after other sequencing reads were identified 
in the sample that were not identified in the PCR positive control; though not observed in the 
figures as a result of the threshold (2%) that was used.  
Eighteen familia were identified in the TB case samples at month 6 (Figure 4.11). The month 6 
samples were similar to the month 2 samples with the exception of an increase in 
Paraprevotellaceae (38.5%, n= 5/13). The most common familia were the same; 




Veillonellaceae, Neisseriaceae (76.9%, n=10/13), Prevotellaceae (61.5%, n= 8/13) and 
Fusobacteriaceae (46.2%, n= 6/13). There was a decrease in the relative abundance of 
Prevotellaceae in the month 6 samples in comparison to month 2. Sample 78 was completely 







Figure 4:10: The relative abundance of familia observed in samples obtained at month 2 from the TB case 
group, categorized into (A) Bacteriologically confirmed TB and (B) Clinically diagnosed TB Only families 
with a minimum of 2 % relative abundance are represented. 
 
Figure 4:11: The relative abundance of familia observed in samples obtained at month 6 from the TB case 
group, categorized into (A) Bacteriologically confirmed TB and (B) clinically diagnosed TB Only families 
with a minimum of 2 % relative abundance are represented. 
  
(A) Bacteriologically confirmed TB (B) unconfirmed TB 




4.3.2.2 Taxonomic classification of well-defined ill controls at Month 2 and month 6  
Month 2 and month 6 samples from the ill control group, who were not on TB treatment, were also 
evaluated, to control for normal microbiota variation over time (Figure 4.12 and Figure 4.13). The 
microbial profiles appeared to be similar to the baseline samples with regard to the common 
familia identified: Veillonellaceae, Streptococcaceae, Neisseriaceae Pasteurellaceae, 
Moraxellaceae and Prevotellaceae. There were fewer familia observed at month 2 in comparison 
to month 6 where 22 familia were identified, with the addition of Cardiobacteriaceae, 
Weeksellaceae and Tisseriellaceae. There was an increase in the relative abundance of 
Neisseriaceae from baseline to month 2, and an increase in the presence of Moraxellaceae and 
Paraprevotellaceae and a decrease in the presence of Prevotellaceae from month 2 to month 6. 
familia identified in fewer samples at month 2 and month 6 and at a lower relative abundance 
were Corynebacteriaceae, Carnobacteriaceae, and Aerococcaceae, with the addition of 
Lachnospiraceae and Enterobacteriaceae in the month 6 samples. 
4.3.2.3 Alpha and beta diversity in response to TB treatment 
The alpha diversity appeared lower at baseline compared to month 2 and month 6 in the TB case 
samples, although this was not statistically significantly for either the Shannon (Baseline vs month 
2, p=0.51 and Baseline vs month 6, p= 0.83) or Simpson (Baseline vs month 2, p= 0.32 and 
Baseline vs month 6, p= 0.83) indices (Figure 4.14). The interquartile ranges were also more 
condensed at the later time points which could suggest that after treatment the number of taxa 
was more evenly spread. In the ill control group, the alpha diversity at month 2 was slightly 
decreased in comparison to baseline and month 6 for both the Shannon (Baseline vs month 2, 
p=0.82 and Baseline vs month 6, p= 0.78) and Simpson (Baseline vs month 2, p=0.82 and 
Baseline vs month 6, p= 0.55) indices, although this was not statistically significant (Figure 4.14). 
No distinct clustering was observed for the TB case and ill control groups over time based on the 
Bray-Curtis heatmap (Figure 4.6) or Bray-Curtis and weighted Unifrac PCOA analyses (Adonis 
test, R2= 0.123 and Adonis test R2=0.039, PR>F=0.121, respectively) (Figure 4.15 and 
Addendum 10), suggesting similar taxa composition in samples obtained at the different time 
points, and between TB cases and ill controls. 
On the other hand, differentially abundant familia were observed in month 6 TB cases with fold 
changes of 4 to 8 across the familia; Veillonellaceae, Staphylococcaceae, Prevotellaceae, 





Figure 4:12: The relative abundance of familia observed in the unlikely TB control group (well-defined ill 
controls) at month 2. Only families with a minimum of 2 % relative abundance are represented. 
 
 
Figure 4:13: The relative abundance of familia observed in the unlikely TB control group (well-defined ill 







Figure 4:14: Alpha Diversity measures in TB case and ill-control groups during treatment based on the (A) 
Shannon and (B) Simpson Indices. 
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Figure 4:15: Principal coordinate analysis (Bray-Curtis) showing no differences between respiratory 
samples obtained from the TB case and ill-control group during TB treatment. The PCOA plots were based 
on OTUs classified at the family level. 
 





4.3.3  Baseline TB cases compared to month 6 ill controls as a proxy for healthy 
microbiome (microbiota) 
All participants in the study were ill at recruitment (baseline) and were exposed to antibiotics. 
However, at month 6 in the ill control group (unlikely TB group) participants could be considered 
“healthy” since their antibiotic treatment would have been completed and their “microbiomes” 
possibly restored. Therefore, the baseline TB cases were compared to the month 6 “recovered” 
ill control samples to identify any potential differences between the microbiota of TB cases at 
baseline and a “healthy” microbiota (Figure 4.3 and Figure 4.13). 
Almost all of the month 6 ill controls (84.6%, n=11/13) had Moraxellaceae present in comparison 
to only 61.5% (n=8/13) in the baseline TB cases (Figure 4.13 and Figure 4.3, respectively). 
Neisseriacceae, Paraprevotellaceae, Fusobacteriaceae were more commonly observed in the 
month 6 ill controls than in the baseline TB cases, while Streptococcaceae, Aerococcaceae, 
Enterococcaceae and Prevotellaceae were more commonly observed in the baseline TB case 
(Table 4.2).  
Table 4.2: Common familia present in the baseline TB cases and month 6 ill controls. 
Family Baseline TB cases (n=13) Month 6 ill controls (n=13) 
Streptococcaceae 84.6% (11) 69.2% (9) 
Neisseriacceae, 46.1% (6) 61.5% (8) 
Fusobacteriaceae, 15.4% (2) 53.8% (7) 
Veillonellaceae  53.8% (7) 53.8% (7) 
Paraprevotellaceae 15.4% (2) 46.1% (6) 
Prevotellaceae 46.1% (6) 38.5% (5) 
Aerococcaceae 38.5% (5) 30.8% (4) 
Enterococcaceae 30.8% (4) 7.7% (1) 





The alpha diversity appeared higher in the month 6 ill controls in comparison to the baseline TB 
cases, although this was not statistically significant for either the Shannon (p=0.15) or Simpson 
indices (p=0.11) (Figure 4.17). For both indices, the alpha diversity of the baseline case samples 
appeared to be more variable than that of the month 6 ill control samples. No distinct separation 
between the groups was observed using either beta diversity measure (Bray-Curtis and weighted 







Figure 4:17: Alpha Diversity comparison between baseline TB cases and month 6 ill controls (A) Shannon 






In Chapter 4, we presented the results of a pilot study which aimed to describe the differences in 
the respiratory microbiota in children with and without TB, and the impact of TB treatment on the 
microbiota. The nasopharyngeal microbiota was investigated in children with suspected PTB who 
were categorized into bacteriologically confirmed PTB, clinically diagnosed PTB and unlikely PTB 
groups. Although the sequencing quality was suboptimal for accurately identifying bacteria at the 
genus level, we were able to identify bacterial phyla and familia in all samples based on the 
clustering of forward read sequences as discussed in Chapter 3. We did not identify a distinct 
microbial profile within the TB case group (bacteriologically confirmed/ clinically diagnosed PTB) 
or between the TB case and ill control group at baseline, month 2 and month 6. In addition, there 
was no distinct microbial profile between TB cases after 6 months of TB treatment and ill controls 
that did not receive TB treatment.  
The most abundant phyla identified in all samples and diagnostic categories were Proteobacteria, 
Firmicutes, Bacteroidetes, Fusobacteria and Actinobacteria, to a lesser extent Tenericutes (only 
identified in a few samples). The above-mentioned phyla (with the exception of Tenericutes) are 
commonly identified in human microbiome studies, including those studies investigating the 
nasopharynx. These phyla have been reported in different relative proportions in both infants and 
children during healthy and diseased states (Bogaert et al., 2011; Teo, Mok, Pham, Kusel, 
Serralha, Troy, Barbara J. Holt, et al., 2015). On the other hand, the presence of Tenericutes is 
less common, but similar to another study (Stearns et al., 2015) which identified it in 
nasopharyngeal samples from healthy participants (<19 months of age).  We identified it in ill 
participants of the same age (median age 19 months for participants included in the microbiome 
section) which may suggest that its presence in the samples is age related.  
The respiratory microbiota in TB cases and ill controls 
The most commonly identified familia in both the baseline TB case and ill control groups were 
Streptococcaceae, Veillonellaceae, Prevotellaceae, Moraxellaceae, Pasteurellaceae and 
Neisseriaceae. There were no statistically significant differences in alpha or beta diversity (Bray 
Curtis or weighted UniFrac) between the TB cases and ill controls at baseline or between the 
bacteriologically confirmed and clinically diagnosed TB groups. This may be due to the fact that 
all of the participants suffered from a respiratory illness and had likely been exposed to antibiotics 
prior to recruitment for the study; therefore, they may have had similar microbial profiles. The 
results may also be influenced by the higher taxonomic rank being used for comparisons, which 




sample size which may not be truly representative of the different populations. Conversely, 
differential abundance testing using DeSeq2 suggests that there are differences between the TB 
case and ill control groups at baseline, namely as a result of a lower abundance of 
Pasteurellaceae and Prevotellaceae in TB cases. Differential abundance is useful for determining 
overall shifts in abundance of microbial compositions between two conditions e.g. healthy vs 
diseased/treated vs untreated (Banerjee et al., 2019). This method was particularly useful 
because at a taxonomic level (microbial profile) and using standard diversity measures: alpha 
(Shannon and Simpson indices) and beta analysis (Bray Curtis and weighted uniFrac) suggested 
that “no differences” were apparent among these groups, which may have brought about an 
inaccurate interpretation of the outcome of this study. The use of this method also highlights the 
importance of including quantitative analysis to assist in the understanding of microbiome studies 
when comparing different conditions.  
The familia identified include genera that are typically found in the nasopharynx, but can exist in 
different patterns or associations with each other, depending on age, the presence of specific 
viruses (Allen et al., 2014; Li et al., 2017), early succession patterns (Biesbroek, Tsivtsivadze, 
Elisabeth A. M. Sanders, et al., 2014) and antibiotic use (Teo, Mok, Pham, Kusel, Serralha, Troy, 
Barbara J. Holt, et al., 2015). In healthy individuals, certain genera have been described to be 
dominant depending on age; for example in infants (≤ 6 months) the nasopharynx is composed 
of Streptococcus, Corynebacterium, Staphylococcus and Dolosigranulum (Rosas-Salazar et al., 
2016), while in children (18 months of age) a different microbial pattern is typically seen: 
Moraxella, Haemophilus, Streptococcus and Flavobacteria (Bogaert et al., 2011). During acute 
respiratory rhinovirus infection a decrease in the relative abundance of genera such as 
Streptococcus, Moraxella, Corynebacterium and Haemophlius, with the addition of 
Dolosigranulum was observed (Rosas-Salazar et al., 2016). Contrary to this, another study found 
that the enrichment of Moraxella and a decrease in the relative abundance of taxa such as 
Faecabacterium and Alkkermansia spp could be associated with a history of acute sinusitis 
(Santee et al., 2016). We found a high abundance of the family Streptococcaceae to which the 
genera Streptococcus belongs; it is likely that the main genus in the samples is Streptococcus 
since it is usually identified in nasopharyngeal samples. Assuming that this is the case in our 
study, the presence of Streptococcus could be associated with age; Biesbroek et al (2014) found 
that it has a high abundance between the ages of 12 and 24 months. The presence of this genus 
is also associated with an unstable respiratory microbiome (Biesbroek, Tsivtsivadze, Elisabeth A. 
M. Sanders, et al., 2014) and since all of the participants were ill and likely on antibiotic treatment, 




a stable respiratory microbiome were not observed in high abundance in our study 
(Corynebacteriaceae- genus Corynebacterium and Carnobacteriaceae- genus Dolosigranulum).  
Staphylococcaceae, Enterobacteriaceae, Mycoplasmataceae and Mycobacteriaceae were 
identified in a few baseline samples in the bacteriologically confirmed category, but not seen in 
the clinically diagnosed category. The significance of these bacteria was not evaluated because 
they were only identified in a few samples. However, it is interesting in that of those that were 
bacteriologically confirmed to have TB one participant had Mycobacteriaceae detected in the NPA 
sample which could suggest recent exposure to Mycobacteriaceae and could be further 
investigated in future studies. Also, the same participant also had Mycoplasmataceae and 
Enterobacteriaceae detected which may suggest susceptibility to the acquisition of other 
pathogenic bacteria, however this would have to be evaluated on a larger group to fully 
understand the presence of these pathogens in the samples. Another reason for the presence of 
unexpected microorganisms in the samples (or controls) could be an indication of (1) index 
hopping which is the misassignment of reads in multiplexed libraries that occurs when the DNA 
index of one sample is switched with the index of another sample. (2) Contamination is likely in 
low biomass samples as even a small contaminant signal from laboratory reagents or 
environmental sources such as air within the facility in which the samples are prepared (in this 
study samples were prepared in a general laboratory) can over power the intrinsic signal in a 
sample. (3) Spillover and micro droplets can also be contributing factors to the presence of 
unexpected OTU’s in samples (or control) during library preparation. 
Only one study has described the presence of other respiratory microbiota in children with and 
without TB in children, and was limited to the detection of specific microorganisms, including 
viruses (and fungi). The study showed that there was no clear separation between those with TB 
and those without, but that the microbial profile associated with the TB group was mainly 
composed of viruses (Dube et al., 2016), which is consistent with our finding that the bacterial 
microbiota did not vary significantly between TB cases and ill controls. Other studies that have 
described the respiratory microbiome in relation to TB have investigated the adult lung; and 
although a distinct microbial profile was not identified, differences in diversity (Cui et al., 2012; 
Botero et al., 2014) and relative abundance of phyla and genera between the healthy and PTB 
cases were observed (Eshetie and Van Soolingen, 2019).  
A healthy control group was not included in this study, therefore the baseline microbiota of TB 
cases was compared to the asymptomatic 6 month samples from participants in the ill control 




would have been treated, and the microbiota could have recovered by this point. This was merely 
done to describe potential taxonomic differences between the two groups. The month 6 ill controls 
mainly differed from the TB cases by being dominated by the presence of Pasteurellaceae, 
Streptococcaceae and Moraxellaceae, where the TB cases had more Streptococcaceae present, 
which could support the hypothesis that those with TB had an unstable microbiome in comparison 
to those without TB. Comparing the alpha diversity (Shannon and Simpson) indices between the 
TB cases and ill control group at baseline to the TB cases and month 6 ill control group, it was 
observed that the p values for the Shannon (p= 0.24 versus 0.15 ) and Simpson (p= 0.31 versus 
0.11) indices decreased. This suggests that there may be a difference in diversity between the 
microbiota of TB cases at diagnosis and healthy controls. This warrants further investigation of 
the respiratory microbiota in children but with the inclusion of a healthy control group; and a larger 
population size. 
The respiratory microbiota during TB treatment 
The microbial profiles of the TB cases at baseline and during TB treatment were similar with 
regard to the common familia observed in the samples, Streptococcaceae, Veillonellaceae, 
Pasteurellaceae, Prevotellaceae and Neisseriaceae. However, at a taxonomic level it appeared 
that at month 2 and month 6 there was increase in the presence of Fusobacteriaceae which was 
identified in only a few samples and in low abundance at baseline. From baseline to month 2 there 
was a decrease in the presence and abundance of Moraxellaceae and Pasteurellaceae which 
then seemed to increase in abundance at month 6. On the other hand, in the month 6 samples 
there seemed to be an increase in the presence of Paraprevotellaceae and a decrease in the 
relative abundance of Prevotellaceae in comparison to the month 2 samples. Namasivayam et al 
(2018) reviewed studies that investigated the effects of first line TB treatment on the intestinal 
microbiome in humans and mouse models. A decrease in Paraprevotella and Pasteurella in 
mouse models and Prevotella in humans, in addition to an increase in Fusobacterium and 
Prevotella in humans (Namasivayam et al., 2018) was noted. Our findings are similar in that 
familia associated with the above-mentioned genera increased (Fusobacteriaceae) and 
decreased (Pasteurellaceae) during TB treatment. We also observed an increase in the presence 
of familia Parapreveotellaceae and Prevotellaceae where they observed a decrease in the 
associated genera, Paraprevotellla and Prevotella. This could be attributed to the different effects 
of TB treatment on different microbial niches or the variability of the nasopharyngeal microbiome 




In this study, it appears that TB treatment did not seem to influence the microbial composition, or 
alpha and beta diversity in the TB case group over time, since no major differences were 
observed. This might not be surprising since most of the first line TB drugs (INH, PZA and EMB) 
specifically target M.tb; although RIF has a broad spectrum of activity. Also, perhaps the 
concentration of the drugs in the infants’/childrens’ body was not high enough to have a 
substantial effect on the overall diversity. Some studies have previously reported lower TB drug 
concentrations in children, like a lower concentration of PZA in children under the age of 5 years 
(Graham et al., 2006) and lower concentrations of rifampin (RIF), PZA and EMB when co-infected 
with HIV (Ramachandran et al., 2016; Antwi et al., 2017). This should also be accounted for in 
future studies since treatment is adjusted throughout therapy as doses are adjusted according to 
weight (South African National Department of Health, 2013). Nonetheless, our findings are similar 
to those of Wipperman et al (2017) and Namasivayam et al (2017) who showed that TB treatment 
had a minimal effect on diversity in intestinal microbiota of adults and mice. 
However, differentially abundant familia were observed when comparing baseline TB cases to 
month 6 TB cases (pre and post TB treatment) which indicates that TB treatment may not have 
an overall effect on the diversity of the niche being investigated but may influence the richness 
and or abundance of the identified taxa in the niche. This was similar to what was found by 
Wipperman et al (2017) in an intestinal microbiota study where the overall diversity was not 
affected but certain bacterial taxa was reduced. Determining what drove the reduction (combined 
broad and narrow spectrum activity of TB treatment or solely broad spectrum activity) of specific 
taxa in this study was not investigated but would be an interesting concept to investigate in future 
especially since the findings of this study may have been influenced by the limitations of the study.  
Factors to consider when interpreting effects of treatment on the microbiota should be factored 
in. In this study it is recognized that the nasopharyngeal microbiome is constantly being exposed 
to and is easily accessible for the acquisition of other pathogens, therefore a more accurate 
measure of the effect of TB treatment should rule out other factors that could contribute to 
changes, such as age, the acquisition of other pathogens (bacterial, viral or fungal), temporal 
variation or immune response (García-Rodríguez and Fresnadillo Martínez, 2002), especially if 
significant differences in diversity are found prior to treatment. Further research should be 
conducted on a larger scale while taking into account these factors, to fully assess the effect of 
TB treatment in the respiratory microbiome in children. Additional sampling after completion of 
treatment would also be of value, as alterations to the microbiome can persist after cessation of 




As previously mentioned, all participants were ill and even after 6 months the participants in the 
ill control group still had a microbial profile that resembled an unstable microbiome (i.e. high 
abundance of Streptococcaceae observed). This could imply that at this point their microbiomes 
had not yet fully improved since those organisms that are associated with a more stable 
microbiome were not commonly observed (Corynebacteriaceae: genus Corynebacterium and 
Carnobacteriaceae: genus Dolosigranulum). This could allow for interventional therapy to be 
implemented, such as probiotics to assist in the restoration of microbiota in both groups. However, 
a challenge with the implementation of probiotics include determining the best approach i.e. 
intranasal application or oral supplements and determining the bacteria that would be most 
effective for restoring the microbiota while counteracting pathogens. This warrants the further 
investigation into developing appropriate probiotics that are potentially niche specific. 
Although the alpha and beta diversity measures showed no significant differences in the control 
group at the different time points, a number of changes in the familia were observed over time, 
including an apparent increase in the relative abundance of Neisseriaceae at month 2, and an 
increase in the presence of Moraxellaceae and Paraprevotellaceae and a decrease in the 
presence of Prevotellaceae from month 2 to month 6. Cardiobacteriaceae, Weeksellaceae and 
Tisseriellaceae were also unique to the month 6 ill control samples. The reasons for changes are 
not clear, but some of these might be attributed to the initial treatment prescribed for the 
respiratory illness at baseline, and the recovery of the microbiota following treatment. However, 
this also demonstrates that the nasopharyngeal microbiome can change over time, in the absence 
of continuous antibiotic therapy. Also, it would be important to determine whether certain bacteria, 
viruses or other microbes could have contributed to the increase and decrease of certain groups 
of bacteria.  
Limitations 
The family level was used to describe differences in the microbial profiles between the TB case 
and ill control groups and to measure the diversity in and between samples in the case and ill 
control group at baseline and during TB treatment. Multiple bacterial genera and species can be 
clustered within a higher taxonomic rank and therefore clustering at family level does not provide 
a high level of detail of the range of bacteria present in the respiratory samples. Therefore, 
although more accurate, this level of classification was less specific and may have prevented the 
identification of significant differences between groups. Comparing the findings in this study to 
previously reported studies is difficult as taxonomic profiles and diversity measures can be 




of the 16S rRNA gene and different sample types. Furthermore, there is not much applicable data 
available to compare it to for this age group. 
All participants were ill at the time of recruitment and may have received other antibiotics prior to 
baseline sample collection, as only participants that had received TB treatment for > 2 days in the 
previous two weeks were excluded. This could be a confounding factor, as antibiotics have 
previously been identified as an external interference that can contribute to dysbiosis. The ill 
control group may also have been exposed to additional antibiotics following recruitment, to treat 
their respiratory infections. Since a healthy control group was not included in the study it cannot 
be determined whether the microbial profile is specific to the TB case or ill control group or more 
related to respiratory disease in general. It is therefore necessary to consider the inclusion of age 
matched healthy participants for future studies.  
We mainly focused on describing taxa that were present in children with suspected PTB and no 
associations were made between the presence of these taxa in relation to TB disease. In future 
studies it would be useful to try and associate certain taxa with PTB to determine whether it plays 
a role in disease pathogenesis and severity. Factors that could contribute changes in the 
microbiome such as mode of delivery, seasonal changes, viruses, siblings and breastfeeding 
were not taken into account during analysis and therefore limits the understanding of the presence 
of the familia identified at different time points or even at baseline. It would therefore be crucial to 
incorporate this in future studies since it is known to impact the nasopharyngeal microbiome. 
However, this would also require increased sample size, to enable statistical evaluation.  
Lastly, a small proportion (8/77) of samples were IS samples. This did not appear to influence the 
results as the IS samples only differed from NPA samples by the relative abundance of familia 
and the presence of Leptotrichiaceae. The genus Leptotrichia has previously been identified in 
sputum samples obtained from adult TB cases and controls (Cheung et al., 2013) suggesting that 





TB remains a global health concern especially in the pediatric population group and there are 
gaps in our understanding of this disease in this group. The improvement of sequencing 
technologies and the discovery of the human microbiome provided insight into healthy and 
diseased states, which could assist in our understanding of disease pathogenesis and the effects 
of antibiotics on the microbiome. 
This study aimed to describe the nasopharyngeal microbiota in children with suspected PTB and 
the effects of TB treatment on the nasopharyngeal microbiota. The findings suggest that there are 
no significant differences in the microbiota profile or diversity between the TB cases and ill controls 
at baseline based on alpha and beta diversity (Bray Curtis and weighted UniFrac), which may 
have been influenced by the fact that both groups investigated were ill and probably received 
antibiotic therapy prior to recruitment into the study. Similarly, no significant differences were 
apparent in the alpha diversity after 2 and 6 months of TB treatment in the TB case group which 
may suggest that TB treatment did not have a major influence on the diversity but could have 
contributed to the changes observed to familia in the nasopharyngeal samples. Without the 
addition of differential abundance testing the results would suggest that no differences existed 
between the TB case and ill control group or that TB treatment had no effect on the microbiota. 
This was found to be an imprecise description of the results of the study as at the family level the 
TB cases did differ to the ill controls and changes to the microbiota was observed after TB 
treatment. The inclusion of this test therefore allowed for a more informed interpretation of the 
results for this study and also showed the importance of including quantitative data alongside 
qualitative data analysis. However, these analyses were limited by the small sample size, and in 
particular the poor sequencing quality which limited taxonomic classification to the family level. 





CHAPTER 5:  
Concluding remarks 
Tuberculosis (TB) is an ancient scourge that persists. The initial contributions to understanding 
the pathophysiology of the disease dates to the 1800’s. To date, the major etiological agent has 
been identified with an understanding of disease pathogenesis, and measures to control the 
disease have been implemented through diagnosis and TB treatment. However, in children TB 
disease is somewhat obscured by the unclear clinical presentation and the paucibacillary nature 
of the disease. Through scientific advancements, microbial identification has become easier and 
microbial interplay has become increasingly evident. More so, that human health is established 
through our “microbiome”. Respiratory microbiome research is still in its infancy, but studies have 
found associations between the upper respiratory tract and lower respiratory tract infections such 
as pneumonia (Sakwinska et al., 2014; Kelly et al., 2017), asthma (Teo, Mok, Pham, Kusel, 
Serralha, Troy, Barbara J Holt, et al., 2015; Teo, Mok, Pham, Kusel, Serralha, Troy, Barbara J. 
Holt, et al., 2015) and cystic fibrosis (Prevaes et al., 2016). However, with regard to TB disease, 
respiratory microbiome research has focused on the adult lung, limiting the studies conducted in 
children. 
This study aimed to compare the respiratory microbiota of children with bacteriologically 
confirmed, clinically diagnosed and unlikely TB (well-defined ill controls) and to describe the effect 
of TB treatment on the respiratory microbiota in children with PTB. The aims were achieved by 
completing three main objectives, firstly to determine the presence of various bacterial pathogens 
and the fungal pathogen (Pneumocystis jirovecii) in respiratory samples from children with 
suspected PTB at baseline (study entry), using the Seegene Allplex Respiratory Panel 4 and an 
in-house real-time PCR assay, respectively. Secondly, to describe the respiratory microbiota in 
children with PTB (bacteriologically confirmed/ clinically diagnosed) and without PTB (well-
defined ill controls) and thirdly to describe the effect of TB treatment on the respiratory microbiota 
in children with PTB after 2 and 6 months in comparison to those without PTB. The second and 
third objectives were completed by sequencing the v4 region of the 16S ribosomal RNA (rRNA) 
gene on the Illumina Miseq platform. 
The study population included children aged 0-13 years with suspected PTB that were enrolled 
from secondary and tertiary provincial hospitals (Karl Bremer and Tygerberg Hospital, 
respectively) in Cape Town. Participants were classified as having “bacteriologically confirmed 




investigation and clinical follow-up (Chapter 1, Section 1.9). A healthy control group was not 
included in this study. 
The first section of this study showed no association between the presence or absence of certain 
pathogens (and pathobionts) and the different disease categories evaluated (bacteriologically 
diagnosed/clinically diagnosed and unlikely PTB). This may have been a result of the limited 
sample size, the lack of a healthy control group or being limited to the detection of certain bacteria 
and fungi based on the assays used. Nonetheless, it was observed that Streptococcus 
pneumoniae and Haemophilus influenzae were the most prevalent bacterial species identified in 
participants with suspected PTB, which was not surprising since both pathobionts are among the 
common and transient pathobionts identified in the nasopharynx (Bogaert et al., 2011). However, 
these pathobionts are also associated with unstable colonization patterns in children, which has 
been suggested to increase the risk of development of respiratory infections (Biesbroek, 
Tsivtsivadze, Elisabeth A M Sanders, et al., 2014). This could be relevant to our study since all 
participants that were included in this study suffered from respiratory disease. However, this 
would have to be explored further in relation to a healthy control group to evaluate the significance 
of these pathobionts in our study.  
Atypical pathogens such as Chlamydiae pneumoniae and Mycoplasma pneumoniae were 
detected in both the unlikely TB and the TB case groups, respectively. The presence of atypical 
respiratory pathogens in the unlikely TB group could have provided insight into the cause of the 
clinical disease in these participants, but based on their detection amongst TB cases, the findings 
are difficult to interpret. The limited atypical pathogens detected (bacteria and fungal) may 
suggest that viruses contribute to disease in the unlikely TB controls. Like bacteria, viruses can 
also exist in the nasopharynx without causing disease, i.e. asymptomatic carriage. However, 
viruses are also most likely to contribute to acute respiratory infections in young children (Brealey 
et al., 2015) which supports the likelihood of it contributing to disease in the unlikely TB group. 
This is being explored in the same population but has yet to be combined with our data set. The 
importance of including viruses is that viral and bacterial interactions can exist which can 
contribute to disease severity or acquisition of other pathogenic bacteria. This was previously 
reported in adults with suspected PTB, where being co-infected with both viruses and bacteria 
was associated with more severe TB disease (Mhimbira et al., 2018). Viruses were also seen to 
dominate the microbial profile in children with TB, but the significance of co-detection with viruses 
and bacteria could not be determined (Dube et al., 2016). It was suggested that the host becomes 




the lung pathology associated with PTB or becomes predisposed to an accelerated clinical course 
or presentation of symptoms due to intercurrent infections that caused immunosuppression (Dube 
et al., 2016). The detection of certain microorganisms in our study provided insight into what was 
present in the nasopharynx in children with suspected PTB but to better understand the 
significance and association of these pathogens (and pathobionts), they should be evaluated 
alongside viruses (and fungi) to contribute to our understanding of disease pathogenesis, severity 
and clinical presentation of disease in those with and without PTB and in healthy controls. 
Certain risk factors for the presence of bacterial pathogens were evaluated of which only mode 
of delivery and breastfeeding were found to be statistically significantly associated. Nonetheless, 
some studies found that these particular risk factors are associated with the carriage of 
microorganisms as seen for mode of delivery (Esposito and Principi, 2018) or offer potential 
protective benefits against respiratory infections (Biesbroek, Tsivtsivadze, Elisabeth A. M. 
Sanders, et al., 2014), where other studies did not see an association with breastfeeding (Kaleida 
et al., 1991; Bakhshaee et al., 2015). In future, this would need to be evaluated alongside a 
healthy control group and on a larger scale to determine the relevance in our population.  
The second part of this study focused on describing the nasopharyngeal microbiota in children 
with suspected PTB as well as to describe the effect of TB treatment on nasopharyngeal 
microbiota. Although the term microbiota describes bacteria, viruses and fungi etc., the focus of 
this study was on the bacterial assemblage of organisms in the nasopharynx. This section of the 
study focused on a subset of participants (TB cases (drug susceptible TB cases) and well-defined 
ill-controls) and established and assessed the utility of the 16S rRNA library sequencing in our 
setting. 
No distinct microbial profile was identified for the TB cases (bacteriologically confirmed/clinically 
diagnosed TB) or ill control group at baseline or at follow up time points. The alpha and beta 
diversity (Bray-Curtis and weighted UniFrac) measures also showed no significant differences 
between the TB cases or ill control group at baseline or at follow up time points. This may have 
been due to the fact that all participants were ill and that healthy participants were not included or 
due to the fact that the majority of participants were exposed to antibiotics prior to and after 
recruitment. First-line TB treatment did not seem to largely influence the microbial composition 
and diversity in this population. Contrary to the standard alpha and beta diversity measures used 
in this study, the addition of differential abundance testing indicated that shifts in abundance of 
certain Familia between the TB case group at baseline and month 6 occurred. Which indicates 




composition of taxa but could influence the abundance of certain taxa. However, evaluating this 
on a larger scale and with a healthy control group may provide better insight into the microbial 
composition and diversity changes after TB treatment. The use of 16S rRNA sequencing informs 
us of what pathogens (or commensals) are present (specifically bacteria) in a particular niche or 
sample, however, it does not provide insight into what other (non-bacterial) pathogens or 
pathobionts are present or what they are doing. Shotgun metagenomics may be more appropriate 
for this as it provides more information regarding the microbial functionality and biological 
processes that are taking place (Segata et al., 2013) but has additional financial, expertise and 
analytical challenges. As far as it is known no study has investigated the role of the 
nasopharyngeal microbiome in relation to TB disease which makes it difficult to compare to other 
studies. The studies that have investigated the role of the respiratory microbiome in relation to TB 
disease either investigated the lung microbiome (microbiota) in adults (Cui et al., 2012; Botero et 
al., 2014; Eshetie and Van Soolingen, 2019) or identified nasopharyngeal microorganisms using 
other PCR-based methods (Dube et al., 2016), which allows us to compare the presence of 
certain pathogens but not the role these pathogens play in these children specifically. This 
signifies the importance of investigating these findings further. 
Limitations of microbiome sequencing in our study 
This pilot study was limited by technical issues related to sample collection and storage, DNA 
quality, 16S library preparation and sequencing and data analysis. Limited sample volume limited 
our ability to re-extract samples with poor quantity or quality DNA, and suboptimal storage 
conditions (long term at -20°C) may have compromised sample integrity. All respiratory samples 
collected at baseline and follow up visits (month 2 and month 6) and selected for microbiome 
analysis, were included, irrespective of DNA quality, sample type (NPA versus IS), time point 
(month 1 versus month 2) or whether the sample DNA was amplifiable by PCR. Under ideal 
circumstances, samples would be excluded on the basis of these factors to exclude confounders, 
however, due to the limited number of participants that were selected for this section of the work, 
all samples were included. Poorer DNA quality is often seen in low biomass respiratory samples 
which are also easily contaminated (Faner et al., 2017). This should be kept in mind when 
analyzing microbiome results as contamination may provide an inaccurate representation of what 
is present in the samples. However, in our study contamination did not seem to majorly influence 
the results, but this highlights the importance of including adequate controls in the study. 
Paired-end sequencing (2x300 bp) of the v4 region of the 16S rRNA gene was done on the 




Department of Biotechnology, University of the Western Cape. This introduced additional 
challenges as the library preparation was performed at two different facilities, which was not ideal 
especially because of the consistency that is required to conduct thorough microbiome research. 
Furthermore, due to the infrastructural challenges in South Africa, load shedding was experienced 
during the sequencing run and due to failure of the back-up generator, sequencing was terminated 
prematurely, resulting in shorter reverse reads. These challenges highlight limitations in 
conducting research in resource limited settings. Due to these challenges, only the forward reads 
were used for the microbiome analysis which may be a reason why the sequences could only be 
classified to a higher taxonomic level (family). The database (Greengenes) used for the 
sequencing alignment is the default database in the QIIME pipeline, and is the most frequently 
used; but is also the least updated of the available databases for 16S taxonomic assignment 
(Pollock et al., 2018). Taxonomic assignment is a primary component of microbial community 
analysis, so choosing a suitable database is essential as it may influence post analysis and 
interpretation of the community composition (Park and Won, 2018). Park and Won (2018) 
evaluated bacterial reference databases (Greenegenes, SILVA and EzBioCloud) with a mock 
community and found that Greengenes predicted fewer genera than expected. This was thought 
to be due to the fact that the database was not updated (since 2013) and therefore would not 
contain newly identified novel bacterial sequences. However, in our study some common bacteria 
(Escherichia and Enterococcus sp) could not be identified at the genus level, which may be due 
to the sequences not being specific enough, due to suboptimal sequencing quality, to accurately 
identify taxa at the genus level and the short read length which influences taxonomic assignment; 
as a result the family level was used.  
This could also be a disadvantage of using OTUs for taxonomic clustering as sequences are 
clustered based on similarity to the database, therefore any errors in the database caused by 
sequencing/PCR error or by incorrectly labelled sequences may lead to misclassification or 
identification (Pollock et al., 2018). In recent years an alternative approach to using OTUs has 
been introduced, namely amplicon sequence variants (ASVs) or exact sequence variants (ESVs) 
(Callahan, McMurdie and Holmes, 2017). This has also been incorporated into QIIME 2 which 
has since succeeded QIIME 1. ASVs are inferred by a de novo process where sequences are 
differentiated from errors, partly based on the expectation that biological sequences are more 
likely to be repeatedly observed than are error sequences. Consequently, ASV inference is not 
performed separately on each read but by sample. This could potentially be beneficial in low 
biomass samples, such as respiratory samples, that are prone to contamination and could be 




sequencing data makes it difficult to compare results from one study to another. Therefore, the 
selection of pipeline, database or clustering method used should be guided by what is commonly 
used for the biological site being investigated and what is available at hand in the research setting 
where the analysis will be conducted. 
The relative abundance of OTUs was used in our study to normalize the data, however this 
approach is not always recommended as it has been reported that it can lead to samples 
clustering by sequencing depth (Goodrich et al., 2014). This approach was used as the alternative 
method, rarefaction, was considered to be a more stringent approach which would have 
substantially reduced the amount of sequences to work with. Rarefaction requires equal number 
of sequences to be selected from each sample, which can be selected based on the sample with 
the least amount of sequences. A disadvantage to this approach is that data from high sequence 
count samples will be discarded, but may at the same time be a conservative approach to view 
the abundances of rarer taxa across the samples (Goodrich et al., 2014). Identifying rarer taxa in 
our study was not particularly pertinent as we aimed to describe the nasopharyngeal microbiota 
as whole in children with suspected PTB and therefore we considered using the relative 
abundance of OTUs to be sufficient for this pilot study.  
In a general sense, microbiome research is a fairly new concept and much of the focus of this 
research has been on gastrointestinal microbiome research in comparison to other microbial 
habits, such as the respiratory microbiome which is still in its infancy. Therefore, various methods 
are being implemented to conduct research and the best practice has yet to be determined. 
Goodrich et al (2014) and Pollock et al (2018) reviewed and proposed various (general) 
approaches that should be considered during microbiome research this ranged from sample 
collection to contamination issues. A standardized protocol could be established based on this 
reviewed literature and should be considered for future microbiome projects. The main suggestion 
is that all data should be recorded throughout the project and that consistency is key. In future, a 
single database could be generated prior to starting the study which would include participant 
information and different factors that could influence the overall result, e.g. antibiotic use and the 
duration it was used and distributed to the respective researchers. For example, including the 
sample type and the way in which the sample was stored, i.e. stored in a cryoprotectant and 
temperature at which it was stored after collection. Controls could also be obtained at this point 
which could account for possible contamination during sample collection. As for library 
preparation and sequencing this would depend on the availability of appropriate equipment 




resource limited settings, but each step during library preparation should be recorded and 
accounted for.  
Future recommendations 
Not many studies highlight the challenges that are experienced alongside research outputs. In 
doing this it assists researchers who are experiencing similar challenges and informs them of 
possible ways in which it can be overcome. Other challenges such as lack of support can also be 
a factor in microbiome research, especially when this type of research is a fairly new research 
concept that is being explored in the researcher’s department. However, this can be addressed 
through collaborations with other researchers and departments (as was seen in this study). For 
example, Stellenbosch University recently established the African Microbiome Institute, it is a 
fairly new establishment that has the potential to offer the necessary support that is not always 
readily available for departments that are trying to broaden their microbiome research. This could 
be a facility where students interact with one another about challenges that is experienced and 
ways in which it could possibly be approached alongside research outputs. Additionally, 
identifying researchers and students with similar research interests, such as exploring the gut 
microbiome or the respiratory microbiome will allow for the ideal opportunity to discuss 
approaches from sample collection to sequencing analysis which could possibly assist in 
establishing standardized protocols that could be used depending on the specific research 
project. These protocols would be a useful guide for departments while establishing some sort of 





In conclusion, this study observed no significant differences in terms of alpha or beta diversity 
between the respiratory microbiotas in children with bacteriologically confirmed, clinically 
diagnosed and unlikely PTB categories or before and after TB treatment. However, differential 
abundance testing indicated that TB cases and ill controls differed and that TB treatment 
contributed to shifts in certain Familia after TB treatment. The Seegene Allplex respiratory panel 
data was comparable to the microbiota data as bacteria identified with the Seegene respiratory 
panel belonged to familia identified in the samples that were sequenced. This provides confidence 
in the sequencing information that was obtained irrespective of the challenges experienced and 
the lack of stringent quality filtering steps after sequencing. Additionally, the microbiotas of both 
TB cases and ill controls appeared unstable which should be investigated further. The instability 
of the microbiome in the ill control groups may be related to other factors such as poor nutrition 
or environmental exposures like smoking. This warrants further research as possible interventions 
like probiotics, nutritional support could potentially prevent future respiratory disease in this 
vulnerable population. This study contributed to the data available with regard to respiratory 
microbiome (microbiota) in children with suspected PTB in a TB endemic setting and also 
highlighted the challenges of conducting research in resource limited settings and suggests ways 
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This document provides information for an application for Illumina technology that has been 
demonstrated internally and may be of interest to customers. This information is provided as‐is and 
is not an Illumina product and is not accompanied by any rights or warranties. Customers using or 
adapting this information should obtain any licenses required and materials from authorized 
vendors. Illumina products mentioned herein are for research use only unless marked otherwise. 
While customer feedback is welcomed, this application is not supported by Illumina Technical 















Metagenomic studies are commonly performed by analyzing the prokaryotic 16S ribosomal RNA gene 
(16S rRNA), which is approximately 1,500 bp long and contains nine variable regions interspersed 
between conserved regions. Variable regions of 16S rRNA are frequently used in phylogenetic 
classifications such as genus or species in diverse microbial populations. 
Which 16S rRNA region to sequence is an area of debate, and your region of interest might vary 
depending on things such as experimental objectives, design, and sample type. This protocol 
describes a method for preparing samples for sequencing the variable V3 and V4 regions of the 16S 
rRNA gene. This protocol can also be used for sequencing other regions with different region‐specific 
primers. This protocol combined with a benchtop sequencing system, on‐board primary analysis, and 
secondary analysis using MiSeq Reporter or BaseSpace, provides a comprehensive workflow for 16S 
rRNA amplicon sequencing. 
 
Workflow Summary: 
1 Order amplicon primers–The protocol includes the primer pair sequences for the V3 and V4 region 
that create a single amplicon of approximately ~460 bp. The protocol also includes overhang 
adapter sequences that must be appended to the primer pair sequences for compatibility with 
Illumina index and sequencing adapters. Illumina does not sell these primers. They must be 
ordered from a third party. See Amplicon Primers, on page 3 for more information on amplicon 
primers. 
 
2 Prepare library–The protocol describes the steps to amplify the V3 and V4 region and using a 
limited cycle PCR, add Illumina sequencing adapters and dual‐index barcodes to the amplicon 
target. Using the full complement of Nextera XT indices, up to 96 libraries can be pooled together 
for sequencing. 
 
3 Sequence on MiSeq–Using paired 300‐bp reads, and MiSeq v3 reagents, the ends of each read are 
overlapped to generate high‐quality, full‐length reads of the V3 and V4 region 
in a single 65‐hour run. The MiSeq run output is approximately > 20 million reads and, assuming 
96 indexed samples, can generate > 100,000 reads per sample, commonly recognized as sufficient 
for metagenomic surveys. 
4 Analyze on MSR or BaseSpace–The Metagenomics workflow is a secondary analysis option 
built into the MiSeq Reporter (on‐system software) or available on BaseSpace (cloud‐based 
software). The Metagenomics Workflow performs a taxonomic classification using the 
Greengenes database showing genus or species level classification in a graphical format. 
This protocol can be used to sequence alternative regions of the 16S rRNA gene and for other targeted 
amplicon sequences of interest. When using this protocol for amplicon sequencing other than 16S 
rRNA, use the Generate FASTQ Workflow (secondary analysis option). For more information, see MiSeq 
Reporter Metagenomics Workflow, on page 20. 
 
DISCLAIMER 
The information in this Illumina Demonstrated Protocol is being provided as a courtesy; in 
some cases reagents are required to be purchased from non‐authorized third‐party suppliers. 
Illumina does not guarantee nor promises technical support for the performance of our 







Figure 1    16S V3 and V4 Amplicon Workflow 
 
User‐defined forward and reverse primers that are complementary upstream and downstream of the region of 
interest are designed with overhang adapters, and used to amplify templates from genomic DNA. A subsequent 
limited‐cycle amplification step is performed to add multiplexing indices and Illumina sequencing adapters. 
Libraries are normalized and pooled, and sequenced on the MiSeq system using v3 reagents. 
Amplicon Primers 
•    The gene‐specific sequences used in this protocol target the 16S V3 and V4 region. They are 
selected from the Klindworth et al. publication (Klindworth A, Pruesse E, Schweer T, Peplles J, 
Quast C, et al. (2013) Evaluation of general 16S ribosomal RNA gene PCR primers for classical and 
next‐generation sequencing‐based diversity studies. Nucleic Acids Res 41(1).) as the most 
promising bacterial primer pair. Illumina adapter 
overhang nucleotide sequences are added to the gene‐specific sequences. The full length primer 
sequences, using standard IUPAC nucleotide nomenclature, to follow the protocol targeting this 
region are: 
16S Amplicon PCR Forward Primer = 5' 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 
16S Amplicon PCR Reverse Primer = 5' 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC 
•    This method can also be utilized to target other regions on the genome (either for 16S with other 
sets of primer pairs, or non‐16S regions throughout the genome; ie any amplicon). The overhang 
adapter sequence must be added to the locus‐specific primer for the region to be targeted 
(Figure 1). The Illumina overhang adapter sequences to be added to locus‐specific sequences 
are: 
Forward overhang: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG‐[locus‐ 
specific sequence] 







•    The following considerations are recommended for designing other locus‐specific primers: 
a Illumina recommends targeting regions that result in an amplicon that when sequenced with 
paired‐end reads has at least ~50 bp of overlapping sequence in the middle. For example, if 
running 2x300 bp paired‐end reads Illumina recommends having an insert size of 550 bp or 
smaller so that the bases sequenced at the end of each read overlap. 
b    The locus‐specific portion of primer (not including overhang sequence) must have a melting 
temperature (Tm) of 60°–65°C. You can use online PCR primer sequence analysis tools (e.g. 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) to check the properties of 
primer designs. For the Tm calculation only, the gene‐specific portion must be used in 
calculation. For hairpin and dimer calculations, the fully‐ assembled primer sequence (including 
the overhang) should be used. 
c Illumina recommends using standard desalting purification when ordering oligo primer sets. 
 
NOTE 
For more information on reagents used in the protocol, see Consumables and Equipment, 










16S Library Preparation Workflow 
 
 
The following diagram illustrates the workflow using the 16S Library Preparation Protocol. Safe 
stopping points are marked between steps. 
 
Figure 2    16S Library Preparation Workflow 
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This step uses PCR to amplify template out of a DNA sample using region of interest‐ specific 
primers with overhang adapters attached. For more information on primer sequences, see 





For more information on consumables and equipment for this protocol see Consumables and 
Equipment, on page 21. 
 
 
Item                                                                               Quantity                                    Storage 
Microbial Genomic DNA (5 ng/µl in 10 mM Tris 
pH 8.5) 
2.5 µl per sample                        ‐15° to ‐25°C
 
Amplicon PCR Reverse Primer (1 µM)                     5 µl per sample                            ‐15° to ‐25°C 
 
Amplicon PCR Forward Primer (1 µM)                    5 µl per sample                            ‐15° to ‐25°C 
 
2x KAPA HiFi HotStart ReadyMix                              12.5 µl per sample                      ‐15° to ‐25°C 
 
Microseal 'A' film 
 
96‐well 0.2 ml PCR plate                                                 1 plate 
 
[Optional] Bioanalyzer chip (Agilent DNA 1000 kit 






















Microbial DNA (5 ng/µl)                                              2.5 µl 
 
Amplicon PCR Forward Primer 1 µM                      5 µl 
 
Amplicon PCR Reverse Primer 1 µM                        5 µl 
 
2x KAPA HiFi HotStart ReadyMix                          12.5 µl 
 









2     Seal plate and perform PCR in a thermal cycler using the following program: 
•     95°C for 3 minutes 
•     25 cycles of: 
—    95°C for 30 seconds 
—    55°C for 30 seconds 
—    72°C for 30 seconds 
•     72°C for 5 minutes 
•     Hold at 4°C 
 
3 [Optional] Run 1 µl of the PCR product on a Bioanalyzer DNA 1000 chip to verify the size. Using 
the V3 and V4 primer pairs in the protocol, the expected size on a Bioanalyzer trace after the 
Amplicon PCR step is ~550 bp. 
 
Figure 3    Example Bioanalyzer Trace after Amplicon PCR Step
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This step uses AMPure XP beads to purify the 16S V3 and V4 amplicon away from free primers 





Item                                                                                   Quantity                                       Storage 
 
10 mM Tris pH 8.5                                                                  52.5 µl per sample                          ‐15° to ‐25°C 
 
AMPure XP beads                                                                  20 µl per sample                             2° to 8°C 
 
Freshly Prepared 80% Ethanol (EtOH)                           400 µl per sample 
 
96‐well 0.2 ml PCR plate                                                      1 plate 
 
[Optional] Microseal 'B' film 
 




•    Bring the AMPure XP beads to room temperature. 
 
Procedure 
1 Centrifuge the Amplicon PCR plate at 1,000 × g at 20°C for 1 minute to collect 
condensation, carefully remove seal. 
 
2 [Optional - for use with shaker for mixing] Using a multichannel pipette set to 25 µl, transfer 




Transfer the sample to a 96‐well MIDI plate if planning to use a shaker for mixing. If 
mixing by pipette, the sample can remain in the 96‐well PCR plate. 
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3 Vortex the AMPure XP beads for 30 seconds to make sure that the beads are evenly dispersed. Add 
an appropriate volume of beads to a trough depending on the number of samples processing. 
 
4     Using a multichannel pipette, add 20 µl of AMPure XP beads to each well of the 
Amplicon PCR plate. Change tips between columns. 
 
5 Gently pipette entire volume up and down 10 times if using a 96‐well PCR plate or seal plate and 
shake at 1800 rpm for 2 minutes if using a MIDI plate. 
 
6     Incubate at room temperature without shaking for 5 minutes. 
 
7     Place the plate on a magnetic stand for 2 minutes or until the supernatant has cleared. 
 
8 With the Amplicon PCR plate on the magnetic stand, use a multichannel pipette to remove 









9 With the Amplicon PCR plate on the magnetic stand, wash the beads with freshly prepared 
80% ethanol as follows: 
a Using a multichannel pipette, add 200 µl of freshly prepared 80% ethanol to each sample 
well. 
b    Incubate the plate on the magnetic stand for 30 seconds. 
c    Carefully remove and discard the supernatant. 
 
10   With the Amplicon PCR plate on the magnetic stand, perform a second ethanol wash as follows: 
a Using a multichannel pipette, add 200 µl of freshly prepared 80% ethanol to each sample 
well. 
b    Incubate the plate on the magnetic stand for 30 seconds. 
c    Carefully remove and discard the supernatant. 
d    Use a P20 multichannel pipette with fine pipette tips to remove excess ethanol. 
 
11   With the Amplicon PCR plate still on the magnetic stand, allow the beads to air‐dry for 
10 minutes. 
 
12   Remove the Amplicon PCR plate from the magnetic stand. Using a multichannel pipette, add 52.5 
µl of 10 mM Tris pH 8.5 to each well of the Amplicon PCR plate. 
 
13   Gently pipette mix up and down 10 times, changing tips after each column (or seal plate and shake 
at 1800 rpm for 2 minutes). Make sure that beads are fully resuspended. 
 
14   Incubate at room temperature for 2 minutes. 
 
15   Place the plate on the magnetic stand for 2 minutes or until the supernatant has cleared. 
 
16   Using a multichannel pipette, carefully transfer 50 µl of the supernatant from the Amplicon PCR 
plate to a new 96‐well PCR plate. Change tips between samples to avoid cross‐contamination. 
SAFE STOPPING POINT 
If you do not immediately proceed to Index PCR, seal plate with Microseal “B” 
















Item                                                                                   Quantity                                       Storage 
 
2x KAPA HiFi HotStart ReadyMix                                   25 µl per sample                             ‐15° to ‐25°C
 
Nextera XT Index 1 Primers (N7XX) from the 
Nextera XT Index kit 
(FC‐131‐1001 or FC‐131‐1002) 
 
5 µl per sample                               ‐15° to ‐25°C
Nextera XT Index 2 Primers (S5XX) from the 
Nextera XT Index kit (FC‐131‐1001 or FC‐131‐ 
1002) 
5 µl per sample                               ‐15° to ‐25°C
 
PCR Grade Water                                                                  10 µl per sample 
 
TruSeq Index Plate Fixture (FC‐130‐1005)                     1 
 
96‐well 0.2 ml PCR plate                                                      1 plate 
 
Microseal 'A' film                                                                    1 
Procedure 
1 Using a multichannel pipette, transfer 5 µl from each well to a new 96‐well plate. The remaining 
45 µl is not used in the protocol and can be stored for other uses. 
 
2 Arrange the Index 1 and 2 primers in a rack (i.e. the TruSeq Index Plate Fixture) using the 
following arrangements as needed: 
a Arrange Index 2 primer tubes (white caps, clear solution) vertically, aligned with rows A 
through H. 
b    Arrange Index 1 primer tubes (orange caps, yellow solution) horizontally, aligned with 
columns 1 through 12. 









Figure 4    TruSeq Index Plate Fixture 
 
A    Index 2 primers (white caps) 
B    Index 1 primers (orange caps) 
C    96‐well plate 
 
3     Place the 96‐well PCR plate with the 5 µl of resuspended PCR product DNA in the 
TruSeq Index Plate Fixture. 
 
4     Set up the following reaction of DNA, Index 1 and 2 primers, 2x KAPA HiFi HotStart 















DNA                                                                                          5 µl 
 
Nextera XT Index Primer 1 (N7xx)                                  5 µl 
 
Nextera XT Index Primer 2 (S5xx)                                   5 µl 
 
2x KAPA HiFi HotStart ReadyMix                                 25 µl 
 
PCR Grade water                                                                 10 µl 
 
Total                                                                                50 μl 
 
 
5     Gently pipette up and down 10 times to mix. 
 
6     Cover the plate with Microseal 'A'. 
 









8     Perform PCR on a thermal cycler using the following program: 
•     95°C for 3 minutes 
•     8 cycles of: 
—    95°C for 30 seconds 
—    55°C for 30 seconds 
—    72°C for 30 seconds 
•     72°C for 5 minutes 
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PCR Clean‐Up 2 
 
 





Item                                                                                   Quantity                                       Storage 
 
10 mM Tris pH 8.5                                                                  27.5 µl per sample                          ‐15° to ‐25°C 
 
AMPure XP beads                                                                  56 µl per sample                             2° to 8°C 
 
Freshly Prepared 80% Ethanol (EtOH)                           400 µl per sample 
 
96‐well 0.2 ml PCR plate                                                      1 plate 
 
[Optional] Microseal 'B' film 
 




1     Centrifuge the Index PCR plate at 280 × g at 20°C for 1 minute to collect condensation. 
 
2 [Optional - for use with shaker for mixing] Using a multichannel pipette set to 50 µl, transfer 
the entire Index PCR product from the PCR plate to the MIDI plate. Change tips between samples. 
 
NOTE 
Transfer the sample to a 96‐well MIDI plate if planning to use a shaker for mixing. If 
mixing by pipette, the sample can remain in the 96‐well PCR plate. 
 
3 Vortex the AMPure XP beads for 30 seconds to make sure that the beads are evenly 
dispersed. Add an appropriate volume of beads to a trough. 
 







5 Gently pipette mix up and down 10 times if using a 96‐well PCR plate or seal plate and shake at 
1800 rpm for 2 minutes if using a MIDI plate. 
 
6     Incubate at room temperature without shaking for 5 minutes. 
 
7     Place the plate on a magnetic stand for 2 minutes or until the supernatant has cleared. 
 
8 With the Index PCR plate on the magnetic stand, use a multichannel pipette to remove and 
discard the supernatant. Change tips between samples. 
 
9     With the Index PCR plate on the magnetic stand, wash the beads with freshly prepared 
80% ethanol as follows: 
a Using a multichannel pipette, add 200 µl of freshly prepared 80% ethanol to each sample 
well. 
b    Incubate the plate on the magnetic stand for 30 seconds. 
c    Carefully remove and discard the supernatant.
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10   With the Index PCR plate on the magnetic stand, perform a second ethanol wash as follows: 
a Using a multichannel pipette, add 200 µl of freshly prepared 80% ethanol to each sample 
well. 
b    Incubate the plate on the magnetic stand for 30 seconds. 
c    Carefully remove and discard the supernatant. 
d    Use a P20 multichannel pipette with fine pipette tips to remove excess ethanol. 
 
11   With the Index PCR plate still on the magnetic stand, allow the beads to air‐dry for 10 minutes. 
 
12   Remove the Index PCR plate from the magnetic stand. Using a multichannel pipette, add 27.5 
µl of 10 mM Tris pH 8.5 to each well of the Index PCR plate. 
 
13   If using a 96‐well PCR plate, gently pipette mix up and down 10 times until beads are fully 
resuspended, changing tips after each column. If using a MIDI plate, seal plate and shake at 1800 
rpm for 2 minutes. 
 
14   Incubate at room temperature for 2 minutes. 
 
15   Place the plate on the magnetic stand for 2 minutes or until the supernatant has cleared. 
 
16   Using a multichannel pipette, carefully transfer 25 µl of the supernatant from the Index PCR plate 
to a new 96‐well PCR plate. Change tips between samples to avoid cross‐ contamination. 
SAFE STOPPING POINT 
If you do not plan to proceed to Library Quantification, Normalization, and Pooling, on page 
16, seal the plate with Microseal “B” adhesive seal. Store the plate at ‐15° to ‐25°C for 









[Optional] Validate Library 
 
 
Run 1 µl of a 1:50 dilution of the final library on a Bioanalyzer DNA 1000 chip to verify the size. Using 
the V3 and V4 primer pairs in the protocol, the expected size on a Bioanalyzer trace of the final library 
is ~630 bp. 
 
Figure 5    Example Bioanalyzer Trace of Final Library
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Library Quantification, Normalization, and Pooling 
 
 
Illumina recommends quantifying your libraries using a fluorometric quantification method that uses 
dsDNA binding dyes. 
 
Calculate DNA concentration in nM, based on the size of DNA amplicons as determined by an Agilent 
Technologies 2100 Bioanalyzer trace:
(concentration in ng/µl) 




(660 g/mol × 500) 




×       106             =                        45 nM
 
Dilute concentrated final library using Resuspension Buffer (RSB) or 10 mM Tris pH 8.5 to 4 nM. Aliquot 
5 µl of diluted DNA from each library and mix aliquots for pooling libraries with unique indices. 
Depending on coverage needs, up to 96 libraries can be pooled for one MiSeq run. 
 
For metagenomics samples, >100,000 reads per sample is sufficient to fully survey the bacterial 
composition. This number of reads allows for sample pooling to the maximum level of 96 libraries, 
given the MiSeq output of > 20 million reads.
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Library Denaturing and MiSeq Sample Loading 
 
 
In preparation for cluster generation and sequencing, pooled libraries are denatured with NaOH, 
diluted with hybridization buffer, and then heat denatured before MiSeq sequencing. Each run must 
include a minimum of 5% PhiX to serve as an internal control for these low‐ diversity libraries. Illumina 





Item                                                                                   Quantity                                       Storage 
 
10 mM Tris pH 8.5 or RSB (Resuspension Buffer)       6 µl                                                      ‐15° to ‐25°C 
 
HT1 (Hybridization Buffer)                                                1540 µl                                               ‐15° to ‐25°C 
 
0.2 N NaOH (less than a week old)                                  10 µl                                                   ‐15° to ‐25°C 
 
PhiX Control Kit v3 (FC‐110‐3001)                                   4 µl                                                      ‐15° to ‐25°C 
 
MiSeq reagent cartridge                                                       1 cartridge                                        ‐15° to ‐25°C 
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1     Set a heat block suitable for 1.7 ml microcentrifuge tubes to 96°C 
 
2 Remove a MiSeq reagent cartridge from ‐15°C to ‐25°C storage and thaw at room 
temperature. 
 
3     In an ice bucket, prepare an ice‐water bath by combining 3 parts ice and 1 part water. 
 
Denature DNA 
1 Combine the following volumes of pooled final DNA library and freshly diluted 0.2 N NaOH in a 
microcentrifuge tube: 
•     4 nM pooled library (5 µl) 
•     0.2 N NaOH (5 µl) 
 
2 Set aside the remaining dilution of 0.2 N NaOH to prepare a PhiX control within the next 12 
hours. 
 
3     Vortex briefly to mix the sample solution, and then centrifuge the sample solution at 280 
× g at 20°C for 1 minute. 
 
4     Incubate for 5 minutes at room temperature to denature the DNA into single strands. 
 
5     Add the following volume of pre‐chilled HT1 to the tube containing denatured DNA: 
•     Denatured DNA (10 µl)
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•     Pre‐chilled HT1 (990 µl) 
Adding the HT1 results in a 20 pM denatured library in 1 mM NaOH. 
 
6     Place the denatured DNA on ice until you are ready to proceed to final dilution. 
 
Dilute Denatured DNA 
1     Dilute the denatured DNA to the desired concentration using the following example: 
 
NOTE 
Illumina recommends targeting 800–1000 K/mm² raw cluster densities using MiSeq v3 
reagents. It is suggested to start your first run using a 4 pM loading concentration and 




2 pM                  4 pM                  6 pM                  8 pM                 10 pM
20 pM denatured 
library 
60 µl                    120 µl                   180 µl                   240 µl                   300 µl
 
Pre‐chilled HT1                     540 µl                   480 µl                   420 µl                   360 µl                   300 µl 
 
 
2     Invert several times to mix and then pulse centrifuge the DNA solution. 
 
3     Place the denatured and diluted DNA on ice. 
 
Denature and Dilution of PhiX Control 
Use the following instructions to denature and dilute the 10 nM PhiX library to the same loading 
concentration as the Amplicon library. The final library mixture must contain at least 5% PhiX. 
1     Combine the following volumes to dilute the PhiX library to 4 nM: 
•     10 nM PhiX library (2 µl) 
•     10 mM Tris pH 8.5 (3 µl) 
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2 Combine the following volumes of 4 nM PhiX and 0.2 N NaOH in a microcentrifuge tube: 
•     4 nM PhiX library (5 µl) 
•     0.2 N NaOH (5 µl) 
 
3     Vortex briefly to mix the 2 nM PhiX library solution. 
 
4 Incubate for 5 minutes at room temperature to denature the PhiX library into single strands. 
 
5     Add the following volumes of pre‐chilled HT1 to the tube containing denatured PhiX 
library to result in a 20 pM PhiX library: 
•     Denatured PhiX library (10 µl) 
•     Pre‐chilled HT1 (990 µl) 
 
6     Dilute the denatured 20 pM PhiX library to the same loading concentration as the 
Amplicon library as follows:
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2 pM                  4 pM                  6 pM                  8 pM                 10 pM
20 pM denatured 
library 
60 µl                    120 µl                   180 µl                   240 µl                   300 µl
 
Pre‐chilled HT1                     540 µl                   480 µl                   420 µl                   360 µl                   300 µl 
 
 
7     Invert several times to mix and then pulse centrifuge the DNA solution. 
 
8     Place the denatured and diluted PhiX on ice. 
 
Combine Amplicon Library and PhiX Control 
 
NOTE 
The recommended PhiX control spike‐in of ≥ 5% for low diversity libraries is possible with 
RTA v1.17.28 or later, which is bundled with MCS v2.2. For optimal performance, update to v3 
software (MCS 2.3). If you are using an older version of the MiSeq software or sequencing 
these libraries on the GA or HiSeq, Illumina recommends using ≥ 25% PhiX control spike‐in. 
 
1 Combine the following volumes of denatured PhiX control library and your denatured amplicon 
library in a microcentrifuge tube: 
•     Denatured and diluted PhiX control (30 µl) 
•     Denatured and diluted amplicon library (570 µl) 
 
2 Set the combined sample library and PhiX control aside on ice until you are ready to heat 
denature the mixture immediately before loading it onto the MiSeq v3 reagent cartridge. 
 
3 Using a heat block, incubate the combined library and PhiX control tube at 96°C for 2 minutes. 
 
4     After the incubation, invert the tube 1–2 times to mix and immediately place in the ice‐ 
water bath. 
 
5     Keep the tube in the ice‐water bath for 5 minutes. 
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Perform the heat denaturation step immediately before loading the library into the MiSeq 
reagent cartridge to ensure efficient template loading on the MiSeq flow cell.
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MiSeq Reporter Metagenomics Workflow 
 
 
After samples are loaded, the MiSeq system provides on‐instrument secondary analysis using the 
MiSeq Reporter software (MSR). MSR provides several options for analyzing MiSeq sequencing 
data. For this demonstrated 16S protocol, select the Metagenomics workflow. 
 
By following this 16S Metagenomics protocol, the Metagenomics workflow classifies organisms from 
your V3 and V4 amplicon using a database of 16S rRNA data. The classification is based on the 
Greengenes database (http://greengenes.lbl.gov/). The output of this workflow is a classification of 
reads at several taxonomic levels: kingdom, phylum, class, order, family, genus, and species. The 
analysis output includes: 
 
•    Clusters Graph – shows numbers of raw cluster, clusters passing filter, clusters that did not align, 
clusters not associated with an index, and duplicates. 
•    Sample Table – summarizes the sequencing results for each sample. 
•    Cluster Pie Chart – a graphical representation of the classification breakdown for each sample. 
 
See the MiSeq Reporter Metagenomics Workflow – Reference Guide (Part # 15042317) for detailed 
instructions and guidance. 
 
The method described in this 16S Metagenomics protocol can be used for any targeted amplicon 
sequencing, relevant to virus research, mutation detection, or other microbiology‐ related studies. If 
you use the protocol for other targeted amplicon sequencing studies, select the MiSeq Reporter 
Generate FASTQ Workflow for on‐instrument generation of FASTQ files for downstream analysis. For 
specific guidance on the Generate FASTQ Workflow, see the MiSeq Reporter Generate FASTQ 
Workflow – Reference Guide (Part # 15042322).
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The protocols described in this guide assume that you are familiar with the contents of this section 




Table 1    Acronyms 
Acronym           Definition 
 
HT1                 Hybridization Buffer 
 
IEM                 Illumina Experiment Manager 
 
MSR                 MiSeq Reporter 
 
PCR                 Polymerase Chain Reaction 
 
rRNA               Ribosomal RNA 
 
RSB                 Resuspension Buffer 
 
 
Consumables and Equipment 
Check to make sure that you have all of the necessary user‐supplied consumables and 
equipment before proceeding to sample preparation. 
 
Table 2    User‐Supplied Consumables 
 
Consumable                                                                             Supplier 
 
1.7 ml microcentrifuge tubes                                                       General lab supplier 
 
10 µl barrier pipette tips                                                               General lab supplier 
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10 µl multichannel pipettes                                                          General lab supplier 
 
10 µl single channel pipettes                                                        General lab supplier 
 
20 µl barrier pipette tips                                                               General lab supplier 
 
20 µl multichannel pipettes                                                          General lab supplier 
 
20 µl single channel pipettes                                                        General lab supplier 
 
200 µl barrier pipette tips                                                             General lab supplier 
 
200 µl multichannel pipettes                                                        General lab supplier 
 
200 µl single channel pipettes                                                     General lab supplier 
 








Consumable                                                                             Supplier 
 
1000 µl multichannel pipettes                                                     General lab supplier 
 
1000 µl single channel pipettes                                                   General lab supplier 
96‐well 0.2 ml skirtless PCR plates or 
Twin.Tec 96‐well PCR plates 
Bio‐Rad, part # MSP‐9601
 
Agencourt AMPure XP 60 ml kit                                               Beckman Coulter Genomics, part # 
A63881 
Ethanol 200 proof (absolute) for molecular biology 
(500 ml) 
Sigma‐Aldrich, part #  E7023
 
Amplicon PCR Forward Primer (Standard desalting) 
 
Amplicon PCR Reverse Primer (Standard desalting) 
 
KAPA HiFi HotStart ReadyMix (2X)                                        KAPA Biosystems, part # KK2601 
 
Microseal ‘A’ adhesive seals                                                        Bio‐Rad, part # MSA‐5001 
 
Microseal ‘B’ adhesive seals                                                         Bio‐Rad, part # MSB‐1001 
 
MiSeq Reagent Kit v3 (600 cycle)                                               Illumina, catalog # MS‐102‐3003 
 
Nextera XT Index Kit                                                                     Illumina, catalog # FC‐131‐1001 or 
Illumina, catalog # FC‐131‐1002 
 
PhiX Control Kit v3                                                                        Illumina, catalog # FC‐110‐3001 
 
PCR grade water                                                                             General lab supplier 








RNase/DNase‐free 8‐well PCR strip tubes and caps           General lab supplier 
RNase/DNase‐free multichannel reagent reservoirs, 
disposable 
VWR, part # 89094‐658
 
Tris‐HCl 10 mM, pH 8.5                                                                General lab supplier 
[Optional] 96‐well storage plates, round well, 0.8 ml 
(“MIDI” plate) 
Fisher Scientific, part # AB‐0859
 
 
Table 3    User‐Supplied Equipment 
 
Equipment                                                                    Supplier 
 
2.5 L ice bucket                                                                    General lab supplier 
96‐well thermal cycler 









Equipment                                                                    Supplier  
Fluorometer for quantitation with 
 
dsDNA binding dyes 
General lab supplier
 
Magnetic stand‐96                                                              Life Technologies, catalog # AM10027 
 
Microplate centrifuge                                                        General lab supplier 
 
TruSeq Index Plate Fixture Kit (reusable)                  Illumina, catalog # FC‐130‐1005 
 
[Optional] 2100 Bioanalyzer Desktop System          Agilent, part # G2940CA 
 
[Optional] Agilent DNA 1000 Kit                                  Agilent, part # 5067‐1504 
 
[Optional] High Speed Micro Plate Shaker                VWR, catalog # 13500‐890 (110V/120V) 
or 























The dual indexing strategy uses two 8 base indices, Index 1 (i7) adjacent to the P7 sequence, and Index 
2 (i5) adjacent to the P5 sequence. Dual indexing is enabled by adding a unique Index 1 (i7) and Index 
2 (i5) to each sample. The 96 sample Nextera XT Index Kit (FC‐131– 
1002) use 12 different Index 1 (i7) adapters (N701–N712) and 8 different Index 2 (i5) adapters (S501–
S508). The 24 sample Nextera XT Index Kit (FC‐131–1001) uses 6 different Index 1 (i7) adapters (N701–
N706) and 4 different Index 2 (i5) adapters (S501–S504). In the Index adapter name, the N or S refers 
to Nextera XT sample preparation, 7 or 5 refers to Index 1 (i7) or Index 2 (i5), respectively. The 01–12 
refers to the Index number. A list of index sequences is provided for generating sample sheets to 
demultiplex the samples: 
 
Index 1 (i7)                      Sequence                                  Index 2 (i5)                      Sequence N701                                     
TAAGGCGA                               S501                                       TAGATCGC N702                                     CGTACTAG                                
S502                                       CTCTCTAT N703                                     AGGCAGAA                              S503                                       
TATCCTCT N704                                     TCCTGAGC                                S504                                       AGAGTAGA 
N705                                     GGACTCCT                                S505                                       GTAAGGAG N706                                     
TAGGCATG                                S506                                       ACTGCATA N707                                     CTCTCTAC                                 
S507                                       AAGGAGTA N708                                     CAGAGAGG                              S508                                       
CTAAGCCT N709                                     GCTACGCT 
N710                                     CGAGGCTG N711                                     
AAGAGGCA N712                                     
GTAGAGGA 
 
Low Plexity Pooling Guidelines 
Illumina uses a green laser or LED to sequence G/T and a red laser or LED to sequence A/C. At each 
cycle, at least one of two nucleotides for each color channel are read to ensure proper registration. It 
is important to maintain color balance for each base of the index read being sequenced, otherwise 
index read sequencing could fail due to registration failure. If you choose the dual‐indexed sequencing 







compatible barcodes for each index (index 1 and index 2). The following tables illustrate possible 
pooling strategies: 
 
Table 4    Libraries Pooled: 6 or fewer; Sequencing Workflow: Single Index 
 
Plex                           Index 1 (i7) Selection                               Index 2 (i5) Selection 
1‐plex (no 
pooling) 
Any Index 1 adapter                                     Any Index 2 adapter
 
2‐plex                            •  [option 1] N702 and N701 
•  [option 2] N702 and N704 
 
3‐plex                            •  [option 1] N701, N702, and N704 
•  [option 2] N703, N705, and N706 
 
4‐ or 5‐plex                 •  [option 1] N701, N702, N704, and any 
other Index 1 adapter 
•  [option 2] N703, N705, N706, and any 
other Index 1 adapter 
 




Table 5    Sequencing Workflow: Single or Dual Index 
 
Plex                           Index 1 (i7) Selection                               Index 2 (i5) Selection 
7–12 plex, Dual 
Index 
•  [option 1] N701, N702, N704, and any 
other Index 1 adapter (as needed) 
•  [option 2] N703, N705, N706, and any 
other Index 1 adapter (as needed) 
•  [option 1] S501 and S502 
•  [option 2] S503 and S504 
•  [option 3] S505 and S506





•  N701–N706 and any other Index 1 
adapter (as needed) 
•  Any Index 2 (i5) adapter





N701, N702, N703, N704, 
N705, N706, and any other 
Index 1 adapter 
•  [option 1] S501, S502, and 
any other Index 2 adapter (as 
needed) 
•  [option 2] S503, S504, and 
any other Index 2 adapter (as 
needed) 
•  [option 3] S505, S506, and 






These strategies represent only some of the acceptable combinations. Alternatively, check the real 
sequences of each index in the tables to make sure that each base position has a signal in both color 
channels for the index read: 
 
Good                                                                                   Bad 
 
Index 1                                Index 2                                 Index 1                                 Index 2 
 
705       GGACTCCT                  503       TATCCTCT                  705       GGACTCCT                     502       CTCTCTAT 
 
706       TAGGCATG                  503       TATCCTCT                  706       TAGGCATG                     502       CTCTCTAT 
 
701       TAAGGCGA                 504       AGAGTAGA                 701       TAAGGCGA                    503       TATCCTCT 
 
702       CGTACTAG                  504       AGAGTAGA                 702       CGTACTAG                     503       TATCCTCT 
 
√ √ √ √ √ √ √ √                                √ √ √ √ √ √ √ √                               √ √ √ √ √ √ √ √                              √ √ √ √ xxxx 
 
 
√=signal in both color 
x=signal missing in one color channel 
 
Prevent PCR Product Contamination 
The PCR process is commonly used in the laboratory to amplify specific DNA sequences. Unless proper 
laboratory hygiene is used, PCR products can contaminate reagents, instrumentation, and genomic 
DNA samples, causing inaccurate and unreliable results. PCR product contamination can shut down lab 
processes and significantly delay normal operations. 
Make sure that the lab is set up appropriately to reduce the risk of PCR product 
contamination: 
•    Physically Separate Pre-PCR and Post-PCR Areas 
• Physically separate laboratory space where pre‐PCR processes are performed (DNA 
extraction, quantification, and normalization) from the laboratory space where PCR products 
are made and processed (post‐PCR processes). 
•     Never use the same sink to wash pre‐PCR and post‐PCR troughs. 
•     Never share water purification systems for pre‐PCR and post‐PCR processes. 
• Store all supplies used in the protocols in the pre‐PCR area, and transfer to the post‐ PCR area 
as needed. 
•    Use Dedicated Equipment and Supplies 
• Dedicate separate full sets of equipment and supplies (pipettes, centrifuges, oven, heat 





•     Dedicate separate storage areas (freezers and refrigerators) to pre‐PCR and post‐PCR 
consumables. 
Because the pre‐ and post‐amplification reagents are shipped together, it is important to unpack the 
reagents in the pre‐PCR lab area. After unpacking the reagents, move the post‐ amplification 
reagents to the proper post‐PCR storage area. 
 
Pre‐PCR and Post‐PCR Lab Procedures 
To prevent PCR product contamination, it is important to establish lab procedures and follow best 







0.5% Sodium Hypochlorite (10% Bleach). 
CAUTION 
To prevent sample or reagent degradation, make sure that all vapors from the cleaning 
solution have fully dissipated before beginning any processes. 
 
Daily Cleaning of Pre‐PCR Area 
A daily cleaning of the pre‐PCR area using a 0.5% Sodium Hypochlorite (10% Bleach) 
solution helps to eliminate PCR product that has entered the pre‐PCR area. 
Identify pre‐PCR areas that pose the highest risk of contamination, and clean these areas with a 
0.5% Sodium Hypochlorite (10% Bleach) solution before beginning any pre‐PCR processes. High‐
risk areas might include, but are not limited to, the following items: 
•    Benchtops 
•    Door handles 
•    Refrigerator/freezer door handles 
•    Computer mouse 
•    Keyboards 
 
Daily Cleaning of Post‐PCR Area 
Reducing the amount of PCR product in the post‐PCR area helps reduce the risk of 
contamination in the pre‐PCR area. Daily cleaning of the post‐PCR area using a 0.5% Sodium 
Hypochlorite (10% Bleach) solution helps reduce the risk of contamination. 
Identify post‐PCR areas that pose the highest risk of contamination, and clean these areas with a 
0.5% Sodium Hypochlorite (10% Bleach) solution daily. High‐risk areas might include, but are not 
limited to, the following items: 
•    Thermal cyclers 
•    Bench space used to process amplified DNA 
•    Door handles 
•    Refrigerator/freezer door handles 
•    Computer mouse 
•    Keyboards 
 
Weekly Cleaning of All Lab Areas 





0.5% Sodium Hypochlorite (10% Bleach). 
•    Clean all benchtops and laboratory surfaces. 
•    Clean all instruments that are not cleaned daily. 
•    Thoroughly mop lab floors. 
•    Make sure that personnel responsible for weekly cleaning are properly trained on 
prevention of PCR product contamination. 
 
Items Fallen to the Floor 
The floor is contaminated with PCR product transferred on the shoes of individuals coming from the 
post‐PCR area; therefore, anything falling to the floor must be treated as contaminated. 
•    Disposable items that have fallen to the floor, such as empty tubes, pipette tips, gloves, lab coat 






•    Non‐disposable items that have fallen to the floor, such as a pipette or an important sample 
container, must be immediately and thoroughly cleaned. Use a 0.5% Sodium Hypochlorite 
(10% Bleach) solution to remove PCR product contamination. 
•    Clean any lab surface that has come in contact with the contaminated item. Individuals handling 
anything that has fallen to the floor, disposable or non‐disposable, must discard their lab gloves 
and put on a new pair. 
 
Best Practices 
When preparing libraries for sequencing, always adhere to good molecular biology practices. Read 
through the entire protocol before starting to make sure that all of the required 
materials are available and your equipment is programmed and ready to use. 
 
Handling Liquids 
Good liquid handling measures are essential, particularly when quantifying libraries or diluting 
concentrated libraries for making clusters. 
•    Small differences in volumes (±0.5 µl) can sometimes cause large differences in cluster numbers 
(~100,000). 
•    Small volume pipetting can be a source of potential error in protocols requiring the generation of 
standard curves, such as qPCR, or small but precise volumes, such as the Agilent Bioanalyzer. 
•    If small volumes are unavoidable, use due diligence to make sure that pipettes are correctly 
calibrated. 
•    Make sure that pipettes are not used at the volume extremes of their performance 
specifications. 
•    Prepare the reagents for multiple samples simultaneously, to minimize pipetting errors, especially 
with small volume enzyme additions. As a result, pipette one time from the reagent tubes with a 
larger volume, rather than many times with small volumes. Aliquot to individual samples in a single 
pipetting movement to allow for standardization 
across multiple samples. 
 
Handling Magnetic Beads 
 
NOTE 
Cleanup procedures have only been validated using the 96‐well plates and the magnetic stand 
specified in the Consumables and Equipment list. Comparable performance is not guaranteed 
when using a microcentrifuge tube or other formats, or other magnets. 
 
•    Before use, allow the beads to come to room temperature. 





•    Immediately before use, vortex the beads until they are well dispersed and the color of the liquid 
is homogeneous. 
•    When pipetting the beads, pipette slowly and dispense slowly due to the viscosity of the solution. 
•    Take care to minimize bead loss, which can affect final yields. 
•    Change the tips for each sample, unless specified otherwise. 







•    When removing and discarding supernatant from the wells, use a single channel or multichannel 
pipette and take care not to disturb the beads. 
•    When aspirating the cleared solution from the reaction plate and wash step, it is important to keep 
the plate on the magnetic stand and not disturb the separated magnetic beads. Aspirate slowly to 
prevent the beads from sliding down the sides of the wells and into the pipette tips. 
•    To prevent the carryover of beads after elution, approximately 2.5 µl of supernatant is left when 
the eluates are removed from the bead pellet. 
•    Be sure to remove all of the ethanol from the bottom of the wells, as it can contain residual 
contaminants. 
•    Keep the reaction plate on the magnetic stand and let it air‐dry at room temperature to prevent 
potential bead loss due to electrostatic forces. Allow for the complete evaporation of residual 
ethanol, because the presence of ethanol affects the performance of the subsequent reactions. 
Illumina recommends at least minutes drying time, but a longer drying time can be required. 
Remaining ethanol can be removed with a 10 µl pipette. 
•    Avoid over drying the beads, which can impact final yields. 
•    Do not scrape the beads from the edge of the well using the pipette tip. 
•    To maximize sample recovery during elution, incubate the sample/bead mix for 
2 minutes at room temperature before placing the samples onto the magnet. 
 
Avoiding Cross‐Contamination 
Practice the following to avoid cross‐contamination: 
•    Open only one adapter tube at a time. 
•    Change the tips for each sample, unless specified otherwise. 
•    Pipette carefully to avoid spillage. 
•    Clean pipettes and change gloves between handling different adapter stocks. 
•    Clean work surfaces thoroughly before and after the procedure. 
 
Potential DNA Contaminants 
When handling and processing samples using this protocol, use best practices to avoid PCR 







Temperature is an important consideration for making libraries: 
•    Keep libraries at temperatures ≤37°C, except where specifically noted. 
•    Place reagents on ice after thawing at room temperature. 
 
Equipment 
•    Review the programming instructions for your thermal cycler user guide to make sure that it is 
programmed appropriately using the heated lid function. 







Table1 Nextera indexing sequences 
Index 1 (i7) Sequence  Index 2 (i5)  Sequence 
N701 TAAGGCGA S517 AGATCGC 
N702 CGTACTAG S502  CTCTCTAT 
N703 AGGCAGAA  S503  TATCCTCT 
N704 TCCTGAGC S504 AGAGTAGA 
N705 GGACTCCT S505 GTAAGGAG 
N706 TAGGCATG S506 ACTGCATA 
N707 CTCTCTAC S507 AAGGAGTA 
N708 CAGAGAGG S508 CTAAGCCT 
N709 GCTACGCT   
N710 CGAGGCTG   
N711 AAGAGGCA   





Addendum 4  
Index design in in a 96 well plate format 
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A        B C    D  E  F   G H 
Final library pool consisting of 20µl of 
each grouped sample library pool 
 Library pooling, Groups A-G each have 12 samples pooled, where H has 11 samples pooled. 20µl from each 














Commands: Qiime and R 
#QIIME input commands 
#files demultiplexed at UWC 
#Demultiplexing single read illumina Amplicon libraries in QIIME 
#commands are boxed 
$qiime>multiple_split_libraries_fastq.py-i/"filelocation"/single_read-
o/"filelocation"/sampleid_by_file--read_indicator_R1 
#This script runs split_libraries_fastq.py on data that are already demultiplexed (split up according to 
sample, with one sample per file). The script supports the following types of input: a directory containing 
many files, where each file is named on a per-sample basis (with different prefixes before the read number), 
a directory containing many directories, where each directory is named on a per-sample basis 
$qiime > pick_open_reference_otus.py -i seqs.fna -r ./greengenes/rep_set/97_otus.fasta -o 
./openpick_otu 
#This script is broken down into 4 possible OTU picking steps, and 2 steps involving the creation of OTU 
tables and trees. The commands for each step are described below, including what the input and resulting 
output files are. Additionally, the optional specified parameters of this script that can be passed are 
referenced. #Step 1) Prefiltering and picking closed reference OTUs The first step is an optional prefiltering 
of the input fasta file to remove sequences that do not hit the reference database with a given sequence 
identity (PREFILTER_PERCENT_ID). This step can take a very long time, so is disabled by default. The 
prefilter parameters can be changed with the options: –prefilter_refseqs_fp –prefilter_percent_id This 
filtering is accomplished by picking closed reference OTUs at the specified prefilter percent id to produce: 
prefilter_otus/seqs_otus.log prefilter_otus/seqs_otus.txt prefilter_otus/seqs_failures.txt 
prefilter_otus/seqs_clusters.uc Next, the seqs_failures.txt file is used to remove these failed sequences 
from the original input fasta file to produce: prefilter_otus/prefiltered_seqs.fna This prefiltered_seqs.fna file 
is then considered to contain the reads of the marker gene of interest, rather than spurious reads such as 
host genomic sequence or sequencing artifacts. #If prefiltering is applied, this step progresses with the 
prefiltered_seqs.fna. Otherwise it progresses with the input file. The Step 1 closed reference OTU picking 
is done against the supplied reference database. This command produces: step1_otus/_clusters.uc 
step1_otus/_failures.txt step1_otus/_otus.log step1_otus/_otus.txt 






#Next, the sequences that failed to hit the reference database in Step 1 are filtered from the Step 1 input 
fasta file to produce: step1_otus/failures.fasta 
#Then the failures.fasta file is randomly subsampled to PERCENT_SUBSAMPLE of the sequences to 
produce: step1_otus/subsampled_failures.fna. Modifying PERCENT_SUBSAMPLE can have a big effect 
on run time for this workflow, but will not alter the final OTUs. 
#Step 2) The subsampled_failures.fna are next clustered de novo, and each cluster centroid is then chosen 
as a “new reference sequence” for use as the reference database in Step 3, to produce: 
step2_otus/subsampled_seqs_clusters.uc step2_otus/subsampled_seqs_otus.log 
step2_otus/subsampled_seqs_otus.txt step2_otus/step2_rep_set.fna 
#Step 3) Pick Closed Reference OTUs against Step 2 de novo OTUs Closed reference OTU picking is 
performed using the failures.fasta file created in Step 1 against the ‘reference’ de novo database created 
in Step 2 to produce: step3_otus/failures_seqs_clusters.uc 
step3_otus/failures_seqs_failures.txtstep3_otus/failures_seqs_otus.log step3_otus/failures_seqs_otus.txt 
#Assuming the user has NOT passed the –suppress_step4 flag: The sequences which failed to hit the 
reference database in Step 3 are removed from the Step 3 input fasta file to produce: 
step3_otus/failures_failures.fasta 
#Step 4) Additional de novo OTU picking It is assumed by this point that the majority of sequences have 
been assigned to an OTU, and thus the sequence count of failures_failures.fasta is small enough that de 
novo OTU picking is computationally feasible. However, depending on the sequences being used, it might 
be that the failures_failures.fasta file is still prohibitively large for de novo clustering, and the jobs might take 
too long to finish. In this case it is likely that the user would want to pass the –suppress_step4 flag to avoid 
this additional de novo step. 
#A final round of de novo OTU picking is done on the failures_failures.fasta file to produce: 
step4_otus/failures_failures_cluster.uc step4_otus/failures_failures_otus.log 
step4_otus/failures_failures_otus.txt 
#A representative sequence for each cluster is chosen to produce: step4_otus/step4_rep_set.fna 
#Step 5) Produce the final OTU map and rep set If Step 4 is completed, the OTU maps from Step 1, Step 
3, and Step 4 are concatenated to produce: final_otu_map.txt 
#If Step 4 was not completed, the OTU maps from Steps 1 and Step 3 are concatenated together to 
produce: final_otu_map.txt 
#Next, the minimum specified OTU size required to keep an OTU is specified with the –min_otu_size flag. 
For example, if the user left the –min_otu_size as the default value of 2, requiring each OTU to contain at 
least 2 sequences, the any OTUs which failed to meet this criteria would be removed from the 





#If –min_otu_size 10 was passed, it would produce: final_otu_map_mc10.txt 
#The final_otu_map_mc2.txt is used to build the final representative set: rep_set.fna 
#Step 6) Making the OTU tables and trees An OTU table is built using the final_otu_map_mc2.txt file to 
produce: otu_table_mc2.biom 
#As long as the –suppress_taxonomy_assignment flag is NOT passed, then taxonomy will be assigned to 
each of the representative sequences in the final rep_set produced in Step 5, producing: 
rep_set_tax_assignments.log rep_set_tax_assignments.txt This taxonomic metadata is then added to the 
otu_table_mc2.biom to produce: otu_table_mc_w_tax.biom 
#As long as the –suppress_align_and_tree is NOT passed, then the rep_set.fna file will be used to align 
the sequences and build the phylogenetic tree, which includes the de novo OTUs. Any sequences that fail 
to align are omitted from the OTU table and tree to produce: otu_table_mc_no_pynast_failures.biom 
rep_set.tre 
#If both –suppress_taxonomy_assignment and –suppress_align_and_tree are NOT passed, the script will 
produce: otu_table_mc_w_tax_no_pynast_failures.biom 
#It is important to remember that with a large workflow script like this that the user can jump into 
intermediate steps. For example, imagine that for some reason the script was interrupted on Step 2, and 
the user did not want to go through the process of re-picking OTUs as was done in Step 1. They can simply 
rerun the script and pass in the: –step_1_otu_map_fp –step1_failures_fasta_fp parameters, and the script 
will continue with Steps 2 - 4. http://qiime.org/scripts/pick_open_reference_otus.html 
##Output files loaded into R studio 








#these steps are for importing data and and renaming the merged files which are used in subsequent steps 
biom_file <- paste("sorted_otu_w_tax.biom", sep = "") 





# Now import the .biom-formatted otu_table-tax_table file. 
biom_otu_tax <- import_biom(biom_file)  
# Add sample data to the dataset using merge 
map <- import_qiime_sample_data(map_file) 
# merge the two into a single phyloseq object containing the otu info and sample metadata 
merged <- merge_phyloseq(biom_otu_tax, map) 
#renames taxonomy shorter names 
colnames(tax_table(merged))=c("Domain", "Phylum", "Class", "Order", "Family", "Genus", "OTU") 
#lists names of rows and columns  
rownames(sample_data(merged)) 
colnames(sample_data(merged)) 
treefile = "rep_set.tre" 
tree.obj = import_qiime(treefilename = treefile) 
otu.table = merge_phyloseq(merged, tree.obj) 
#summary information on dataset used 
#used phyloseq object which was the file called "merged" 
summarize_phyloseq(merged) 
# do other things as in phyloseq_analysis.R script 
mergedtaxonomy <- tax_table(merged) 
mergedranks <- rank_names(merged) 
meta <- meta(merged) 
############ 
##To SUBSET data 
# e.g. by Type == "SAMPLE" or Time_point == "Baseline" etc. 
sub_base <- merged %>% subset_samples(Time_point == "Baseline") %>% prune_taxa(taxa_sums(.) > 
0, .) 
sub_base_case <- merged %>% subset_samples(Time_point == "Baseline" & TB_treatment =="CASE") 





sub_base_control <- merged %>% subset_samples(Time_point == "Baseline" & TB_treatment 
=="CONTROL") %>% prune_taxa(taxa_sums(.) > 0, .) 
####month2 subset 
sub_month2 <-merged %>% subset_samples(Time_point == "month2") %>% prune_taxa(taxa_sums(.) > 
0, .) 
sub_month2_case <- merged %>% subset_samples(Time_point == "month2" & TB_treatment =="CASE") 
%>% prune_taxa(taxa_sums(.) > 0, .) 
sub_month2_control <- merged %>% subset_samples(Time_point == "month2" & TB_treatment 
=="CONTROL") %>% prune_taxa(taxa_sums(.) > 0, .) 
####momth6 subset 
#split the cases into clinically diagnosed and bacteriologically confirmed 
sub_month6 <-merged %>% subset_samples(Time_point == "month6") %>% prune_taxa(taxa_sums(.) > 
0, .) 
sub_month6_case <- merged %>% subset_samples(Time_point == "month6" & TB_treatment =="CASE") 
%>% prune_taxa(taxa_sums(.) > 0, .) 
sub_month6_control <- merged %>% subset_samples(Time_point == "month6" & TB_treatment 
=="CONTROL") %>% prune_taxa(taxa_sums(.) > 0, .) 
####SUBSET BY CONTROL 
subcon_base <- merged %>% subset_samples(Time_point == "contamination CONTROL") %>% 
prune_taxa(taxa_sums(.) > 0, .) 
subMock_base <- merged %>% subset_samples(Time_point == "Mock CONTROL2") %>% 
prune_taxa(taxa_sums(.) > 0, .) 
subMock1_base <- merged %>% subset_samples(Time_point == "Mock CONTROL1") %>% 
prune_taxa(taxa_sums(.) > 0, .) 
sub_type <- merged %>% subset_samples(SAMPLE_type == "NP") %>% prune_taxa(taxa_sums(.) 
> 0, .) 
sub_typeIS <- merged %>% subset_samples(SAMPLE_type == "IS") %>% prune_taxa(taxa_sums(.) 
> 0, .) 
################################################################ 





#e.g. for generating a graph at the phylum level for the baseline cases; the sub_case file generated above 
was used in the command below and the taxonomic level was selected as phylum (this can be done for 
every other taxonomic level, just replace phylum with genus, order, class etc..) 
# the command included a filter(Abundance > 0.02) which filters out low abundance taxa i.e. everything 
above 2% was included? 
#edited script to family/Genus etc. changed colour palette 
#set colours and theme for Phyla so that they will always be the same 
theme_set(theme_bw()) 
#phyla colours used are dodgerblue3, mediumseagreen, mediumpurple4, mediumturquoise, 
mediumslateblue, mediumvioletred, mediumspringgreen 
getPalette = colorRampPalette(c("mediumslateblue", "mediumturquoise", "mediumvioletred", 
"dodgerblue3", "mediumseagreen","burlywood", "ivory", "beige", "aquamarine", "aliceblue",  
"darkslategray", "darkorange", "firebrick", "deepskyblue", "floralwhite","brown", "green", 
"mediumspringgreen","violet","blue","coral2","cornsilk1",black","forestgreen","darkorchid","hon
eydew","hotpink1","tan1","gray82","blueviolet","magenta","navy","mediumpurple4","pink","golde
nrod","red","seagreen","turquoise4","slateblue","antiquewhite",  "cyan","yellow")) 
phylumList = unique(tax_table(merged)[,"Phylum"]) 
phylumPalette = getPalette(length(phylumList)) 
names(phylumPalette) = phylumList 
all_sample_abundance<-
merged%>%tax_glom(taxrank="Phylum")%>%transform_sample_counts(function(x) {x/sum(x)}) 
%>% psmelt() %>% filter(Abundance > 0.02) %>% arrange(Phylum) 
Phy_abundance_bca <-sub_base_case %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
Phy_abundance_bco <-sub_base_control %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
Phy_abundance_2ca <-sub_month2_case %>% tax_glom(taxrank= "Phylum") %>% 






Phy_abundance_2co <-sub_month2_control %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
Phy_abundance_6ca <-sub_month6_case %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
Phy_abundance_6co <-sub_month6_control %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
#controls at phylum level 
mock_control1 <-subMock1_base %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
mock_control <-subMock_base %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
sequencing_controls <-subcon_base %>% tax_glom(taxrank= "Phylum") %>% 
transform_sample_counts(function(x) {x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% 
arrange(Phylum) 
#### Plots at phylum level: to generate multiple plots at once 










phylumList = unique(tax_table(merged)[,"Phylum"]) 
phylumPalette = getPalette(length(phylumList)) 





#assign a variable to each graph 
a <-ggplot(Phy_abundance_bca, aes(x = X.SampleID, y = Abundance, fill = Phylum))+ 
  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) +  
  theme(axis.title.x = element_blank(), axis.text.x = element_text(size = 8, angle = 270)) +  
  guides(fill = guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ 
  ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum Composition of baseline cases")  
b <-ggplot(Phy_abundance_bco, aes(x = X.SampleID, y = Abundance, fill = Phylum))+ 
  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) +  
  theme(axis.title.x = element_blank(), axis.text.x = element_text(size = 8, angle = 270)) +  
  guides(fill = guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ 
  ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum Composition of baseline controls")  
c <-ggplot(Phy_abundance_2ca, aes(x = X.SampleID, y = Abundance, fill = Phylum))+ 
  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) +  
  theme(axis.title.x = element_blank(), axis.text.x = element_text(size = 8, angle = 270)) +  
  guides(fill = guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ 
  ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum Composition of Month 2 cases")  
d <-ggplot(Phy_abundance_2co, aes(x = X.SampleID, y = Abundance, fill = Phylum))+ 
  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) +  
  theme(axis.title.x = element_blank(), axis.text.x = element_text(size = 8, angle = 270)) +  
  guides(fill = guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ 
  ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum Composition of Month 2 controls")  
e <-ggplot(Phy_abundance_6ca, aes(x = X.SampleID, y = Abundance, fill = Phylum))+ 
  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) +  
  theme(axis.title.x = element_blank(), axis.text.x = element_text(size = 8, angle = 270)) +  
  guides(fill = guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ 
  ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum Composition of Month 6 cases")  





  geom_bar(stat = "identity")+ scale_fill_manual(values = phylumPalette) + theme(axis.title.x = 
element_blank(), axis.text.x = element_text(size = 8, angle = 270)) + guides(fill = 
guide_legend(reverse = TRUE, keywidth = 1, keyheight = 1))+ ylab("Relative Abundance (Phyla > 
2%)") + ggtitle("Phylum Composition of Month 6 controls")  
#use the variables as shown below 
#arrange by column and row 
grid.arrange(a,b,c,d,e,f, ncol = 2, nrow = 3) 
####################################################### 
#graphs for controls 
sequencing_controls<-
subcon_base%>%tax_glom(taxrank="Phylum")%>%transform_sample_counts(function(x) 
{x/sum(x)}) %>% psmelt() %>% filter(Abundance > 0.02) %>% arrange(Phylum) 
S <-ggplot(sequencing_controls, aes(x = X.SampleID, y = Abundance, fill = Phylum))+geom_bar(stat 
= "identity")+ scale_fill_manual(values = phylumPalette) + theme(axis.title.x = element_blank(), 
axis.text.x = element_text(size = 8, angle = 270)) + guides(fill = guide_legend(reverse = TRUE, 
keywidth = 1, keyheight = 1))+ ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum 
Composition of sequencing controls")  
M <-ggplot(mock_control, aes(x = X.SampleID, y = Abundance, fill = Phylum))+geom_bar(stat = 
"identity")+ scale_fill_manual(values = phylumPalette) + theme(axis.title.x = element_blank(), 
axis.text.x = element_text(size = 8, angle = 270)) + guides(fill = guide_legend(reverse = TRUE, 
keywidth = 1, keyheight = 1))+ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum 
Composition of mock control 2")  
m <-ggplot(mock_control1, aes(x = X.SampleID, y = Abundance, fill = Phylum))+geom_bar(stat = 
"identity")+ scale_fill_manual(values = phylumPalette) + theme(axis.title.x = element_blank(), 
axis.text.x = element_text(size = 8, angle = 270)) + guides(fill = guide_legend(reverse = TRUE, 
keywidth = 1, keyheight = 1))+ylab("Relative Abundance (Phyla > 2%)") + ggtitle("Phylum 
Composition of mock control 1")  
grid.arrange(S,M,m, ncol = 2, nrow = 3) 
#the tables below can be used for alpha and beta diveristy 
# Absolute abundances 
#additional commands 





genus.otu.absolute <- abundances(genus) 
# Relative abundances 
phyla.otu.relative <- abundances(phyla, "compositional") 
genus.otu.relative <- abundances(genus, "compositional") 
#Rarefaction (did not use this in the study) 
#rarified <- rarefy_even_depth(merged) 
######### 
#don’t run all commands it takes a while to complete, if you only need the genus table only run that line in 
the script 
#relative abundance at the different taxonomic level 
#DIVERSITY MEASURES 
# add tree file to phyloseq object 
#treefile = "rep_set.tre" 
#tree.obj = import_qiime(treefilename = treefile) 
#otu.table = merge_phyloseq(merged, tree.obj) 
# removing otus that are 0 and transforming to relative abundance  
otu.table = subset_taxa(otu.table, rowSums(otu_table(otu.table)) != 0) 
normalizeSample = function(x) { 
    x/sum(x) 
  } 
otu.relative.table = transformSampleCounts(merged, normalizeSample) 
Phylum.rel.table = tax_glom(otu.relative.table, taxrank = "Phylum") 
Class.rel.table = tax_glom(otu.relative.table, taxrank = "Class") 
Order.rel.table = tax_glom(otu.relative.table, taxrank = "Order") 
Family.rel.table = tax_glom(otu.relative.table, taxrank = "Family") 
Genus.rel.table = tax_glom(otu.relative.table, taxrank = "Genus") 






#alpha diversity colour palette 
library(vegan) 
Shannon_diversity = diversity(otu_table(Family.rel.table), index = "shannon", MARGIN = 2, base = 
exp(1)) 
write.table(Shannon_diversity, file="shannon.txt", sep="\t") 
#edited shannon.txt to include Time_point and TB_treatment metadata and saved it as shannon_edit.txt 
#removed the controls from the file and only looked at samples this was done for all the tests (Shannon 
and Simpson) 
#used to read  saved text file e.g. Shannon file  
shannon_edit <- read.delim("shannon_edit.txt") 
#diversity by timepoint (can't remember if ggboxplot shows "mean +- std error" or "median and IQR" (think 
it's the latter, just check)) 
library(ggpubr) 
library(ggplot2) 
#subset by time point  
BLsub <- subset(shannon_edit, Time_point=="Baseline") 
M6sub <- subset(shannon_edit, Time_point== "month6") 
case_sub <- subset(shannon_edit, TB_treatment =="CASE") 
###exclude data substitue equal sign with "!" 
BL6sub <- subset(shannon_edit, Time_point!= "month2") 
BL6sub <- subset(case_sub, Time_point!= "month2") 
M6con <- subset(shannon_edit, Time_point=="month6") 
#HEALTHY VS CASE SUBSET 
M6con2 <-subset(M6sub, TB_treatment =="CONTROL") 
BLTB <- subset(BLsub, TB_treatment =="CASE") 
splot <- ggboxplot(shannon_edit, x = "Time_point", y = "Shannon_Diversity",ylab = "Shannon", xlab 





BLsplot <- ggboxplot(BLsub, x = "TB_treatment", y = "Shannon_Diversity",ylab = "Shannon", xlab 
= "TB treatment", title = "Shannon test Baseline", fill= "TB_treatment", palette =c("#00AFBB", 
"#E7B800", "#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
BLsplot 
#is there a difference between the cases and control group at baseline  
BLplot1 <- BLsplot + facet_grid(.~Time_point) 
######STATS BETWEEN TWO GROUPS########### 
BLstatsplot <- BLsplot + stat_compare_means(method= "wilcox.test") 
BLstatsplot 
splot <- ggboxplot(shannon_edit, x = "Time_point", y = "Shannon_Diversity", ylab = "Shannon",xlab 
= "Time point", title = "Shannon test", color = "Time_point", palette =c("#00AFBB", "#E7B800", 
"#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
M6splot <- ggboxplot(M6sub, x = "TB_treatment", y = "Shannon_Diversity",ylab = "Shannon", xlab 
= "TB treatment", title = "Shannon test Month6", palette =c("#00AFBB", "#E7B800", "#FC4E07"),add 
= "jitter", outlier.shape = NA, width = 0.5) 
BL6splot <- ggboxplot(BL6sub, x = "Time_point", y = "Shannon_Diversity",ylab = "Shannon", xlab 
= "Time point", title = "Shannon test BL vs M6", fill= "TB_treatment",palette =c("#00AFBB", 
"#E7B800", "#FC4E07"), add = "jitter", outlier.shape = NA, width = 0.5) 
BL6statsplot <- BL6splot + stat_compare_means(method= "wilcox.test") 
# outlier.shape = NA makes outliers invisible (boxplots show outliers as points, so adding jitter points may 
make some points plot twice) 
# jitter makes points not clump on each other, but spread out 
#diversity by timepoint, Split view into case vs control: 
splot2 <- splot + facet_grid(.~TB_treatment) 
splot2 
#is there a difference between time points in the cases and control groups? 
statsplot2 <- splot2 + stat_compare_means(method="kruskal.test") 
casplot <- ggboxplot(case_sub, x = "Time_point", y = "Shannon_Diversity", 
                     ylab = "Shannon", xlab = "Time point", title = "Shannon test (Case group)", color = 
"Time_point", palette =c("#00AFBB", "#E7B800", "#FC4E07"), add = "jitter", outlier.shape = NA, 





######stats measure  
#stat compare inputs the p value on the graph 
#the data not normally distirbuted used kruskal wallis test (non-parametric test) 
statsplot1 <- splot + stat_compare_means(method="kruskal.test") 
statsplot2 <- splot2 + stat_compare_means(method="kruskal.test") 
#diversity between cases and controls 
splot3 <- ggboxplot(shannon_edit, x = "TB_treatment", y = "Shannon_Diversity", ylab = "Shannon", 
xlab = "Treatment arm", title = "Shannon test", color = "TB_treatment", palette =c("#00AFBB", 
"#E7B800", "#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
splot3 
#diversity between case vs control, Split view into timepoints: 
splot4 <- splot3 + facet_grid(.~Time_point) 
splot4 
########Simpsons############# 
#USED THE FAMILY RELATIVE ABUNDANCE TO GENERATE PLOTS  
library(vegan) 
Simpson_diversity = diversity(otu_table(Family.rel.table), index = "simpson", MARGIN = 2, base = 
exp(1)) 
write.table(Simpson_diversity, file="simpsonF1.txt", sep="\t") 
#edited shannon.txt to include Time_point and TB_treatment metadata and saved it as 
shannon_edit.txt 
simpson_edit <- read.delim("simpson_edit.txt") 
splot <- ggboxplot(simpson_edit, x = "Time_point", y = "Simpson_index",ylab = "Simpson", xlab = 
"Time point", title = "Simpson test", color = "Time_point", palette =c("#00AFBB", "#E7B800", 
"#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
splot <- ggboxplot(simpsonF_edit, x = "Time_point", y = "Simpson_index", ylab = "Simpson", xlab 
= "Time point", title = "Simpson test", color = "Time_point", palette =c("#00AFBB", "#E7B800", 





splot <- ggboxplot(simp_ISM1, x = "Time_point", y = "Simpson_index",  ylab = "Simpson", xlab = 
"Time point", title = "Simpson test", color = "Time_point", palette =c("#00AFBB", "#E7B800", 
"#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
splot  
#diversity by timepoint, Split view into case vs control: 
splot2 <- splot + facet_grid(.~TB_treatment) 
splot2 
#is there a difference between time points in the cases and control groups? 
statsplot2 <- splot2 + stat_compare_means(method="kruskal.test") 
statsplot2 
#diversity between cases and controls 
splot3 <- ggboxplot(simpson_edit, x = "TB_treatment", y = "Simpson_index",ylab = "Simpson", xlab 
= "Treatment arm", title = "Simpson test", color = "TB_treatment", palette =c("#00AFBB", 
"#E7B800", "#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
splot3 <- ggboxplot(simp_ISM1, x = "TB_treatment", y = "Simpson_index", ylab = "Simpson", xlab 
= "Treatment arm", title = "Simpson test", color = "TB_treatment", palette =c("#00AFBB", 
"#E7B800", "#FC4E07"), add = "jitter", outlier.shape = NA, width = 0.5) 
splot3 
#diversity between case vs control, Split view into timepoints: 
splot4 <- splot3 + facet_grid(.~Time_point) 
splot4 
statsplot4 <- splot4 + stat_compare_means(method="kruskal.test") 
statsplot4  
#is there a difference between the cases and control group at baseline  
BLsplot <- ggboxplot(BLsub, x = "TB_treatment", y = "Simpson_index",  ylab = "Simpson", xlab = 
"TB treatment", title = "Simpson test Baseline", fill= "TB_treatment",palette =c("#00AFBB", 
"#E7B800", "#FC4E07"), add = "jitter", outlier.shape = NA, width = 0.5) 
BLsplot 
BLplot1 <- BLsplot + facet_grid(.~Time_point) 






###Baseline cases vs m6 cases 
BL6splot <- ggboxplot(BL6sub, x = "Time_point", y = "Simpson_index",ylab = "Simpson", xlab = 
"Time point", title = "Simpson test BL vs M6", fill= "TB_treatment",palette =c("#00AFBB", 
"#E7B800", "#FC4E07"),  add = "jitter", outlier.shape = NA, width = 0.5) 
BL6splot <- ggboxplot(simpblTBcon6, x = "Time_point", y = "Simpson_index", ylab = "Simpson", 
xlab = "Time point", title = "Simpson test BL vs M6", fill= "TB_treatment", palette =c("#00AFBB", 
"#E7B800", "#FC4E07"),add = "jitter", outlier.shape = NA, width = 0.5) 
BL6statsplot <- BL6splot + stat_compare_means(method= "wilcox.test") 
#######Beta diversity 
subsample <- merged %>% subset_samples(Sample_seqcon == "sample") %>% 
prune_taxa(taxa_sums(.) > 0, .) 
sub_base <- merged %>% subset_samples(Time_point == "Baseline") %>% 
prune_taxa(taxa_sums(.) > 0, .) 
cas_conTB <- subsample %>% subset_samples(TB_diagnosis != "control" & TB_treatment == 
"CASE") %>% prune_taxa(taxa_sums(.) > 0, .) 
any(taxa_sums(subsample) ==0) 
merged1 <- prune_taxa(taxa_sums(sub_base)>1, sub_base) 
merged2 <- subset_taxa(merged1, Phylum !="p_") 
merged2 
merged2a <-subset_taxa(merged2, Class!="Chloroplast") 
merged3 <- subset_taxa(merged2a, Order!="Mitochondria") 
merged3 
otu.table = merge_phyloseq(merged3, tree.obj) 
otu.table = subset_taxa(otu.table, rowSums(otu_table(otu.table)) != 0) 
normalizeSample = function(x) { 
x/sum(x) 
} 





Family.rel.table = tax_glom(otu.relative.table, taxrank = "Family") 
#######Graphs 
beta.ps1 <- plot_ordination(Family.rel.table, bx.ord_pcoa_bray, color="TB_treatment", label = 
"TB_treatment") + geom_point(aes(shape = Time_point), size= 4) +  
  theme(plot.title = element_text(hjust = 0, size = 12)) 
beta.ps1  
beta.ps1 <- beta.ps1 + theme_bw(base_size = 14) + theme(panel.grid.major = element_blank(), 
panel.grid.minor = element_blank()) 
beta.ps2 <- beta.ps1 + geom_line() + scale_color_brewer(palette = "Dark2") 
beta.ps2 
beta.ps3 <- plot_ordination(Family.rel.table, bx.ord_pcoa_bray, color="TB_treatment", label = 
"TB_treatment") +  geom_point(size= 4) +  
  theme(plot.title = element_text(hjust = 0, size = 12)) 
beta.ps3 <- beta.ps3 + theme_bw(base_size = 14) + theme(panel.grid.major = element_blank(), 
panel.grid.minor = element_blank()) 
beta.ps3 + scale_color_brewer(palette = "Dark2") + stat_ellipse() 
metadf.bx <- data.frame(sample_data(ps4fam.rel)) 
bray_ps.bxn <- phyloseq::distance(physeq = ps4fam.rel, method = "bray") 
##Stats test 
adonis.test <- adonis(bray_ps.bxn ~ TB_treatment, data = metadf.bx) 
adonis.test 























SampleVector = sample_data(Fam.Rel.table1B)$TB_treatment 
sample_data(Fam.Rel.table1B)$TB_treatment 
#duplicate to create a color vector and replace value w/ color  
#Colorvector can only replace numbers!  
Colorvector <-SampleVector 
Colorvector <- replace(Colorvector, which (Colorvector == "3"), "chocolate") 
Colorvector <- replace(Colorvector, which (Colorvector == "4"), "chartreuse") 
Colorvector <- replace(Colorvector, which (Colorvector == "5"), "cadetblue") 
FamilyData <- otu_table(Fam.Rel.table1B) 
FamilyData.Bray.dist <-vegdist(FamilyData, method = "bray") 
Family.Bray.clus <-hclust(FamilyData.Bray.dist, "aver") 
Bray.dist = distance(FamilyData, method="bray") 
cluster.Bray = hclust(Bray.dist, "aver") 











# Define the ranks you want to include 





#Now Plot Heat map with dendograms 
mypalette <- colorRampPalette(c('#ffffff','#4169E1','#0000CD')) 
pdf("Bray Curtis heatmap Family.pdf", height = 10, width = 15) 
heatmap.2(FamilyData, margins = c(10,20),  
          density.info = "none", 
          trace = "none", 
          keysize = 0.75, 
          key.title = "Relative abundance", 
          offsetRow = 1, offsetCol = 1, 
          dendrogram = "both", 
          Rowv = as.dendrogram(Family.Bray.clus), 
          Colv = as.dendrogram(cluster.Bray), 
          labRow=tax_table(Fam.Rel.table1B.New.Names)[,"catglab"], 
          cexRow = .9, 
          labCol = sample_data(Fam.Rel.table1B)$heatmap, 
          cexCol = .9, 
          col = mypalette(17), 
          symm=F,symkey=F,symbreaks=T, scale="none", 





























Method= weighted Unifrac 
Method= weighted unifrac 
TB case and ill control comparison 
Time point comparison between all samples 
Method= Weighted UniFrac 






adonis(formula = wUniF.dist ~ sample_data(Family.rel.table)$TB_treatment)  
 
Permutation: free 
Number of permutations: 999 
 
Terms added sequentially (first to last) 
 
                                        Df SumsOfSqs MeanSqs F.Model         R2 Pr(>F) 
sample_data(Family.rel.table)$TB_treatment  1    0.1161 0.11612 0.56406 0.02296   0.72 
Residuals                                  24    4.9409 0.20587         0.97704        
Total                                      25    5.0570                 1.00000  
 
 













adonis(formula = wUniF.dist ~ sample_data(Family.rel.table)$TB_treatment)  
 
Permutation: free 
Number of permutations: 999 
 
Terms added sequentially (first to last) 
 
                                           Df SumsOfSqs MeanSqs F.Model      R2 Pr(>F) 
sample_data(Family.rel.table)$TB_treatment  1    0.1288 0.12885 0.68547 0.00906  0.625 
Residuals                                  75   14.0979 0.18797         0.99094        
Total                                      76   14.2267                 1.00000 
 















adonis(formula = wUniF.dist ~ sample_data(Family.rel.table)$Time_point)  
 
Permutation: free 
Number of permutations: 999 
 
Terms added sequentially (first to last) 
 
                                         Df SumsOfSqs MeanSqs F.Model      R2 Pr(>F) 
sample_data(Family.rel.table)$Time_point  2    0.5644 0.28222  1.5286 0.03967  0.121 
Residuals                                74   13.6623 0.18463         0.96033        
Total                                    76   14.2267                 1.00000 
 
TB case and ill-control group over time 
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